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Symposium on 'Cancer Metastasis and the
Generation of the Metastatic Phenotype'
Growth factors and blood-borne metastasis
P. Alexander
CRC Medical Oncology Unit, Southampton General Hospital,
Southampton S09 4XY, UK.
Unlike lymphoma and leukaemia cells, carcinoma and
sarcoma cells which have gained access to the blood do not
circulate but are generally arrested in the first capillary bed
encountered. The major sites for metastasis are therefore
determined by the venous drainage of the primary tumour. If
this is vena caval lung and bone metastases (via vertebral
venous shunts) predominate, while the liver is the primary
site for metastasis of portal draining tumours. Cells released
from primary or secondary lung tumours gain direct access
to the arterial circulation and are trapped in all of the
different organs of the body in proportion to the blood flow
to the individual organs. However, the probability that such
a trapped cancer cell develops into a metastasis varies by a
factor of 104 between adrenal (highest) and skeletal muscle
and gut (lowest) for the rat sarcomas and carcinomas
studied. That tissue specific host factors are responsible for
this preference is suggested by the finding that tissue injury,
such as an incision in skin, an anastamosis of the intestine or
mechanical trauma to kidney or liver markedly facilitates
metastasis. Growth factors released at sites of injury,
particularly coming from infiltrating macrophages allow
isolated cancer cells delivered via the blood to grow into
macroscopic lesions. In the absence of exogenous stimulating
factors, single cells remain dormant and eventually die.
Genetic aspects of the metastatic phenotype and their
interaction with the host micro environment
M. McMenamin & D Tarin
Nuffield Department ofPathology, John Radcliffe Hospital,
Headington, Oxford, UK.
The work of this laboratory is based on the concept that the
driving force of the metastatic process is created by
regulatory genomic disturbances in a small population of
cells within the primary tumour and that the success or
failure of such cells to form a deposit in distant organs is not
random but dictated by interactions between the tumour
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cells showering out from the primary and metabolic
conditions encountered in the microenvironment or other
organs in the body where they lodge. Superimposed on such
local interactions are systemic effects exerted by the immune
and endocrine systems, the magnitude of which depends on
the type and quantity of exposed antigens and receptors on
the disseminating tumour cells as well as on the constitu-
tional vigour of the host. We have adopted a number of
different approaches in an attempt to identify the gene or
genes involved in metastases. The first approach has been to
introduce a defined gene with known oncogenic potential
into a previously non-metastatic cell and to observe for
phenotypic change. This involved transfections of the c-
Harvey ras oncogene into a non-tumorigenic non-metastatic
cell. A second approach involves transfection of total
genomic DNA from metastatic to non-metastatic cells.
Finally we have examined whether treatment of weakly
metastatic cells with agents known to influence tumour
progression and gene expression (e.g. tetra-phorbol acetate
or 5-azacytidine) can affect metastatic capability. We shall
present results which indicate that, while successful
incorporation and expression of the activated c-Ha-ras
oncogene did not induce non-metastatic 3T3 derived fibro-
sarcoma cells to become spontaneously metastatic,
transfection of the same cell type with DNA from highly
metastatic human and animal cell lines did markedly
augment their spontaneous metastatic capability and their
lung colony forming potential and induce them to form
deposits in many extra pulmonary sites. We have also found
that treatment of some tumour cell lines with azacytidine
and TPA markedly increases their metastatic behaviour after
subcutaneous inoculation and, as several cell divisions must
have occurred in producing the subcutaneous tumour before
the cells disseminated, we consider the change of phenotype
to be heritable and probably caused by alterations in gene
expression.
These results suggest that components of the metastatic
phenotype are heritable, highly conserved in evolution and
can be conferred on previously non-metastatic tumour cells
by transfer of genomic DNA. However the process is so
complex that there is need for caution in interpretation and
points requiring further critical evaluation will be discussed.
Messenger RNAs putatively associated with progression and
metastasis of colorectal cancers
G.D. Birnie*l, P. Elvin', I.B. Kerr2 & C.S. McArdle3
Beatson Institutefor Cancer Research1, Bearsden, Glasgow
G61 IBD and University Departments ofPathology2 and
Surgery3, Royal Infirmary, Glasgow G4 OSF, UK.
Phenotypic differences between cells result from quantitative
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and qualitative differences in the cells' proteins, and these in
turn reflect differences in the populations of the mRNAs in
the cells. Thus, phenotypic changes associated with the
emergence of cells with metastatic potential should be
accompanied by changes in the relative abundances of
specific mRNAs. Molecular cloning techniques allow the
isolation of cDNA probes homologous to previously
uncharacterized mRNAs that are associated with a particular
cellular phenotype. We therefore constructed recombinant
plasmid cDNA libraries representing the poly(A)' RNAs
from normal colonic mucosa and from a liver metastasis
from a colonic adenocarcinoma. Screening of these libraries
with 32P-cDNAs transcribed from poly(A)' RNAs from
specimens of 3 normal colonic mucosae, 3 adenocarcinomas
and 3 liver metastases identified 34 recombinants that
were homologous to RNAs that differed significantly in
abundance between normal and neoplastic colon or between
primary tumours and metastases.
Five of these recombinants and their homologous RNAs
have been characterized further by Southern and Northern
blot and RNA dot-blot analyses. These cDNAs, and other
isolated from the libraries, may prove to be of use both as
diagnostic tools and for defining phenotypic changes
associated with tumour progression and metastasis.
Gene regulation and the control of metastatic behaviour
I.R. Hart, N. Goode & E.J. Ormerod
ICRF Laboratories, Lincoln's Inni Fields, London, WC2A
3PX, UK.
Cellular proliferation constitutes a vital part of the
metastatic process such that understanding mechanisms
involved in the control of mitogenesis may provide insight
into possible approaches to the control of secondary tumour
growth. Binding of extracellular mitogenic ligands to specific
receptors leads to the initiation of active messenger
molecules which mediate transduction of the proliferation
signal from the cell surface to the nucleus. Recent interest
has focused on the possibility that the rapid enhancement of
expression of c-/os and c-myc mRNA plays a role in
transduction of the mitogenic signal in the nucleus.
Using two tumour models, a murine reticulum cell
sarcoma and a series of melanoma variants (human and
murine) of defined metastatic activity, we have begun to
examine the response of malignant tumours to a series of
mitogenic factors in terms of cellular proliferation,
generation of second messenger molecules and expression of
the cellular oncogenes c-fos and c-myc. Metastatic behaviour
of neoplastic cells treated in this fashion has been assessed
by subsequent injection into immunocompetent, syngeneic
mice or immunoincompetent, athymic mice. Early results
show that some of the agents which elicit mitogenic
responses in normal cells inhibit proliferation, and decrease
the metastatic capacity, of their malignant counterparts.
Differences also may exist in the response of high and low
metastatic lines, derived from a common parent, to similar
treatments. The possibility that these variations in growth
regulation may provide an approach to therapy currently is
under investigation.
Selection and characterization of metastatic variants in human
melanoma xenografts
J.F. Dore, S. Bertrand & M. Bailly
INSERM U218, Centre Leon BNrard, 28 rue Lainnec, 69373
LYon Cedex 08, France.
The selection of human melanoma variants and clones with
increased metastatic abilities was attempted by xenografting
human melanoma cell lines in athymic nude mice and in
immunosuppressed new-born rats.
Subcutaneous transplantation in a nude mouse of a
human melanoma metastatic nodule resulted in a sub-
cutaneously growing tumour (NTT) and in spontaneous lung
(NTP) and lymph node (NTG) metastases (Neulat-Duga et
al., Invasion Metast., 4, 209, 1984). NTT, NTP and NTG
cells were first maintained in vivo by subcutaneous passages
in nude mice and then cultured in vitro as cell lines.
Cytogenetic studies of the in vivo passaged cells showed that
the 3 tumour lines differed in their modal chromosome
number. 15 markers were identified, including several
common to all 3 lines; one of these, derived from
chromosome 7 and containing an HSR, was found with a
higher frequency in metastatic tumour lines. In addition, 2
markers derived from chromosome I were both present in
NTT cells but mutually exclusive in NTP and NTG cells.
Thus, all 3 tumour lines have a common origin and
metastases in the nude mouse resulted from a selection
among cell populations. Following 15 in vitro passages, NTP
cells were injected s.c. in nude mice: serial transplantation
was accompanied by an increase in metastatic ability of
tumour cells.
Human melanoma cell lines, tumorigenic but not
metastatic in nude mice, were xenografted to ATS immuno-
suppressed new-born rats. 3 weeks after s.c. injection of 106
cells, nearly all rats developed tumours and a proportion of
them lung and lymph node metastases. Agar cloning of
M4Beu line showed that it is heterogeneous and contains
poorly tumorigenic but highly metastatic cells.
The generation of metastatic mosaicism in B16 murine
melanoma
G.V. Sherbet', M.S. Lakshmi', J. Lunec', S.S.
Bhattacharya2 & C. Parker'
'Cancer Research Unit, University of Newcastle uponI Tyne,
Newt'castle upon Tine NE] 4LP and 2MRC Clinical an(d
Populationi C'togenetics Unit, Edinburgh, UK.
The generation of metastatic heterogeneity is currently
receiving considerable attention. The genome of tumours
with high metastatic potential has been described as being
more labile than that of tumours with low metastatic
potential. The rate of generation of drug resistant variants is
greater in tumours with high metastatic potential as
compared with those with low metastatic potential (Cifone &
Fidler, Proc. Natl Acad. Sci. USA, 78, 6949, 1981). We
investigated the low metastasis Fl and high metastasis
variant BL6 of the B16 murine melanoma for differences in
genetic recombination and differential expression of genetic
messages.
Genetic recombination, seen as sister chromatid exchange
(SCE), increased with increase in metastatic potential.
Metastatic tumour cells from lung showed greater SCE than
the corresponding primary tumour. Metastatic tumour
rejoined bleomycin-induced DNA strand breaks considerably
more slowly than the primary tumour (Sherbet et al., Br. J.
Cancer, 54, 164, 1986). This reduced repair may be
conducive to the exchange of chromatid segments. The SCEs
occurred predominantly in a hypertriploid subpopulation.
Primary tumours also showed a transition to a
predominantly hypertriploid state in the progression to the
metastatic state. Alkylating agents such as mitomycin C and
ethylmethanesulphonate considerably enhanced the SCE
incidence in this hypertriploid subpopulation. It is suggested
that metastatic variants may be generated in this genetically
unstable subpopulation by a process of genetic
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A cDNA library of the BL6 variant was constructed in
Xgt 10. A differential screening of this library with cDNA
probes prepared from FI and BL6 cells has shown that some
messages are differentially expressed in these variants. The
cDNA clones corresponding to these messages have been
isolated and are being characterised.
Joint Symposium (with ACP) on 'DNA repair'
Molecular cloning of genes involved in the excision repair
system of mammalian cells
J.H.J. Hoeijmakers', M. van Duin', M. Koken', A.
Westerveld', G. Weeda2, A.J. v.d. Eb2 & D. Bootsmal
IDepartment oJ Cell Biology & Genetics, Erasmus University,
P.O. Box 1738, 3000 DR Rotterdam and 2Department of
Medical Biochemistry, State University Leiden, 2333 AL
Leiden, The Netherlands.
To deepen our understanding of the mechanism and genetic
control of mammalian excision repair it is essential to
identify the genes and proteins involved. To this aim we
have adopted several strategies. One of the most
straightforward approaches relies on the 'correction' of
repair defective mutant cells by DNA mediated transfer of
the normal gene, recruited from genomic DNA of a repair
competent cell line. This strategy has been successful using
several CHO-mutants, but has failed thus far for xeroderma
pigmentosum (XP) cells. We have found that in contrast to
(CHO) Chinese hamster ovary DNA repair mutants- SV40
transformed XP-fibroblasts are practically unsuited for
genomic DNA transfections because of the limited amounts
of exogenous DNA incorporated by these (and other human)
cells.
Using a representative of CHO complementation group 2
we have cloned the human excision repair gene ERCC-J.
The status of the characterization of this gene and its
product will be reported. As steps towards the isolation of
ERCC-3 (complementation group 3) and ERCC-6 (group 6)
genes we have generated primary and secondary
transformants in transfection experiments of human DNA to
excision deficient CHO mutants 27-1 (Dr R. Wood) and
UV-61 (Dr L. Thompson). The isolation of the ERCC-3
gene from cosmid libraries is in progress.
As reported (van Duin et al., Cell, 44, 913, 1986) a
significant aminoacid sequence conservation was discovered
between the excision repair proteins RADIO from yeast and
ERCC-1 from man. This prompted us to examine whether
other human genes are conserved as well and whether they
can be isolated on the basis of nucleotide homology with
cloned yeast repair genes.
Use of repair defective CHO cells to clone human repair genes
C.A. Weber, K.W. Brookman, J.L. Minkler, E.P. Salazar,
S.A. Stewart & L.H. Thompson
Biomedical Sciences Division, Lawrence Livermore National
Laboratory, Livermore, CA 94550, USA.
The Chinese hamster ovary (CHO) cell line UV5 (which is
defective in the incision step of nucleotide excision repair)
and EM9 (which has high sister chromatid exchange (SCE)
levels and is defective in DNA single and double strand
break repair) were used to identify human genes that correct
these repair deficiencies and to study repair processes. Repair
proficient, gpt-expressing primary transformants were
obtained by cotransforming mutant cells with the plasmid
pSV2gpt and DNA from a human/hamster hybrid line. The
secondary transformant 5T4-I (UV5) and the tertiary
transformant 9TTT3 (EM9) which are relatively free of
human sequences other than a repair gene were obtained by
using DNA sheared to <50kb from primary or secondary
transformants, respectively. Cosmid clones containing the
correcting human genes (ERCC2 for UV5 and XRCCI for
EM9) were identified and purified by screening cosmid
libraries made from 5T4-1 and 9TTT3 DNAs using HeLa
DNA as the probe. Transformation of mutant cells with
these cosmid DNAs demonstrated that 8/21 (UV5) and 2/9
(EM9) have a functional repair gene. In the UV5 study, UV
survival curves demonstrate that primary, secondary, and
cosmid transformants have, in all but one case, similar or
slightly higher levels of UV resistance compared to normal
cells (AA8). The levels of UV induced mutation at the aprt
locus for 5T4-1 and cosmid transformants vary from 50-
150% of normal. Measurements of the initial rate of incision
using alkaline elution indicate that, while the UV5 rate is
3% of AA8, rates of cosmid transformed lines are similar to
AA8 and the 5T4-1 rate is 170% of AA8. In the EM9 study,
y-ray survival curves of 9TTT3 and cosmid transformants
show, in most cases, levels of resistance similar to AA8.
Primary and cosmid transformants had normal levels of SCE
and chromosomal aberrations induced by BrdUrd. Alkaline
elution studies measuring single strand break repair after y-
ray exposure in 9TTT3 and cosmid transformants indicate
normal levels of repair. Restriction enzyme site maps of the
5T4-1 derived cosmids have been determined and show
ERCC2 is between 15 and 25 kb. The cosmids will be used to
obtain the corresponding cDNA for sequencing, analyzing
gene structure, and producing the encoded protein.
DNA damage inducible responses in mammalian cells
P. Herrlichl, M. Imagawa2, P. Angell, M. Buescher', M.
Karin2, H.J. RahmsdorfI & B. Stein'
'Kern/orschungszentrum Karlsruhe, Institute for Genetics,
Post/ach 3640, D-7500 Karlsruhe 1, FGR and 2Department of
Pharmacology, M036, School ofMedicine, University of
California San Diego, La Jolla, CA 92093, USA.
Genotoxic agents as well as mediators of inflammation or
substances imitating these mediators such as the phorbol
esters cause an active genetic response. This response is
largely transient but may have significant long lasting
effects on cells. The immediate reaction (minutes after a UV
or phorbol ester treatment) includes the induced expression of
c-fos, proteases, metallothioneins, DNA and RNA viruses.
Interesting late endpoints (hours) are the overreplication of
genes and the secretion into the extracellular space of a
number of factors one of which is mutagenic. Using deletion
mutants of the human c-fos and collagenase genes we have
defined the cis acting elements which mediate the induction
by UV and by phorbol esters. These elements bind specific
regulatory proteins. As an example, the TPA responsive
element (TRE) of the collagenase gene ranges from positions
-73 to -65. A synthetic oligonucleotide of this sequence
(5'-ATGAGTCAG-3') suffices to confer TPA dependent
regulation to the thymidine kinase promoter. By footprinting
and competition experiments a specific DNA binding protein
has been defined and purified using affinity chromatography.
The activity of this trans-acting factor is increased by TPA
treatment of cells. TRE sequences occur in several TPA
inducible genes. These bind the same factor suggesting that
the factor forms the major signal receiving structure for the
genetic actions of phorbol esters (Angel et al., Mol. Cell Biol.,
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Poly (ADP-Ribose) and chromatin organization in DNA
excision repair
F.R. Althaus
Department ofPharmacology & Biochemistry, University of
Zurich-Tierspital, Winterthurerstrasse 260, CH-8057 Zurich,
Switzerland
De novo poly ADP-ribosylation of chromatin proteins is a
stereotype response of higher eukaryotes to DNA damage.
Numerous lines of evidence suggest that this post-
translational protein modification modulates chromatin
functions. The role of poly ADP-ribosylation in DNA
excision repair may be conceptualized as follows. All target
proteins of poly ADP-ribosylation hitherto identified share
the capacity to bind to DNA. Recent results suggest that
reversible poly(ADP-ribose)-modification of these proteins
may serve as a general shuttle mechanism for DNA-protein
interactions. In vitro poly ADP-ribosylation of nucleosomal
core particles reduces DNA-protein interactions. In vivo, the
rapid shuttling of DNA binding proteins on damaged
templates may facilitate local changes of chromatin structure
in DNA excision repair, such that newly synthesized repair
patches appear in 'free' DNA domains with increased
accessibility to chemical and enzymatic probes (J. Biol.
Chem., 261, 5758, 1986). This step is completely blocked in
poly(ADP-ribose)-depleted mammalian cells treated to repair
C-8 substituted deoxyguanosine adducts. As a consequence,
dG-8 adducts remain unexcised and accumulate in free DNA
domains. By this mechanism, poly ADP-ribosylation of
chromatin proteins may modulate the biological expression
of DNA damage.
Characterisation of cytotoxic drug hypersensitive Chinese
hamster cells
I.D. Hickson
Department of Clinical Oncology, University of Newcastle
upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne,
NE] 4LP, UK.
As part of a study of the molecular mechanisms of DNA
repair in mammalian cells, we have isolated mutants of a
Chinese hamster ovary cell line which exhibit hypersensitivity
to DNA damaging agents. We currently have over 20 such
mutants, of which 14 are under detailed investigation. Of
these, 5 (designated MMC-1 to -5) were isolated on the basis
of sensitivity to mitomycin C (MMC), 2 as sensitive to
bleomycin (designated BLM-1 and -2), 6 sensitive to MMS
(MMS-1 to -6) and 1 adriamycin-sensitive (ADR-1).
Mutants MMC-I to -5 are 4- to 7-fold hypersensitive to
MMC, as judged by D37 values, and vary in their cross-
sensitivities to other DNA damaging agents. Using alkaline
elution to study the induction and repair of DNA
interstrand cross-links following exposure to MMC, we have
shown that MMC-4 and, more particularly, MMC-5 cells
accumulate higher levels of DNA cross-links than do CHO-
KI cells, but repair this damage normally. In contrast,
MMC-2 cells (which are 10-fold cross-sensitive to UV light)
are defective in the repair of cross-links. Mutants BLM-1
and -2, which are 7- and 14-fold sensitive to bleomycin
respectively, differ markedly in their response to bleomycin
treatment. BLM-I cells receive equivalent levels of DNA
strand breaks to wild-type cells and are proficient in DNA
repair. In contrast, BLM-2 cells (which are 2-fold cross-
sensitive to X-rays) not only accumulate higher levels of
both single- and double-strand DNA breaks than parental
cells, but also repair both forms of lesion with reduced
efficiency.
ADR-1 cells accumulate more DNA strand breaks
following adriamycin treatment but repair this damage with
normal efficiency. In this case breaks are protein-concealed,
a characteristic of topoisomerase IT-dependent scissions.
By an analysis of the drug sensitivity of cell hybrids, we
have shown that the MCC, bleomycin and adriamycin-
sensitive mutants are all phenotypically recessive, and
represent 7 different complementation groups. Only MMC-1
and -5 are genetically identical. Complementation analysis
with the MSS sensitive lines is in progress.
Analysis of spontaneous mutation frequencies in the
MMC and MMS sensitive lines reveals several alterations
from wild-type. Mutants MMC-4 and MMC-5 show
respectively a 10-fold elevated and a 2-fold reduced mutation
frequency to thioguanine resistance. Of the MMS sensitive
lines, MMS-1, MMS-2 and MMS-5 have a mutator
phenotype, while MSS-4 is hypomutable. Differences also
exist in the frequency of drug-induced mutations in these
lines.
Following DNA transfection with a human gene bank, we
have isolated drug-resistant derivatives of MMC-4 and
BLM-2 that contain integrated human DNA sequences.
Work is in progress to recover this DNA by cosmid rescue.
DNA repair and drug resistance - Clinical relevance
A.L. Harris
Cancer Research Unit, Royal Victoria Infirmary, Newcastle
upon Tyne NE] 4LP, UK.
A minority of human tumours are curable with chemo-
therapy (lymphomas, acute leukaemias, childhood tumours,
choriocarcinomas, teratoma; ovarian and oat cell lung
cancer, rarely). In these cases, tumours are responsive to
doses of cytotoxic drugs that are not excessively toxic to
the host. This suggests that there are hypersensitive
populations of tumour cells that can be eliminated or greatly
reduced. In vitro study of cell lines from chemosensitive
tumours does show they are more sensitive in vitro - nearly
as sensitive as ataxia telangiectasia cells. Thus defective
DNA repair may be a common basis for the drug sensitive
tumours - perhaps relating to certain stages of normal
differentiation.
A comparison of the degree of drug sensitivity and
resistance with the mechanisms of sensitivity and resistance
in a family of CHO mutants and other cell lines suggests
that at different degrees of resistance different mechanisms
predominate. DNA repair by various mechanisms is a major
determinant of sensitivity over the range of 14-fold sensitive
to 3-fold resistant. Thus the responsiveness of curable
tumours may be particularly determined by repair.
At levels of 10-fold resistance, 2 main mechanisms
predominate - P-glycoprotein and glutathione transferases -
neither of which may require gene amplification. Gene
amplification for particular target enzymes or resistance
genes (P glycoprotein) can produce 10-1000-fold resistance.
The degree of resistance or sensitivity that is clinically
relevant is probably 3-fold - this would make the difference
between resistance or response. Thus DNA repair is
probably most important in the chemocurable tumours.
06 methyltransferase is the most clear case of a repair
enzyme being related to resistance. It can be depleted in cells
by the base 06 methylguanine. In most human tumours the
enzyme level is lower than in normal tissues so it may be
possible to lower the level below a critical threshold in
tumours compared with normal tissue and sensitise tumours
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Recovery from DNA damage is a more pleiotropic
response than repair of specific lesions. The factors relating
to poor prognosis of tumours obviously are also related to
failure of therapeutic modalities, e.g. poorly differentiated
tumours, high stage tumours. Since the factors relating to
cell growth may also be related to recovery from DNA
damaging drugs and radiation, we investigated EGF
receptors in 2 common epithelial carcinomas - breast cancer
and bladder cancer. In each case, EGFr were related to poor
differentiation of the tumour and also were the most
significant prognostic factor in the primary tumour,
independently of the stage of the tumour. The role of the
EGFr in modulating resistance to cytotoxic drugs is
currently being evaluated.
In E. coli there are several inducible responses to DNA
damage and an increasing number of enzyme activities are
being shown to be increased by DNA damage in human
cells. Glutathione transferases have a direct DNA repair
function, they can convert hydroperoxythymine residues to
hydroxyuracil, which is then a substrate for a specific
glycosylase. To investigate inducible responses in mammalian
cells, we have made CHO cells resistant to adriamycin,
mitomycin C or chlorambucil.
The chlorambucil resistant line is cross-resistant to
melphalan and nitrogen mustard, but no other alkylating or
cytotoxic drugs. A cytoplasmic protein is increased 10-fold in
abundance and may be a basic glutathione transferase (GT).
At equitoxic doses of nitrogen mustard there are equal
crosslinks and isolated nuclei produce equal numbers of
crosslinks at equimolar doses of nitrogen mustard. If GTs
are inducible by DNA damage, this will be an important
protective mechanism in a pleiotropic mammalian response
to DNA damage. They may also be relevant to normal tissue
distribution of damage by cytotoxic drugs.
Complementation of alkylation repair deficiencies by gene
transfer
G.P. Margison
Department of Carcinogenesis, Paterson Institutefir Cancer
Research, Christie Hospital anid Holt Radium Institute,
Manchester M20 9BX, UK.
Exposure of mammalian cells to alkylating agents can result
in mutation, chromosome damage, transformation or cell
death. The contribution of individual DNA lesions to these
effects can be investigated using cloned genes that code for
specific DNA repair functions to complement repair deficient
cells. Results thus obtained with Chinese hamster V79 and
murine haemopoietic stem cells indicate that the formation
of 06-alkylguanine in DNA can be responsible for the toxic,
mutagenic and clastogenic effects of certain alkylating
agents, particularly chloroethylating agents.
Trichothiodystrophy - A UV-sensitive disorder
A.R. Lehmann & C.F. Arlett
mentation group as xeroderma pigmentosum, group D.
We have carried out a detailed molecular and cellular
study of the effects of UV light on cells cultured from 4
further TTD patients and have found a variety of different
responses. Cells from patient 1 were normal in cell survival,
excision repair, DNA and RNA synthesis following UV
irradiation, whereas in cells from patient 2 all these
responses were similar to those of excision-defective XP cells.
In cells from patient 3 cell survival was normal following
UV-irradiation, even though excision repair was only 50% of
normal, and RNA synthesis was severely reduced. In patient
4 excision repair was normal but RNA synthesis was
reduced. Our results suggest that the abnormal UV response
of most TTD cell strains may be used for confirmation of
the clinical diagnosis and for prenatal diagnosis of TTD.
They pose a number of questions about the relationship
between the molecular defect in DNA repair and the clinical
symptoms of XP and TTD.
Repair of X-ray induced DNA damage in mutant mammalian
cells
J. Thacker
MRC Radiobiology Unit, Chilton, Didcot, Oxon OXI] ORD,
UK.
The nature and complexity of the processes which repair
ionising radiation damage in mammalian cells are largely
unknown. An important approach to understanding these
processes is to identify and characterise mutants with an
altered capacity to recover from radiation damage. A human
mutation, leading to the syndrome ataxia telangiectasia
(A-T), gives cancer proneness and radiosensitivity at both
tissue and single cell levels but as yet there is no consensus on
the molecular basis of the disorder. Recently mutants have
been sought from established mammalian cell lines with some
success: we have isolated 3 new mutants and have shown by
cell fusion studies with these and other recently-isolated
mutants that there are at least 6 genes controlling radiation
sensitivity in hamster cells. Several of these mutants are
being used as vehicles for the molecular cloning of the
normal human genes compensating for their defects.
Our group has made particular use of gene transfer and
recombinant DNA methods to characterise radiation-
sensitive mutants. Measurements of the rejoining of
transferred genes carrying a double-strand break at specific
sites have revealed that A-T cells have a significant reduction
in rejoin fidelity. Molecular analysis of rejoined molecules
characterized this loss of fidelity as deletion of sequence
around the break site. One of our X-ray sensitive hamster
mutants (irs]) shows similar loss of rejoin fidelity with this
assay, while other hamster mutants show normal fidelity
levels. Radiation damage may give sufficient loss of genetic
information to require repair by recombination of DNA
helices. Using gene transfer assays we have shown that the
xrs series of hamster mutants have a large decrease in ability
to integrate DNA into their genomes, presumably by non-
homologous recombination, while homologous recombi-
nation is little affected.
MRC Cell Mutation Unit, Sussex University7, Falmer,
Brighton BN] 9RR, UK.
Trichothiodystrophy (TTD) is an autosomal recessive
disorder characterised by brittle hair with reduced sulphur
content, ichthyosis, peculiar face and mental and physical
retardation. Some patients are photosensitive. A previous
study by Stefanini et al. (Human Genet., 74, 107, 1986)
showed that cells from 4 patients with TTD had a molecular
defect in DNA repair, which was in the same comple-
Metabolic inhibitors: Tools for dissecting DNA repair
A. Collins
Department ofBiochemistry, University ofAberdeen,
Marischal College, Aberdeen AB9 IAS, UK.
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reactions about which surprisingly little is known. A
biochemical approach that has yielded valuable information
makes use of known inhibitors of DNA metabolism. For
instance, inhibitors of DNA polymerase cause the
accumulation in UV-irradiated cells of incomplete repair
sites, seen as breaks in the DNA. (However, paradoxically,
repair DNA synthesis seems not to be reduced.)
Hydroxyurea, a well known inhibitor of ribonucleotide
reductase, causes depletion of the cellular pool of DNA
precursors, and consequently inhibits DNA repair.
Can these artificial manipulations of repair be related to
the 'real world'? First, many cells in an organism are in a
non-dividing state with small DNA precursor pools,
resembling hydroxyurea-treated growing cells. Second, cells
of certain human diseases show a delay in completion of
repair (i.e. breaks accumulate); while in other cases, the
response of cells to DNA repair inhibitors can be diagnostic.
Third, various therapeutic drugs are found among the
known DNA repair inhibitors.
Interrupting DNA repair leads to increased cell killing. It
might also be expected to contribute to mutagenesis. Recent
work suggests that this is the case.
The therapeutic use of radiosensitizers and their relation to
DNA repair inhibition
I.J. Stratford
MRC Radiobiology Unit, Chilton, Didcot, Oxon OX]] ORD,
UK.
Radiation causes damage to cells via fast free radical
processes. Time resolved techniques, such as pulse radiolysis
and rapid mixing, have identified many of the radical species
likely to be responsible for damage and, in addition, have
shown how the fate of these radicals can be modulated by
protectors e.g. thiols, or sensitizers e.g. electron affinic
agents. The molecular changes caused by radiation occur as
a function of direct energy deposition in the target molecules
or as a consequence of the interaction of radiolytic products
of water, primarily OH radicals, with DNA.
Hypoxic cells are radiation resistant and can contribute to
failure of radiotherapy. Thus, development of methods for
increasing the radiation sensitivity of these hypoxic cells
would be important. This can be done by enhancing the
types of molecular damage alluded to above by using
electron affinic nitroimidazoles or by depleting cellular thiol
pools.
Cross-linking and drug resistance
B.W.Fox & P.M. O'Connor
Paterson Institute for Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
The dimethanesulphonate esters present an interesting series
of agents which do not require metabolic activation and
apart from the basic interaction of the alkylating groups
with the target site, do not produce significant toxic or other
biologically active metabolic products. The level of
unrepaired DNA-DNA interstrand crosslinks is a critically
important lesion which would seriously impair mitosis and
subsequent integrity of a cell. Based on microbial evidence,
the level of such cross-linking necessary to kill a cell is
probably beyond the limits of detection by techniques
currently available. Thus any meaningful relationship of the
sensitivity of the cell to the degree of unresolved
crosslinking, at pharmacologically sensible levels of drug
treatment, cannot be drawn for many bifunctional
antitumour agents. Reverse extrapolation of the levels of
DNA interstrand crosslinking from a number of bifunctional
antitumour agents, measured at supralethal dose levels
suggest that less than fifty unresolved interstrand crosslinks
per cell are associated with an LD50 level of the drug. The
high level of drug needed to carry out the experiment
adversely affects the repair systems themselves. The problems
associated with the modelling of such agents for cross-
linking activity have been studied in relation to a series of
ali-cyclic and aromatic dimethanesulphonates. The basic
chemistry of these agents in the environment of the lesion
determines the type of DNA-protein cross-linking, which in
turn may determine the sensitivity of the cell.
Abstracts of members' proferred papers
DNA repair
Complementation of a DNA repair defect in a mammalian cell
by expression of a cloned bacterial gene
J. Hall, H. Kataoka & P. Karran
Imperial Cancer Research Fund, Clare Hall Laboratories,
Blanche Lane, South Mimms, Herts EN6 3LD, UK.
Mammalian expression vectors derived from pSV2gpt and
encoding all or part of the E. coli ada+ gene have been
constructed. Following transfection and stable integration
into Mex- CHO cells, the whole ada+ gene conferred
resistance to both cell killing and mutagenesis by MNNG.
An N-terminal fragment of the ada+ gene, which encodes
only the methylphosphotriester DNA repair domain, did not
significantly protect CHO cells against MNNG toxicity or
mutagenesis. These observations suggest that the increased
resistance to cell killing observed in these transfected cells is
due to their higher levels of 06-methylguanine-DNA methyl-
transferase activity. A third plasmid has been constructed
which contains only the coding information for the C-
terminal 06-methylguanine-DNA methyltransferase repair
domain of the Ada protein. Following transfection into
CHO cells, 3 cell lines expressing this bacterial polypeptide
have been cloned. All 3 clones exhibit enhanced resistance to
killing by MNNG. However, the degree of resistance
exhibited is different, despite the fact that their overall levels
of 06-methylguanine-DNA methyltransferase measured in
cell free extracts are the same. This suggests that variations
in expression of 06-methylguanine-DNA methyltransferase
activity may exist among cells within a cloned population.
This variability may provide a model for the Mex-
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Forward and reverse mutation at the HPRT locus is decreased
in Chinese hamster cells expressing E. Coli alkyltransferase
M. Fox', J. Brennand2 & G.P. Margison'
IPaterson Institute for Cancer Research, Manchester M20
9BX and 2CBL, ICI, The Heath, Runcorn, Cheshire, UK.
In order to further assess the importance of 06-alkylguanine
(0'-AG) in the mutagenic effects of alkylating agents, we
have transfected Chinese hamster cells with the mammalian
cell expression vector pZipenoSV(X)I containing sections of
the E. coli ada gene that code for 06-AG and alkyl-
phosphotriester (AP) alkyltransferase (ATase) or 06-AG
ATase alone. The recipients were wild type and
hypoxanthine phosphoribosyl transferase deficient (HPRT-)
line in both of which endogenous ATase activity was almost
negligible (2-4fmolmg-1 protein). Following transfection a
total of ~-40 G418 resistant colonies were screened for
ATase activity and positive clones expressed between 250
and 1500 fmol ATase mg- protein. The mutagenic responses
of the transfected cells have been analysed at the HPRT
locus. At equitoxic doses a 50-fold reduction in MNU
induced mutation (HPRT' -HPRT-) in cells transfected
with the dual function gene and 4-fold reduction in cells
transfected only with the 06-AG ATase section was observed.
Similar effects were obtained when cell lines were
mutagenised with EMS. In the more specific reverse
mutation assay HPRT--HPRT+ significant protection
against the mutagenic effects of a number of monofunctional
alkylating agents was also observed. There was a good
correlation between the levels of ATase expression in the
different cell lines and the reduction in mutagenic
effectiveness observed. The data indicate a critical role for
alkylation at the 06 position of guanine in both forward and
reverse mutation at the HPRT locus.
The repair of 06-n-butylguanine and 02_ and 04-n-
butylthymine in rat liver
K. Hellstern, K. Myers & R. Saffhill
Paterson Institute for Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
Butylating agents are potent carcinogens (Druckrey et al., Z.
Krebhsorch. 69, 103, 1967) but their mechanism of tumour
induction has been little studied. However, by analogy with
methylating carcinogens promutagenic DNA modifications
are most likely to be responsible for the initiation of
malignant transformation. Until recently little was known of
the reaction of butylating agents with DNA. n-N-Butyl-N-
nitrosourea (BNU) reacts with DNA in vitro to form the
expected range of products (Saffhill et al., Biochem, Biophys.
Acta., 823, 111, 1985) which include 06-nBug, and 04-nBuT
in addition to sec-butyl adducts arising from a rearrange-
ment of the butyl group (Saffhill, Carcinogenesis, 5, 621,
1984). Using radioimmunoassay methods, the repair of 06_
nBuG has been observed in CHO cells following treatment
with BNU even though the corresponding methyl adduct is
not repaired. We now report the formation and repair of O6_
nBuG, 02-nBuT and 04-nBuT in the DNA of rat liver
following in vivo treatment with BNU. Two hours following
treatment, the levels of the butyl adducts in the DNA were
14.7. 8.5 and 23.7umolmol of parent base respectively for
06-nBuG, 02-nBuT and 04-nBuT and the adducts were
removed with half times of 6, 5 and 4 h respectively.
Flow cytometric studies on the effects of an ADP-Ribosyl
transferase inhibitor in mouse leukaemic cells
P.J. Smith, J.V. Watson & S. Shall
MRC Clinical Oncology and Radiotherapeutics Unit,
Cambridge and School ofBiological Sciences, University of
Sussex, UK.
The inhibitor 3-aminobenzamide (3AB) has been used
extensively to study the role of poly(ADP-ribosyl)ation in
specific cellular functions including DNA repair, pathways
for drug cytotoxicity and differentiation. To clarify
interpretation of such studies we have used various flow
cytofluorimetric techniques to examine the effects of 3AB
alone on cell cycle traverse, RNA synthesis and mito-
chondrial function (by rhodamine uptake). The responses of
L1210 cells were compared with those of a resistant variant
(L25A). Continuous exposure of L1210 cells to 3AB(5-
30mM) caused a concentration dependent decrease in cell
cycle traverse and an eventual (at 24-48h) G2 block. L25A
cells grew more slowly and maintained a greater number of
cells in G2. At cytostatic concentrations (25mM) for L1210
cells G1 emptying was inhibited for a period of 1Oh prior to
S phase recovery and recruitment into G2 block. Cells
blocked in G2 could no longer undergo endo-reduplication
and commitment to mitosis appeared to be a lethal event.
3AB (5-30mM; 2-24h exposure) reduced cellular RNA
content in all phases of the cell cycle and cytostasis was
associated with the inability to reach a threshold RNA:DNA
ratio. Tests for mitochondrial function showed that cells
exposed to 5-25mm 3AB for up to 24h were metabolically
active, indeed there was a drug related enhancement of
rhodamine 123 uptake in S phase cells suggesting an increase
in the mitochondrial transmembrane potential. We conclude
that 3AB not only modifies the probability of cell cycle
transit by altering cellular RNA content but also changes the
metabolic status of cycling cells - factors which should be
considered in interactive studies with cytotoxic agents.
ADP-Ribosyl transferase inhibitors potentiate the cytotoxicity
of base, but not nucleoside, analogues
K. Moses, B.W. Durkacz & A.L. Harris
Cancer Research Unit, University ofNewcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
The base analogues, 6-mercaptopurine (6MP) and 6-
thioguanine (6TG), are widely used in the treatment of
childhood and adult leukaemias. Since inhibitors of ADP-
ribosyl transferase (ADPRT) are known to potentiate the
cytotoxicity of monofunctional alkylating agents, we
investigated the effects of these inhibitors (the benzamides)
on the cytotoxicity of a range of base and nucleoside
analogues in CHOKI cells. 3mM 3-aminobenzamide
potentiated the cytotoxicity of 6TG with a dose enhancement
factor (DEF) at 10% survival of 2.0, and 6MP with a DEF
of 3.1. Similar results were obtained with a range of ADPRT
inhibitors. The cytotoxicity of the nucleoside analogue, 6-
thioguanosine, is not potentiated by the benzamides.
Likewise, the benzamides potentiated the cytotoxicity of
5-fluoro-1-uracil, but not 5-fluorodeoxyuridine. These
observations may reflect a differential effect of the
benzamides on the transport of nucleosides and bases. We
are investigating the effect of the benzamides on
transport. Using the nucleoid technique, there was an
increase in DNA strand breaks with increasing 6TG
concentrations. No further increase in strand breaks was
detected when acetyl-aminobenzamide was present. There is180 JOINT MEETING OF THE BACR AND THE ACP
no change in the NAD (which is the substrate for ADPRT)
levels of 6TG treated cells. This contrasts with the effect of
monofunctional alkylating agents which result in a decrease
in NAD levels, and an increase in the number of strand
breaks in the presence of the benzamides. Using
synchronised cells, we have shown that to obtain
potentiation of cytotoxicity of 6TG, the benzamides must be
present during the GI phase of the cell cycle. These results
suggest that, for 6TG and 6MP, the potentiation of
cytotoxicity is not mediated by an inhibition of DNA repair,
which is the widely cited mode of action of the benzamides.
The role of poly(ADP-Ribose) synthetase in the biological
effects of benzamides
M.R. Purnell, J.M. Lunn & A.L. Harris
Cancer Research Unit, University ofNewcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
3-Aminobenzamide has been used extensively as a probe for
the function of poly (ADP-ribose) synthetase. However,
doubts have been cast as to its specificity at the
concentrations required to elicit a biological response. To
investigate the role of poly(ADPR) in proliferation and
MNU potentiation, we have used 4 different benzamides
with differing ki values in human lung adenocarcinoma A549
cells. 3-Acetamidobenzamide (AAB), 3-methoxybenzamide,
benzamide and 3-aminobenzamide inhibited cell proliferation
in order of potency of their ki values; more rigorous analysis
revealed that a plot of IC50 vs. ki (poly(ADPR)) was convex,
suggesting that another process may be involved at very high
(>10mM) concentrations. This was confirmed by the
observation that potentiation of MNU, which required lower
inhibitor concentrations, correlated better with ki than did
inhibition of proliferation. Nicotinamide starvation lowered
the IC50 for AAB, suggesting that inhibition of proliferation
was mediated via a NAD dependent process. Benzamides
have been reported to affect glucose transport and
metabolism. To assess the contribution of this on prolifera-
tion, we studied the influence of glucose concentration on
inhibition of proliferation and potentiation of MNU cyto-
toxicity. The IC50 for AAB was not significantly altered by
changing the glucose concentration from 0.3gl-1 to 3gl-1.
Potentiation of MNU toxicity was only slightly increased
(-20%) when the glucose concentration was decreased from
2g1- 1 to 0.2g1 1, suggesting perturbation of glucose
metabolism plays a very minor role in the enhancement of
MNU cytotoxicity. We therefore conclude that poly(ADP-
ribose) synthetase plays the major role in the mechanism of
action of benzamide with regard to inhibition of
proliferation and potentiation of MNU cytotoxicity in these
cells.
Characterization of the corrected UV excision repair in a
human XPD-like hybrid cell transfected with the phage T4
DENV gene
J. Arrand, S. Squires, N. Bone & R.T. Johnson
CRC Mammalian Cell DNA Repair Group, Department of
Zoology, Cambridge, UK.
A plasmid carrying the T4 denV gene, encoding the
pyrimidine dimer-specific endonuclease V, and the neoR gene
(Valerie, et al., Proc. Natl Acad. Sci. USA, 82, 7656, 1985)
has been introduced by DNA transfection into a UV
excision repair defective human cell. High transfection
frequencies were achieved (2-5 x 10- 3) when both markers,
neoR and UVR, were selected. 15 clones showing an enhanced
resistance to killing by UV were examined in detail for their
repair capabilities using a variety of techniques. The
integrated denV plasmid (1-2 copies per cell) improved the
UV survival of many though not all clones. The extent of
UV resistance correlates well with the ability of the cells to
recover DNA synthesis after UV radiation. The UV
endonuclease activity of the denV gene results in a higher
level of DNA breaks and UDS in many of the transfectants.
Estimates of the overall excision repair indicates that, for the
first 3 h after irradiation, -4 times more incision events
occur in the cells with the denV gene (about half of that of a
normal human fibroblast). Variation in UV resistance among
the transfectants is now being related to the extent of denV
expression (the number of RNA copies varies widely) and to
the rate of repair site completion. In the transfectants about
half of the repair sites remain unsealed for abnormally long
periods. These studies demonstrate that the product of a
prokaryote repair gene can integrate well with the
endogenous repair machinery in a human cell and can
partially compensate for the lack of UV endonuclease
activity in an XPD-like cell.
Gamma-radiation sensitivity and inhibition of DNA synthesis
in human tumour cells in vitro
C.N. Parris, C.F. Arlett, A.R. Lehmann, M.L.H. Green &
J.R.W. Masters
Institute of Urology, London WC2H 9AE and MRC Cell
Mutation Unit, University ofSussex, Brighton BNI 90G, UK.
Cells derived from individuals with the DNA-repair defective
syndrome ataxia telangiectasia (A-T) are hypersensitive to
gamma-radiation and this is associated with a lack of
inhibition of DNA synthesis post-irradiation when compared
to normal cells. In this study we show that cells derived from
testicular germ cell tumours are more sensitive to cis-platin
and gamma-irradiation than bladder cancer cells,
corresponding with clinical experience. The testicular tumour
cells also exhibit a reduced inhibition of DNA synthesis
post-irradiation compared with bladder cancer cells (Table).
A-T cells are similar to bladder cancer cells in their
sensitivity to cis-platin, but more sensitive than the normal
cells (Table).
Do IC90 cis-platin %DNA synthesvis
Cell line Cell type (Gy) (ngml-1) (40Gy)
AT5BIVA Ataxia telan. 1.0 220 92
MRC5 Normal 1.9 473 40
RT112 Bladder 1.7 370 35
HT1376 Bladder 2.1 200 43
SuSa Testis 1.2 50 62
833 K Testis 1.5 60 61
The sensitivity of testicular tumour cells to cis-platin and gamma-
irradiation may be analogous to that of AT and related to altered or
defective DNA repair.
Genomic recombination events in a cell line sensitive to
difunctional agents
D.A. Lydall & J.J. Roberts
Department ofMolecular Pharmacology, Institute ofCancer
Research, Sutton, Surrey SM2 5PX, UK.
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excision repair and recombination events are required for the
repair of DNA interstrand crosslinks. We have studied a cell
line derived from the Walker 256 carcinoma that is sensitive
to difunctional but not to monofunctional agents and
determined its recombination proficiency in comparison with
a derived, resistant, subline (of normal sensitivity).
The plasmid pDRl which contains two truncated (and
therefore nonfunctional) non tandem, but overlapping
segments of the neo gene separated by a functional
transcription unit coding for the gpt gene (Subramani &
Rubnitz, Mol. Cell. Biol., 5, 659, 1985). The plasmid pDRI
was transfected into the Walker cells (using the gpt gene to
select transfectants) and subsequently recombination of the
integrated defective neo gene segments was assayed by the
appearance of G418 resistant cells. The effect of treatment of
the cells with cis-platin on recombination frequency has also
been determined. Recombination between the homologous
regions of the segments was confirmed by Southern blot
analysis.
Excision repair of UV damage is insensitive to etoposide
C.S. Downes, A.M. Mullinger & R.T. Johnson
CRC Mammalian Cell DNA Repair Group, Department of
Zoology, Cambridge CB2 3EJ, UK.
Novobiocin, an inhibitor of DNA topoisomerase II, blocks
the excision repair of UV damage, acting at a pre-incision
step. A pre-incision topoisomerase action has therefore been
postulated as a controlling stage in excision repair. But we
have shown (Downes et al., Carcinogenesis, 6, 1343, 1985)
that novobiocin also affects mitochondrial structure and
ATP metabolism; this action may account for its inhibition
of excision repair. We have now investigated the effects of
etoposide, another inhibitor of topoisomerase II, on UV
repair in human cells. Etoposide is a more specific agent
with no side-effects on mitochondria; but at concentrations
where its inhibition of topoisomerase II produces DNA
strand breaks (and its effects are ultimately toxic), etoposide
is without effect on excision repair. UV irradiation does not
induce additional strand breaks in the presence of etoposide;
nor does etoposide prevent the accumulation of breaks at
repair sites in the presence of DNA polymerase inhibitors;
nor does it affect religation of repair-induced breaks, or
break-induced chromosome decondensation. There is
therefore no need to suppose that topoisomerase II is
involved at any stage in excision repair.
Induced mutation frequencies and differential
chemosensitivities in human tumour cells in vitro
C.N. Parris & J.R.W. Masters
Institute of Urology, Department ofHistopathology, St Paul's
Hospital, London WC2H 9AE, UK.
Drug resistance in tumours may develop as a result of
mutations induced by chemotherapy. Testicular germ cell
tumours, in contrast to most other types of cancer, are
curable even in advanced stages using chemotherapy. We
compared spontaneous and induced mutation frequencies
(MF) in continuous cell lines derived from two testicular
germ cell tumours (833 K, SuSa) and one bladder cancer
(RTI 12). Forward mutations at the hypoxanthine guanine
phosphoribosyl transferase locus (HGPRT) were selected
following exposure to 10 igml- 1 6-thioguanine. Induced
mutation frequencies were compared following exposure to
equitoxic and equimolar concentrations of ethyl methane
sulphonate (EMS). (Table).
Induced MF at
Sponstaneous Induced MF at equimolar EMC conc.
Cell line MF/survivor ID50 EMSconc. (0.6mgml-1)
RT1l2 7.5x 10-6 5.6x 10-5 2.4x 10-
833K 5.3 x 10-6 1.2 x 10- 2.5 x 10-5
SuSa 6.9x 10- 7.1 x 10-6 1.4x 10-
At equitoxic doses mutations were higher in the bladder than in the
testicular cell lines, but were similar at equimolar doses of EMS.
Different frequencies of mutation in these cell lines, particularly at
equitoxic doses of EMS, may mediate the response of these tumours
to chemotherapy.
Changes in cellular uptake of alkyl-aziridine analogues of the
radiosensitizer RSU 1069 as a function of the basicity of the
compounds
J.M. Walling, I.J. Stratford & G.E. Adams
MRC Radiobiology Unit, Chilton Didcot, Oxon OX]] ORD,
UK.
Alkyl aziridine analogues of the hypoxic cell radiosensitizer
RSU 1069 that are less toxic in vivo have been synthesized.
There is a prospect that the therapeutic ratio of some of
these analogues will be greater than RSU 1069. In particular,
RB 7040, the tetramethyl substituted aziridine, is a more
efficient sensitizer in vitro than RSU 1069, especially at low
concentrations. RSU 1069 and its analogues are weak bases
and it is known that such compounds may concentrate
intracellularly. We have investigated to what extent variation
in drug uptake influences the sensitizing efficiency of RSU
1069 and its analogues. This was done by determining the
pH dependence of cellular drug uptake and making
comparison with the sensitizing properties of the analogues
at extracellular pH values (pHe) in the range 5.4 to 8.4.
Three compounds were chosen for study: RSU 1069, RSU
1165 and RB 7040 (values of pKa of 6.04, 7.38 and 8.45
respectively). Following exposure of V79 cells to these agents
for 1 h at room temperature, the ratio of intra- to extra-
cellular concentration (Ci/Ce) was near unity at pH 5.4.
Increasing pHe to 8.4 resulted in no change in the ratio
Ci/Ce for RSU 1069; in contrast, for RSU 1165 and RB
7040 values of Ci/Ce increased 3 x and 11 x respectively.
Radiosensitisation by RSU 1069 was independent of pHe
over the range studied, whereas increasing pH led to an
apparent increase in sensitizing efficiency of both RSU 1165
and RB 7040. However, when normalized for difference in
drug uptake at the different values of pHe sensitization was
independent of pH,,. This study suggests that subtle changes
in basicity (pKa) may have potential for therapeutic
exploitation on the basis of selective drug uptake,
particularly since pH gradients are known to exist across
tumours.
Metastasis and growth factors
Transfection of metastatic capability with total genomic DNA
from metastatic cell lines
A.J. Haylel, D.L. Darling', P.A. Whittaker2, K.A.
Fleming', & D. Tarin'
'Nuffield Department ofPathology, Nuffield Department of
Pathology, John Radcliffe Hospital, Oxford OX3 9DU and
2Department ofBiochemistry, University ofOxford, South
Parks Road, Oxford OX] 3QU, UK.
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melanoma cell line, which is capable of metastasis in the
nude mouse, to a tumorigenic but nonmetastatic mouse cell
line resulted in the latter acquiring the ability to colonise
distant organs in a substantial proportion of animals
inoculated i.v. with the cells. The results also showed that
these cells could form colonies in extrapulmonary sites and
Southern blot analysis indicated the presence of human
DNA. Additional studies involving transfection of DNA
from a highly metastatic mouse cell line (of histiocytic
origin) into a very weakly metastatic mouse mammary
carcinoma cell line resulted in marked augmentation of
spontaneous metastasis from tumours formed by the
recipient cells in the mammary fat pad. Transfections were
performed using the calcium phosphate precipitation method
and incorporated a dominant co-selectable marker (the gene
for amino-glycoside transferase, which confers resistance to
neomycin). The survival of cell clones in neomycin-
containing medium provided further evidence of incor-
poration of exogenous DNA and these clones were pooled
before injection to increase the numbers that could be
screened for metastatic behaviour. The results indicate that
components of the metastatic phenotype are heritable, highly
conserved in evolution and can be dominantly conferred on
previously non-metastatic tumour cells by transfer of
genomic DNA. These findings open opportunities for the
isolation of genes involved in metastatic behaviour and for
studies of their regulation.
Expression of oncogenes in a rat glioma cell line induced
transplacentally with ethylnitrosourea
P.C. Rumsby, L.J. Green, V.T. Chow & J.P. Roscoe
Department of Cell Pathology, School of Pathology,
Middlesex Hospital Medical School, London WIP 7LD, UK.
The induction of rat brain gliomas by transplacental
treatment with ethylnitrosourea (ENU) has proved to be a
good model for studying the development of tumours
(Roscoe & Claisse, Nature, 262, 314, 1976). We have looked
at oncogene expression in the cloned glioma cell line, A15A5
and a cloned line from a normal adult rat brain, ARBO C9,
using Northern blot analysis.
Hybridisation with a human genomic N-ras probe revealed
increased expression of 2 species of mRNA, 3.8 and 3.4kb,
in the glioma cells. There was no expression of Ki- or Ha-ras
nor in this system, of c-cis or epidermal growth factor
receptor-related mRNAs which have been found in several
human neural tumours.
Hybridisation with a v-myc probe gave bands at 2.4 and
2.7kb and less distinct ones at 3.8 and 1.8kb. A human c-
myc probe hybridised weakly to the 2.4kb species. The
normal ARBO C9 cell line had mainly the 2.7kb species and
A1SA5 the 2.4kb mRNA. There was no hybridisation with a
human N-myc probe.
The neu oncogene has been implicated as the activating
oncogene in some other ENU-induced glioblastomas
(Bargmann et al. Cell, 45, 649, 1986). There was no
difference in the expression of a 5kb neu mRNA in the
ARBO C9 and A15A5 cell lines suggesting that in this
glioma any activation by neu is by small qualitative change
in the gene rather than by alteration in the level of neu
expression.
The clinical significance of c-myc oncogene expression in
colorectal cancer
D.J. Jones' 2, A.K. Ghosh2, M. Moore2 & P.F. Schofield'
lDepartment ofSurgery and 2Paterson InstitutefJr Cancer
Research, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
The c-mYc oncogene is involved in the regulation of cell
proliferation; elevated levels of c-myc mRNA and its product
p62c-myc have been detected in solid tumours and cell lines
using molecular biological techniques. Oncogene expression
has recently been assessed using monoclonal antibodies to
oncoproteins generated against synthetic peptides. We
studied c-myc expression in colorectal carcinomas from 100
patients, prospectively followed for 3 years, using Myc 1-
6E10 which recognizes p62c-myc in paraffin-embedded
material (Stewart et al., Br. J. Cancer, 53, 1, 1986). Tissue
sections were stained using an immunoperoxidase technique,
and assessed independently by two observers. Paradoxically
staining was predominantly cytoplasmic despite the reported
nuclear location of p62c-myc (Evan & Hancock, Cell, 43,
253, 1985). In normal mucosa, maturing crypt cells and
surface epithelial cells were weakly positive. All carcinomas
stained positively but with varying intensity. However,
though distinctive staining patterns could be distinguished
for both normal mucosa and for carcinomas, there was also
considerable background staining of stromal elements. There
was no significant relationship between staining intensity and
conventional pathological features or prognosis. These
results suggest that c-myc expression is a feature of normal
maturing epithelial cells and that expression is increased in
the majority of carcinomas and may be related to malignant
transformation, but not to clinical behaviour. Paradoxical
cytoplasmic and stromal staining may be due to fixation
artefact. Alternatively in tissue sections Myc 1-6E10 may
cross-react with proteins other than p62c-mjyc (cf. Evan et
al., Mol. Cell. Biol., 5, 3610, 1985). Data obtained on
histological sections using this antibody should therefore be
interpreted with caution.
Differential responses to activators of cAMP in metastatic
human melanoma variants
E.J. Ormerod & I.R. Hart
ICRF Labor-atories, Lincoln's Inn Fields, London,
WC2A 3PX, UK.
Recently we described the derivation of a series of human
melanoma cell lines exhibiting differential lung colonising
capacity in nude mice. (Ormerod et al., Cancer Res., 46, 884,
1986.) In the present study we have examined the response
of these variants to activators of cyclic adenosine 3-5-
monophosphate (cAMP).
The response of the low-metastatic parental DX3 line and
the high-metastatic LT5. 1 variants to cholera toxin,
forskolin, theopylline and melanocyte stimulating hormone
was assessed in terms of in vitro growth rates, morphology,
plating efficiencies and cAMP levels. Differences were found
between the lines in the way that they responded to 10 -9M
cholera toxin such that the in vitro growth rate of the DX3
line was hardly affected by the presence of this agent
whereas cell division of LT5. 1 variants ceased completely
within 5-7 days although cAMP levels were elevated 5-10-
fold in both lines. Pretreatment of LT5.1 cells prior to s.c. or
i.v. injection into athymic nude mice retarded tumour
growth and reduced lung nodules 3-5 fold respectively.
Currently we are determining whether in vivo treatments can
bring about similar reductions in metastatic burdens.
That variants of a human melanoma cell line show
differential responses to cholera toxin might reflect
differences in cAMP metabolism and its growth regulatory
function in high and low metastatic lines.JOINT MEETING OF THE BACR AND THE ACP 183
Regulation of proliferative and metastatic activity of a murine
tumour by 12-0-tetradecanoylphorbol 13-acetate (TPA)
N. Goode & I.R. Hart
ICRF Laboratories, Lincoln's Inn Fields, London WC2A 3PX,
UK.
Cell division of the macrophage tumour M5076 is inhibited
by a variety of agents known to induce differentiation in
other tumours (Talmadge et al., Cancer Res., 42, 1850,
1982). The purpose of this study was to investigate the
relationship between this response to one such agent, TPA,
and the in vii'o behaviour of the cells.
A TPA resistant M5076 line (TPAR) was derived by
culturing cells continually in 500ngml-I TPA. Exposure of
the wild-type cells to 50ngml- 1 TPA for 24h inhibited
cellular proliferation by >95% as determined by [3H1-
thymidine (3H-TdR) incorporation, whereas TPAR cells were
still able to grow at I jigml 1. The doubling time of TPAR
cells in normal growth medium was 26h compared with 32h
for the parental cell line. Experimental metastatic activity
was determined by injecting 5 x 104 viable cells i.v. into
groups of syngeneic C57 mice (10 mice/group) and counting
liver tumour nodules 3 weeks later. M5076 cells produced a
median of 190 hepatic nodules (range 148-200). While pre-
treatment of the cells with 50ngml-I TPA for 24h resulted
in a median of 9 hepatic nodules (range 0-31). Numbers of
liver tumours resulting from TPAR cells were not reduced
(median 142, range 22-194) but their smaller size was
reflected by the lower liver weight (mean of 1.2g ivs. 2.3g for
livers from mice receiving M5076 cells). Similarly, the s.c.
injection of 105 viable cells of M5076 produced palpable
tumours within 2 weeks and a time to tumour weight of
0.7g of 4 weeks whereas tumours resulting from TPAR cells
were palpable at 3-4 weeks after injection and attained a
weight of 0.4g 7 weeks after s.c. injection. The basis of this
reduction of malignant capacity of TPAR cells is currently
under investigation.
Monoclonal antibodies to oncoproteins do not distinguish
between normal liver, hepatocellular carcinoma and
preneoplastic liver lesions in rats
M.J. Embleton & P.C. Butler
Cancer Research Campaiign Laboratories, University¢ of
Nottinighacm, Nottingham7 NG7 2RD, UK.
Fischer F344 rats were treated with a diet containing 0.06%
2-acetyl-aminofluorene (AAF), administered as a series of 2
week cycles separated by periods of carcinogen-free diet.
During 4 such cycles they developed various liver lesions
including cirrhosis, oval cell proliferation, foci of cells
containing raised levels of gamma-glutamyl transpeptidase
and hyperplastic nodules. Nine months after commencing
AAF diet they began to develop primary hepatocellular
carcinomas. Specimens of normal liver, tumour and
preneoplastic liver were frozen for histological study, and
both plasma membrane and total soluble extracts were
prepared from these tissues. A panel of murine monoclonal
antibodies to proteins coded by the nivc, mnb, r-as, sis, erb-B
and src oncogenes were tested for reactivity with cryostat
sections of normal liver, tumours and preneoplastic liver by
immunoperoxidase staining. Reactivity with tissue extracts
was tested by radio-immunoassay using 1251-labelled anti-
mouse Ig as second antibody.
The anti-oncoprotein antibodies produced variable
staining of normal liver sections, anti-myc and anti-myb
products reacting more strongly than the others. Hepato-
cellular carcinoma tissue and livers containing identifiable
premalignant lesions showed little difference from normal
liver, other than increased cellular heterogeneity within some
tumours. Radioimmunoassays indicated reactivity of all 6
antibodies with extracts of normal, preneoplastic and
neoplastic livers. There was a slight increase in reactivity of
anti-myc and anti-myb products with some tumour extracts,
but no major differences. It was concluded that conversion
from the normal to the malignant phenotype in rat liver was
not accompanied by gross changes in expression of oncogene
products detected by these antibodies.
Levels of soluble class I and class I-like molecules in sera from
mice bearing metastasising and non-metastasising tumours
M. Blackmore, S. Thompson & G.A. Turner
Department of Clinical Biochemistrj, The Medical School,
Framlington Place, Newcastle upon Tjne, NE2 4HH, UK.
Recently discovered truncated MHC class I molecules have
been implicated in the host response to cancer (Festenstein &
Garrido, Nature, 332, 502, 1986), and may be acting as
serum blocking factors that suppress the immune response.
We have developed a method to measure class I and class
I-like molecules in serum in order to investigate the
possible relationship between the blood levels of these sub-
stances and tumour growth and metastasis. Class I material
was partially purified from serum using lentil lectin coupled
to Sepharose, this extract was labelled with I125 and sub-
jected to immunoprecipitation using various antibodies.
Two groups of antibody have been used; group A recog-
nised classical K and D determinants, group B recognised
molecules that were similar to class I MHC but were
expressed on embryonal carcinomas. The immunoprecipitates
were analysed using ID-SDS/PAGE electrophoresis followed
by autoradiography. Using group A antibodies, molecules
of 39-42 K daltons were identified in serum from healthy
mice and animals bearing different types of tumour. The
levels of these molecules were elevated in the tumour bearers
and also appeared to be more marked if the tumours
metastasised. Using group B antibodies, extra molecules at
34 and 36 K daltons were seen. The 36 K molecule appeared
to be associated with liver metastasis, whereas the 34 K
molecule was elevated in certain tumour-bearers. These
results suggest that increased release of class I and class
I-like molecules is occurring into the blood of tumour bearing
mice; this process could have important consequences for the
understanding and treatment of cancer.
Somatomedin-C (Sm-C)/insulin-like growth factor I is a
mitogen for human small cell lung cancer (SCLC)
V. Macaulay, G.P. Joshi, J.D. Teale, M. Everard, I.E. Smith
& J.L. Millar
Department of Medicine, In.stitute of Cancer Research, Sutton,
Surrey and Department of Clinical Biochemistry, St Luke's
Hospital, Guildford, Surrey, UK.
Rapid proliferation in SCLC may relate to production of
autocrine growth factor(s). Bombesin-like immunoreactivity
(BLI) is secreted by and mitogenic to classic SCLC but not
the faster growing variant lines. Conditioned medium (CM)
from a classic SCLC line, HC12, underwent pressure
filtration yielding a high molecular weight (>10,000)
concentrate depleted of BLI. This preparation enhanced 3H-
thymidine uptake in 2 classic lines HC12, and HX149 over
PBS-supplemented controls; it was found to contain
immunoreactive Sm-C (200 ngml-1), prompting a survey of184 JOINT MEETING OF THE BACR AND THE ACP
human lung cell lines and tissues. Radioimmunoassay
revealed Sm-C (ngmg-1 protein) in all of 3 classic SCLC
lines (HC12 cells 266.7, CM 70.0; HX149 211.1, 60.0; NCI-
H69 150.0, 273.3), CM of one variant, ICR-SC17 (4.4, cells
0) and also in a large cell anaplastic lung line, HX147 (cells
242.5, CM 6.8); a myeloma line (RPMI 8226) was negative.
Sm-C was present in all of 4 SCLC tissue samples (mean
44.7+6.8; non-tumoural lung 20.0), including the biopsy of
origin of ICR-SC17. Large cell anaplastic tissue was positive
(40.0) as were 3 of 4 primary lung squamous carcinomas
(76.8+25.2) but 0 of 2 adenocarcinomas. We assessed the
effect of recombinant Sm-C (0.1-500ngml- 1) on 3H-
thymidine uptake: there was a clear response in 2 of 3 classic
SCLC lines and in one variant: maximal effects were seen in
HC12 at lOOngml -l (uptake 214% over control, P<0.01),
in HX149 at 300ngml-1 (193%, P<0.01), in NCI-H69 at
lOOngml- 1 (137%, NS) and in ICR-SC17 at 200ngml-1
(207%0, P<0.01). There was a similar effect in HX147
(242% at lOOngml-1, P<0.01) but no response in RPMI
8226. Sm-C may function as an autocrine growth factor in
SCLC. We plan to assess additional lung lines, and to
investigate mechanisms of mitogenicity in SCLC.
Comparison of the effects of a phorbol ester and mezerein on
the growth of A549 human carcinoma cells
I. Dale & A. Gescher
CRC Experimental Chemotherapy Research Group,
Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
The diterpene 12-0-tetradecanoylphorbol- 13-acetate (TPA)
exerts a wide range of effects on biological systems, ranging
from tumour promotion to growth inhibition, the latter
being sometimes the result of the induction of terminal
differentiation. As part of an attempt (i) to elucidate the
mechanism by which TPA exerts growth inhibition in the
human A549 lung carcinoma cell line and (ii) to characterise
structural features which confer growth-inhibitory potential
on the TPA molecule we investigated the effects of a
structurally related tumour promoter, the resiniferonol
derivative mezerein (MEZ) on these cells. Cells were
incubated with MEZ or TPA and counted after 5 days.
Additionally incorporation of 3H-thymidine into cells was
assessed 24h after addition of MEZ or TPA to the incubate.
Whereas the concentration of TPA which inhibited growth
or thymidine incorporation by 50% (IC50) was 0.1 nm the
IC50 for MEZ was 5nm. Maximal inhibition of thymidine
incorporation (80%) was achieved after 12 h incubation of
cells with either 10-7 M MEZ or 10-8 M TPA. After an
incubation period of 5-6 days, in which the growth of the
cells exposed to either MEZ or TPA was completely
arrested, cells began to grow again in the presence of either
tumour promoter at a rate similar to that of control cells.
However, on removal of the promoters the cells regained
their sensitivity towards the growth inhibitory potential of
MEZ or TPA. In conclusion, it appears that the growth-
inhibitory property of phorbol esters is also a feature of
other plant-derived tumour promoters. Nevertheless TPA is
a significantly more potent growth inhibitor in A549 cells
than is MEZ.
Epidermal growth factor receptors in colonic adenocarcinoma
M. Moorghen1, K.J. Finney', P.G. Incel, J.P. Sunterl, A.L.
Harris2 & A.J. Watson1
1Departments ofPathology and 2Clinical Oncology, University
ofNewcastle upon Tyne, UK.
demonstrated in a number of normal and neoplastic human
tissues. In this study, tissues obtained from colonic
carcinomas and non-neoplastic colonic mucosae were
investigated for the presence of EGF receptors. Radio-ligand
binding assays using 1-125 failed to show the presence of
EGF receptors in three tumours and their corresponding
normal mucosae. Immunoperoxidase studies, using EGF-Rl
antibody, performed on 8 cases showed positive staining of
both tumour and mucosa in 3 cases and positive staining of
the mucosa only in 2 cases.
These preliminary findings suggest that EGF receptors are
present at a relatively low frequency in human colonic
tissues. This contrasts with the findings of other workers
who have shown EGFr to be absent from human colon. In
rat colonic mucosa, EGF has been shown to act as a trophic
agent in an organ culture system, thus implying the presence
of EGFr.
Further experiments are being performed on larger
numbers to investigate the presence of EGFr and the effects
of EGF.
Epidermal growth factor receptors in human prostate cancer
S.Q. Maddy, G.D. Chisholm & F.K. Habib
Department ofSurgery, University of Edinburgh Medical
School, Teviot Place, Edinburgh EH8 9AG, UK.
Epidermal growth factors (EGF) are powerful mitogens
which stimulate cell division by binding to EGF-receptors on
cell surface membranes. Although EGF receptors have been
measured in benign prostatic hyperplasia (BPH) no one has,
so far, investigated their presence in cancer of the prostate
(CaP). Characterisation of EGF-receptors in CaP was
therefore carried out and the impact of cell differentiation on
receptor levels, investigated. In common with the BPH data
our ligand exchange assay on cancerous tissue demonstrate
the presence of two classes of receptors both of high affinity
(IO-9M) which are specific for EGF and are not displaced
by other growth factors. However, unlike BPH tissue, the
concentrations of EGF receptors in CaP were significantly
lower (P<0.05) and this seemed to correlate with the degree
of differentiation of the tumour: Well differentiated cancer
tissues exhibited high concentrations of the receptors
whereas in poorly differentiated tumours the receptors were
absent.
Immunocytochemical assays by means of an indirect
immunoperoxidase technique employing a murine
monoclonal antibody (donated by Dr M. Waterfield)
confirmed the data obtained by biochemical methods and
revealed a positive correlation between I12'5-labelled EGF
binding and the intensity of staining. Furthermore the
staining by the antibody was confined only to the basal
layers of epithelial cells whilst the adjacent stromal sections
remained clear. The long term implications of these findings
are not evident though obviously our data suggest that the
absence of EGF receptors in cancer might be in some way
related to tumour development.
An epidermal growth factor receptor (EGFr) in human bladder
cancer
K. Smith, J.A. Fennelly, D.E. Neal & A.L. Harris
Cancer Research Unit, University oJ Newcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
Epidermal growth factor receptors (EGFr) have been We have assayed EGFr in bladder cancers to see if theJOINT MEETING OF THE BACR AND THE ACP 185
presence of the receptor is related to the degree of tumour
invasion. Cell membranes and cytosols were prepared by
differential centrifugation and EGFr binding was assayed
using '251-labelled mouse EGF. The binding of EGF to
EGFr was linear with respect to protein concentrations and
was complete within 30min at 26°C. The rate constants of
association and dissociation were 0.903 x 109 M-1 min- and
0.05 min 1 respectively at 26°C. The binding was also
specific to EGF. EGFr cross-linked to EGF could be
visualised in 2 distinct bands (mol. wt. = 120,000 and
150,000) on fluorographs and in the presence of unlabelled
EGF the bands were not seen. Autophosphorylation of
EGFr was enhanced in the presence of EGF and when
exogenous Ca
' + was added, the intensity of the
120,000mol. wt. band was increased. EDTA inhibited
phosphorylation of both proteins. Using Scatchard analysis,
the number of binding sites (Bmax) and the dissociation
constant (Kd) were assayed in 37 bladder cancers. 15
patients had superficial transitional cell carcinoma and 22
patients had invasive transitional cell carcinoma. 6 of the
15 superficial tumours (40.0%) contained EGFr
(Bmax =8.5-32.4fmolmg- protein, mean of 14.6+3.6 s.e.).
The Kd values were 0.23-1.45 x 10-9Mm mean=
0.90+0.23 s.e. 16 of the 22 invasive tumours (72.7%)
contained EGFr (Bmax =8.9-1020fmolmg- I protein,
mean= 141.7+75.5 s.e.). The Kd values were 0.24-
2.38 x 10-9 M, mean =0.90+0.15 x 10 -9M s.e. The difference
in the amount of receptor between invasive and superficial
tumours was significant (P<0.01 Mann-Whitney Test).
Using radioimmunoassay and radioreceptor assays, we
detected ng amounts of EGF and EGF-like peptides in
bladder cytosols. The finding of a higher EGFr concen-
tration in more invasive tumours may suggest that EGFr
expression is related to tumour progression.
Multidrug resistance and anthracyclines
Inherent adriamycin resistance in a murine tumour line.
1: Circumvention with verapamil and norverapamil
S. Merry, D. Kerr, P. Flanigan, R. Milroy, R.I. Freshney &
S.B. Kaye
CRC Department ofMedical Oncology, University of
Glasgow, Glasgow, UK.
The calcium antagonist verapamil (VPM) has been
consistently shown to circumvent resistance to Adriamycin
(ADR) in a number of experimental tumour models in vitro
at concentrations of 5-10 UM. An ongoing randomised
clinical study in small cell lung cancer indicates that plasma
levels of up to 3gM VPM may be obtained without major
toxicity. The major metabolite of VPM is norverapamil
(NVPM) which we have found to be present in equimolar
concentrations in plasma. If NVPM were equally active in
the context of drug resistance the clinical potential of VPM
might be significantly improved. We have investigated the
ability of VPM and NVPM to circumvent inherent resistance
to ADR in the murine tumour line MOG-XMTI in vitro
using (a) monolayer cloning and (b) MTT reduction as end
points. Cloning was carried out with continuous exposure to
drugs and colonies > 16 cells were scored after 10 days. In
the MTT assay exponentially-growing cells were treated with
ADR+ VPM or NVPM for 24h and viability was assessed
after a recovery period of 96h in the absence of drugs. The
ID,0 for ADR as measured by cloning (34+5 nM; n=9) was
reduced 18-fold with 6.6gM VPM and 5-fold by 6.6gM
NVPM. The ID50 for ADR in the MTT assay (126+27nM;
n=3) was reduced 5-fold by either 6.6JM VPM or 6.6JM
NVPM. These data indicate that NVPM may have similar
activity to VPM in overcoming drug resistance. Our
preliminary data indicate that the effects of VPM and
NVPM are additive. Further studies to confirm this
observation are underway.
Cross-resistance patterns and protein alterations in drug
resistant sublines of EMT6 mouse tumour cells
P.R. Twentyman', G.L.E. Koch2, J.G. Reeve', N.E. Fox' &
K.A. Wright'
'MRC Clinical Oncology and Radiotherapeutics Unit and
2Laboratory ofMolecular Biology, Cambridge CB2 2QH,
UK.
A range of drug-resistant sublines of the EMT6 mouse
tumour cell line has been derived by continuous growth in
increasing conCentrations of cytotoxic drugs. Sublines are
now growing in adriamycin (ADM) (10jug ml-') vincristine
(VCR) (10yugml-'), colchicine (COL) (2ugml-1), Ro 31-
1215 (1215) (0.1 igml -) and methotrexate (MTX)
(10 ugml -1). Cross-resistance patterns have been studied
using a tetrazolium (MTT) colorimetric assay to measure
growth inhibition during continuous drug exposure. Cells
made resistant to ADM, VCR, COL or 1215 showed cross-
resistance to the other drugs in this group. The extent of
resistance to 1215 (or to aclacinomycin A) was, however,
considerably lower ( x 5-10) than it was to the other 3 agents
( x 20-100). These cells were all also highly resistant to VP16
( x 20-50) and to mitozantrone ( x 50-300) but not to
melphalan, CCNU or MTX. However, cells made resistant
to MTX also showed a small degree of resistance to ADM,
VCR and COL. These cells could be sensitised to ADM, but
not to MTX, using the calcium transport blocker, verapamil.
A monospecific antibody to the CP22 cytosolic calcium-
binding protein (Koch et al, FEBS Letters, 195, 275, 1986)
and immunoblotting have been used to quantify the presence
of this protein in the various cells. Cellular content of CP22
increased progressively during the development of ADM
resistance but dropped suddenly at the highest level of
resistance. Increased levels of CP22 were seen in some but
not all of the resistant lines and the amount did not predict
for the extent of resistance to any given drug. Further
studies using this antibody and also antibodies to the P-170
glycoprotein are in progress.
Evidence that multidrug resistance in Chinese hamster ovary
cells is associated with alterations in the endoplasmic reticulum
J.G. Reeve', G. Koch2 & P.R. Twentyman'
'MRC Clinical Oncology and Radiotherapeutics Unit and
2Laboratory ofMolecular Biology, MRC Centre, Cambridge
CB2 2QH, UK.
Analysis of microsomal membrane proteins from drug
resistant (CHRC5) and drug sensitive (AUXBI) Chinese
hamster ovary (CHO) cells by SDS gel electrophoresis
revealed, in addition to altered P-glycoprotein expression,
increased levels of a 92kDa protein in the fraction from
CHRC5 cells. The protein was identified as the major
glycoprotein, endoplasmin, by its reactivity with a
monospecific affinity-purified antibody to endoplasmin and
by its calcium-binding properties. Endoplasmin is localised
to the endoplasmic reticulum (ER) and is the same as one of
the major stress-related proteins GRP. Immunoblotting
analyses showed that overall expression of endoplasmin was
not altered but that the higher levels in CHRC5 microsomal
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membranes resulted from increased retention of the
glycoprotein by the microsomal fraction during subcellular
fractionation. These observations indicate that structural
changes in the ER which alter the orientation of vesiculation
upon disruption occur in drug resistant CHO cells and imply
that membrane changes associated with the resistant
phenotype are not confined to the plasma membrane.
Characterisation of a CHO cell line hypersensitive to
topoisomerase II inhibitors
C. Robson, S. Davies, P. Hoban, S. Davies, A. Harris &
I. Hickson
Cancer Research Unit, University ofNewcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
We have isolated a Chinese hamster ovary (CHO) cell line,
designated ADR-1, which exhibits hypersensitivity to a range
of drugs which are thought to inhibit the action of the
enzyme topoisomerase II. These include anthracyclines, other
classes of intercalating agents, and the epipodophyllotoxin
VP16 (etoposide). No significant sensitivity to radiation, or
to mono- and bi-functional alkylating agents, is seen,
although mild cross-sensitivity to the radiomimetic agent
bleomycin is observed.
We have monitored the level of DNA strand breaks
induced by topoisomerase II inhibitors in ADR-1 cells using
alkaline elution. At equimolar adriamycin (doxorubicin)
doses, more protein-associated DNA strand breaks are
induced in ADR-1 cells than in wild-type cells. This
enhanced level of drug-induced strand breaks is not a
function of increased drug uptake as both lines accumulate
similar levels of radiolabelled daunomycin. Both the rate of
repair of strand breaks and the final percentage of strand
breaks rejoined is equivalent in the 2 cell lines. These results
are consistent with there being an enhancement in the level
of topoisomerase II-dependent DNA breakage in ADR-1
cells following exposure to topoisomerase II inhibitors.
Topoisomerase II enzyme partially purified from ADR-1
cells shows altered activity in assays of both covalent binding
to duplex DNA and decatenation of kinetoplast DNA.
Hormonal enhancement of etoposide-induced DNA damage
and cytotoxicity in a breast cancer cell line
R.J. Epstein, P.J. Smith, J.V. Watson & N.M. Bleehen
MRC Unit, Clinical Oncology and Radiotherapeutics, MRC
Centre, Cambridge CB2 2QH, UK.
T47D human breast cancer cells were maintained in
charcoal-stripped medium and exposed to oestradiol at
various intervals prior to administration of etoposide (VP-
16), a topoisomerase-I1-interactive drug. DNA strand-
breakage measured by alkaline unwinding was 40% above
control levels after 4h of oestrogen exposure, and 85%
above controls after 24h exposure. Oestrogen pre-treatment
did not increase DNA damage induced by X-rays or
bleomycin; however, administration of another topoiso-
merase-1I-interactive agent, mitoxantrone, led to a similar
oestrogen-induced increase in damage to that witnessed with
etoposide. No change in rate of DNA repair could be
detected following either X-irradiation or etoposide
treatment of cells pretreated with oestrogen when compared
with controls. The degree of excess damage associated with
oestrogen pre-treatment was reduced by either 4-hydroxy-
tamoxifen or novobiocin co-administration, which is
consistent with an increase in topoisomerase II levels
accompanying oestrogen-induced cell activation. Moreover,
the excess damage documented on alkaline unwinding could
not be detected on nucleoid sedimentation, suggesting further
that the differential strand-breakage is protein-(topoiso-
merase II)-associated. Dose-dependent inhibition of cell
growth, clonogenicity and cell-cycle traverse varied directly
with the extent of DNA damage induced in both oestrogen-
treated and control cells, and analysis of these data suggest
the existence of a cellular subpopulation in which topoiso-
merase-1I-induced DNA damage may occur preferentially
following cell activation by oestrogen. These findings raise
the possibility that novel therapeutic strategies for
established human breast cancer may be feasible using
topoisomerase-I1-interactive drugs.
Comparative biodistribution of daunomycin-HSA-monoclonal
antibody conjugates with different chemical linkages
Y. Ogunmuyiwa, J.A. Clegg, M.V. Pimm, M.R. Price &
R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
The therapeutic effectiveness of drug-monoclonal antibody
conjugates will depend partly on their biodistribution since if
they are rapidly eliminated they are unlikely to reach the
tumour target. In this study daunomycin-carrier-monoclonal
antibody conjugates have been constructed with different
chemical linkages and their biodistributions assessed.
Initially daunomycin (daun) was conjugated to human
serum albumin (HSA) to molar substitution ratios of up to
20:1 either by reaction with 14-bromo-daunomycin to give a
C-N bond between the 14-C of the drug and protein amino
groups, or by reaction of succinylated HSA with the 14-
bromo-daunomycin to give a succinyl ester linkage.
Subsequently these dauno-HSA conjugates were linked to
the 791T/36 monoclonal antibody via a thioether linkage at
a 1:1 HSA:antibody molar ratio. For biodistribution studies
the protein moieties of the dauno-HSA or dauno-HSA-
791T/36 conjugates were labelled with radioiodine (1251 or
1311) and blood survival and biodistribution in mice
compared with radio-iodine labelled HSA, succinylated HSA
HSA-791T/36 and 791T/36 alone. With the 14-C linked
conjugates, blood survival of dauno-HSA, and dauno-HSA-
791T/36 were similar to those of HSA or antibody. Blood
contained more radiolabel than any other organ, the
survivals at 24h being 27% for 791T/36 antibody, 19.1% for
HSA and 20.4% for dauno-HSA-791T/36. In contrast, with
the succinyl ester linkage, dauno-HSA and dauno-HSA-
791T/36 were rapidly cleared from the blood, particularly to
liver and spleen so that blood survivals were <I % at 24h.
Succinylated HSA without drug was similarly cleared, with
survival <1% after 24h.
These studies have demonstrated that the biodistribution
of dauno-carrier-antibody conjugate is markedly dependent
upon their chemical linkages. This is probably related at
least in part to the overall charge on the molecule. The
conjugates with the 14-C linkage would have a net positive
charge and these survived, whereas succinyl ester linked
conjugates would have a net negative charge which
encourages clearance by phagocytic cells.JOINT MEETING OF THE BACR AND THE ACP 187
Anthracycline structure-activity relationships in human lung
spheroids
D.J. Kerr, T.E. Weldon & S.B. Kaye
Department ofMedical Oncology, Glasgow University and
Radiobiology Group, Belvidere Hospital, Glasgow, UK.
Penetration barriers have been demonstrated for adriamycin
in multi-cellular tumour spheroids. Adriamycin enters the
cell by diffusion of the electroneutral molecule through the
lipid domain of the cell membrane and we have hypothesised
that lipophlic anthracycline analogues would tend to diffuse
further into solid tumour masses, with improved cytotoxic
efficacy. The activities of adriamycin, 4'-deoxydoxorubicin,
Daunorubicin, 4-demethoxydaunorubicin, 4'-deoxy, 4'-
iododoxorubicin have been assessed by clonogenic assay (L-
DAN line) in monolayers and growth delay in L-DAN
spheroids. Intracellular anthracycline levels were measured
after exposure to each of these drugs (varying concentrations
for 1 h) by an HPLC assay. These is a significant correlation
(P<0.05) between log oil-water partition co-efficient and log
intracellular drug levels and log spheroid growth delay but




ID90 delay Oil-water drug conc.
Drug (pgml-') (pgml-') (coefficient) (ng 10-cells)
Adriamycin 2.2 10 6.3 14
4'-Deoxy-
doxorubicin 2.3 0.6 15 154
Daunorubicin 1 0.68 17.8 170
4-Demethoxy-
daunorubicin 0.1 0.05 32.3 400
4'-Deoxy-4'-Iodo-
doxorubicin 0.007 0.004 126 1961
Protein microspheres as carriers for adriamycin: Comparison
of potency and drug-loading characteristics
N. Willmott', Y. Chen', J. Cummings2 & A.T. Florence'
'Department of Pharmacy, Universityl ofStrathcli'de, Glasgow
and 2Department oJ Medical Oncology, University ofGlasgow,
Glasgow, UK.
Since the initial descriptions of the preparation of protein
microspheres (MS) albumin has been most frequently used
as drug carrier. However, whether its properties are optimal
for the role of carrier matrix is unknown. Consequently, we
have prepared, by glutaraldehyde stabilisation, adriamycin
(Adx)-loaded protein MS using albumin (9 +2.8 jig
Adxmg-; n=5) and casein (3.1 + I jug Adxmg -; n=6) as
matrix material. We have also developed systems in which
Adx is incorporated into albumin MS via a non-covalent
complex with polyaspartic acid (30.5 + 5.8 jig Adx mg- ;
n=4). Incorporated drug potency was asscssed following
direct injection into SC growths of the non-immunogenic rat
mammary carcinoma SplO7. It was observed that both
albumin (85 jgAdx) and casein (11 pg Adx) systems exerted
marked inhibition of tumour growth (GD= 18.6 and 20.7
days respectively), whereas albumin/polyaspartic acid MS
(121 jig Adx) were less active (GD=4.5 days). To explain
these results the state of Adx in microspherical form was
examined by HPLC with multidiode array spectrophoto-
metric detection. This technique revealed that, in addition to
pure Adx, a chromatographically distinct Adx-derived
species was present in albumin and casein MS. In
albumin/polyaspartic acid MS Adx was present only in
native form, possibly due to its inability to react with
glutaraldehyde when complexed with polyaspartic acid.
These studies reveal the protean nature of Adx incorporated
into albumin and casein microspheres and are consistent
with the presence of an Adx conjugate (probably with
protein), the presence of which correlates with potency in
this system.
Tumour markers
Cellular and serum carcinoembryonic antigen levels in
colorectal cancer
L.G. Durrant', K.C. Ballantyne2, R.A. Robins', D.
Henson3, R.W. Baldwin' & J.D. Hardcastle2
1Cancer Research Campaign Laboratories and Departments of
2Surgery and 3Biochemistry, Universiti, of Nottingham,
Nottingham NG7 2RD, UK.
Carcinoembryonic antigen (CEA) is expressed by -80% of
colorectal cancers (CRC). However serum CEA levels are
raised in under 50% of patients with primary CRC.
Preoperative serum CEA in 66 patients with primary CRC
(42 men, 24 women) was compared with a quantitative
assessment of tumour cell CEA expression, histological
tumour grade, pathological stage and maximum tumour
diameter. Eight tumours were well differentiated, 46
moderately and 12 poorly differentiated. Twelve were Stage
A tumours, 26 Stage B, 16 Stage C and 12 Stage D. Serum
CEA was measured by radioimmunoassay. Tumour cell
CEA expression was measured by flow cytometry on
disaggregated primary tumour cells using 3 anti-CEA
antibodies and the results expressed in fluorescence units
(FLU) for each tumour. Serum CEA levels were elevated
(>lOmmoll-') in 23 patients (34%). However, 92% of
tumours expressed CEA at a cellular level. Mean tumour
fluorescent +s.e. (Fl U): anti-CEA=848 +85.5 normal
mouse immunoglobulin (control) 46.5 +3.9 (t=9.4;
P<0.0001).
Serum CEA levels did correlate with pathological stage
and maximum tumour diameter (P<0.001). Since most
colorectal cancers express CEA at a cellular level elevated
serum levels of CEA are a reflection of tumour load.
Mapping of monoclonal antibody-defined epitopes on
carcinoembryonic antigen, CEA
M.R. Price, P. Tighe & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
The reactivity of a panel of 10 anti-CEA monoclonal
antibodies with CEA molecules was analysed using a variety
of test procedures. These tests were designed to explore
possible relationships between antibody-defined epitopes in
order to construct an epitope map of the molecule.
Assay procedures included indirect radioisotopic anti-
globulin tests using CEA and the normal tissue component,
NCA as target antigens, and double determinant
('sandwich') immunoassays which evaluate both the co-
expression of pairs of epitopes defined by different
antibodies and their topographical relationships on the CEA
molecule. The latter relationships were also analysed by188 JOINT MEETING OF THE BACR AND THE ACP
'cold' antibody inhibition of radiolabelled antibody binding
to CEA. Further classification of epitopes was achieved by
determining their lability to various chemical, physical (heat)
and enzymic treatments.
The epitope map prepared permits the selection of
antibodies which react independently with the epitopes on
CEA molecules so that these may be employed for the more
effective in vivo targeting of diagnostic radioisotopes or
therapeutic agents (cytotoxic drugs, or plant or bacterial
toxins) to the tumour.
The biological and prognostic significance of DNA ploidy in
colorectal cancer
D.J. Jones1' 2, D. Haran3, M. Moore' & P.F. Schofield2
'Paterson Institutefor Cancer Research and 2Department of
Surgery and 3Department ofEpidemiology and Social
Research, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
There is a certain lack of unanimity on the prognostic
significance of DNA ploidy in colorectal carcinoma, which is
apparent from the different aneuploidy rates (14-67%) in
various published studies (Perrez et al, Br. J. Cancer, 43,
526, 1981; Rognum et al ibid, 45, 921, 1982; Woolley et al, J.
Natl Cancer Inst., 69, 15, 1982), and from the interpretation
of the biological significance of the phenomenon. 119
consecutive patients presenting from 1981-83 were
prospectively studied. DNA ploidy status was determined by
flow cytometry according to the method of Hedley et al., (J.
Histochem. Cytochem., 31, 1333, 1983). 39 (33%) were DNA
diploid and 80 (67%) DNA aneuploid. 67% of patients with
DNA diploid tumours survived 3 years compared with only
35% of those with DNA aneuploid tumours (P=0.007).
When DNA ploidy status was included in a Cox regression
analysis with clinicopathological features, only achievement
of 'curative resection', Dukes' stage and age were of
independent prognostic significance. DNA index varied
randomly between tumours, but was constant within an
individual tumour. If an aneuploid population was detected
in a lymph node metastasis, it invariably had the same DNA
index and prognosis, but there was an inverse relationship
between the proportion of aneuploid cells and survival.
DNA aneuploidy was not a prerequisite for malignant
behaviour and the presence of a detectable aneuploid
population did not necessarily result in a highly malignant
phenotype. DNA aneuploidy is probably thus an
epiphenomenon, reflecting genetic diversity among neo-
plasms as distinct from malignant status per se.
Flow cytometry and the rat model of azoxymethane-induced
colonic neoplasia
G.V.N. Appleton', P. Quirke2, M.F. Dixon2, C.C. Bird2 &
R.C.N. Williamson'
IUniversity Department ofSurgery, Bristol Royal Infirmary,
Bristol BS2 8HW and 2Department ofPathology, University
ofLeeds, UK.
The rodent model of azoxymethane-induced colonic carcino-
genesis is helpful in the study of human colorectal cancer.
We have used flow cytometry to investigate the presence of
DNA aneuploidy in rat intestinal tumours, and to evaluate
the rat model as an experimental system. Fifty male
Sprague-Dawley rats weighing 185+9.2g were given azoxy-
methane 15mgkg - 1 week -1 s.c. for 6 weeks and then
underwent 80% small bowel resection (n =25) or jejunal
transection (n=25). Half the animals in each group had
calcium lactate 24g1 1 added to the drinking water. Ten
further non-operated rats (NOP) received azoxymethane 10
days later than the others. 43 rats survived 26 weeks and
yielded 149 colonic and duodenal tumours of which 140 were
measurable by flow cytometry. The incidence of DNA
aneuploidy was 43% in NOP which was higher than in rats
with resection (9%: P<0.0005) or transection (24%:
P<0.0005). There was no significant difference in the
prevalence of DNA aneuploidy between adenomas (32%)
and carcinomas (17%) or between calcium treated (11%)
and non-calcium groups (12%). However metastases were
more commonly DNA aneuploid than the primary tumours
(62% vs. 20%: P<0.005). DNA aneuploidy is present in rat
intestinal tumours and levels can vary widely with
manipulation of the model. Metastases are associated with a
high incidence of DNA aneuploidy.
Electrophoretic studies on protein extracts from normal,
diseased and malignant human tissue
R.C.Y. Ng, A.L. Latner & G.A. Turner
Department ofClinical Biochemistry, The Medical School,
The University ofNewcastle upon Tyne, Newcastle upon Tyne
NE2 4HH, UK.
It is frequently difficult to diagnose the severity of cancer;
there is a need to develop additional tests to help clinicians
plan therapy. Analysis of protein composition in tumour
biopsies represents one approach to this problem. Healthy,
diseased and malignant human tissue biopsies from the
breast, cervix and gastrointestinal tract were extracted with
Triton X-100. Their protein and glycoprotein composition
were investigated using 1D-electrophoresis in SDS-containing
gradient polyacrylamide slab gels (Laemmli, Nature, 227,
680, 1970) followed by Coomassie blue (CB) staining and the
binding of radio-iodinated wheat germ agglutinin (WGA)
(Burridge, Proc. Natl Acad. Sci., USA, 73, 4457, 1976). All
results were examined with reference to histopathology. For
some tumours, comparisons were made between extracts of
the malignant and the healthy or non-malignant tissue of
adjacent areas. After CB staining, extracts from the
malignant tissues showed more electrophoretic bands when
compared with extracts from the control tissues. A particular
consistent change was the appearance of extra band(s) at
50 kd. After staining with radiolabelled WGA, the auto-
radiographs indicated that certain glycoproteins in the
molecular weight range 40-60kd were much reduced in the
malignant extracts. These changes were consistently observed
for all the different types of tumour studied, and suggest that
this type of analysis may be very useful for diagnosis and
prognosis in cancer
Age-related cell surface proteins of human astrocytoma and
mammary carcinoma in culture: Unique age- and tumour
grade-related proteins in astrocytomas
G. Hunt & G.V. Sherbet
Cancer Research Unit, University ofNewcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
The cell surface protein patterns of primary cultures of 10
human malignant astrocytomas have been investigated and
the protein patterns related to the age of the patients.
Cultures of 5 fibroadenomas and 5 carcinomas of the breast
were also examined. In the carcinomas, the expression of 3JOINT MEETING OF THE BACR AND THE ACP 189
groups of proteins with mol. wt. 63 kd (p63), 48kd (p48) and
32 kd (p32) was found to be age-related. No age-related
proteins were found in the fibroadenoma cultures. There
were 4 age-related proteins on the surface of the astrocytoma
cultures: 75 kd (p75), p63, p48 and p32. The age-related
expression of p75, therefore, appears to be unique to
astrocytomas. Of the age-related proteins, tumour grade
influenced the levels of p75 only; grade III tumours showed
lower levels than grade IV tumours. Although not age-
related, the expression of a protein group of mol. wt. 148 kd
(p148) was greatly increased in the astrocytomas as
compared with normal glial cells. The expression of p148
was strongly influenced by tumour grade, grade III tumours
showing lower levels than grade IV tumours. The expression
of these age- and tumour grade-related proteins may be of
significance in view of the reported patterns of age- and
tumour grade-related resistance of malignant glioma to
BCNU.
Two abnormally fucosylated proteins in cancer sera: Markers
of tumour burden and of response to therapy
S. Thompson', D. Guthrie2 & G.A. Turner'
'Department of Clinical Biochemistry, The Medical School,
Newcastle upon Tyne NE2 4HH and 2Department of
Radiotherapy, Newcastle General Hospital, Newcastle upon
Tyne NE4 6BE, UK.
We recently reported a markedly increased level of a diffuse
40-45 Kd band in cancer sera following electrophoresis of
fucoprotein extracts from normal and cancer sera. This band
being subsequently identified as additional forms of
fucosylated haptoglobin #-chains. In an attempt to determine
whether the levels of these haptoglobins correlated with
tumour burden, fucosylated haptoglobin was measured in
sera from ovarian cancer patients who were receiving chemo-
therapy. Increased fucosylated haptoglobin correlated well
with the extent of tumour burden in all 8 patients who were
examined; decreasing as the patients went into remission and
increasing as the tumour recurred.
During these latter experiments another fucosylated
protein of -58 Kd (later identified as a fucosylated form of
x1-antitrypsin) was discovered. Initially, this marker
appeared to be related to the recurrence of cancer. Patients
who had responded to therapy had low levels of this 58Kd
molecule, even when the initial tumour burden was high.
This low level was maintained throughout remission and
only became elevated when there was a recurrence of tumour
growth. However, further studies on 7 patients who did not
respond to therapy revealed elevated levels of this 58 Kd
component throughout the period of treatment. The presence
of this marker can therefore be used to determine if a patient
will not respond to treatment. It would seem possible that
we have discovered a new group of serum markers that may
be useful for developing better methods to monitor the
progress of cancer.
Use of prostate specific antigen assay in the baseline
assessment of patients with advanced prostate cancer
L.A. Emtagel, P.W. Lewis2 & G.R.P. Blackledgel
'Cancer Research Campaign Clinical Trials Unit, Queen
Elizabeth Hospital, Edgbaston, Birmingham BJ5 2TH and
2The General Hospital, Birmingham B4 6NH, UK.
104 patients entering a randomised study comparing ICI
Zoladex 3.6 mg with stilboestrol 3 mgday - were assessed
prospectively using an immunoradiometric assay of prostate
specific antigen (PSA) (Hybritech-Europe) as well as the
usual clinical and biochemical assessments of disease extent.
All the patients had either locally advanced or metastatic
carcinoma of the prostate. All assessments were carried out
prior to therapy. Analysis was made of these entry data.
Using a cutoff point of lOngml-l PSA, the assay gave
92/104 (88.5%) positive values, compared with 68/104 (65.4%)
for AP. This difference was highly significant (x2 =9.77,
P<0.01). Taken together, PSA and AP gave 95/104 (91.4%)
high values. This was not significantly different from PSA
alone.
In the asymptomatic group, 7/36 (19.4%) had a normal
PSA, compared to 17/36 (47.2%) for AP. Of those with
symptoms, 5/68 (7.4%) had a normal PSA, compared to
19/68 (27.9%) for AP. In those with local disease, 8/36
(22.2%) had a normal PSA compared to 20/36 (55.5%) for
AP. In those with bone metastases, 4/68 (5.9%) PSA assays
were normal, but 16/68 (23.5%) AP were normal. Com-
parison of PSA against total alkaline phosphatase (ALKP)
in those with bone metastases showed a normal PSA in 4/68
(5.9%), but a normal ALKP in 19/68 (27.9%). All of these
differences were statistically significant.
The assay is reproducible, and PSA is a better marker of
disease extent in advanced prostate cancer prior to treatment
than either acid phosphatase measured enzymatically or total
alkaline phosphatase in those with bone metastases. Further
studies are underway to determine its value in the
monitoring of patients with advanced prostate cancer.
Immunology
Altered class 1 antigen expression, NK cell sensitivity and
metastatic capacity of melanoma cells induced by interferon-y
T.J. McMillan, J. Rao, C.A. Everett & I.R. Hart
ICRF Laboratories, Lincoln's Inn Fields, London WC2A 3PX,
UK.
We found that IFN-y has a direct effect on malignant
tumour cells such that treated cells form an increased
number of experimental metastases following i.v. injection
into recipient mice.
B16-Fl murine melanoma cells were treated in vitro for
48 h with 1000 Uml - recombinant IFN-y. Intravenous
injection of 5 x 104 tumour cells into syngeneic mice resulted
in a median of 87 (range 70-99) lung tumour nodules
compared with 3 (range 0-15) in mice receiving untreated
control cells. A similar increase was seen when cells were
injected into athymic nude mice (medians of 3: range 0-8 for
control cells and 28; range 19-49 for IFN-y treated cells) but
not when the same cells were injected into NK-cell-deficient
beige nude mice.
Cells were analysed for class 1 antigen expression by
FACS analysis. IFN-y treatment increased H-2 antigen
expression with KbDb expression rising from 5% of controls
to 99% of treated cells.
We have found, like Taniguchi et al. (Int. J. Cancer, 36,
503, 1985), an inverse correlation between H-2 class I
antigen expression and sensitivity to NK cells. Splenic NK
cells were less effective in vitro against IFN-y treated cells
than against untreated controls. (0% cytoxicity versus 28%
cytotoxicity at 200:1 effector: target cell ratio).
These results are consistent with the possibility that IFN-y
pretreatment increases experimental metastatic capacity of
melanoma cells by decreasing their NK cell sensitivity. This
effect could be associated with the alteration of H-2 class I
antigen expression since NK cells may serve to recognise
cells deficient in these antigens (Karre, K. et al. Nature, 319,
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Differential expression of HLA antigens on colorectal tumours
A.M. Buckle', G. Jacob2, K. Rogers2, V. James3,
C.W. Potter' & R.C. Rees'
'Department of Virology, University ofSheffield Medical
School, Beech Hill Road, Sheffield S1O 2RX, 2University
Department of Surgery, Northern General Hospital, Sheffield
and 3Blood Transfusion Centre, Longley Lane, Sheffield, UK.
We have studied the expression of specific HLA antigens on
colorectal carcinomas and colonic epithelium to identify
phenotypic differences which may be associated with the
acquisition of malignant potential. Serial frozen sections of
30 human colorectal carcinomas and adjacent, normal
colonic epithelium were stained with the monoclonal
antibodies NFKI and W6/32 using an indirect immuno-
peroxidase technique. NFK1 recognised a monomorphic
determinant expressed on HLA class II DP, DQ and DR
antigens, and W6/32 recognises a framework determinant of
class I, A, C and C heavy chain. Individual class I, A and B
locus antigens were studied using antibodies against A2 and
Bw4 specificities. NFKI staining revealed areas of class II
positive malignant cells in 14/30 tumours and 0/30 of the
surrounding mucosa (P<0.001 Chi squared). W6/32 staining
revealed areas of class I negative epithelium in 7/30 tumours
and 0/30 of the surrounding mucosa (P<0.001). Loss of
individual A and B locus antigens was demonstrated in
tumours with W6/32 class I positive epithelium.
The altered expression of HLA antigens was confined to
small areas within tumours and confirms the hypothesis of
tumour heterogeneity but its exact relationship to the
metastatic process is unclear and warrants further
investigation.
Potentiation of immunotoxin activity in vitro and in vivo
S.A. Eccles' & D.P. McIntosh2
'Section ofMedicine, Institute of Cancer Research, Sutton,
Surrey and 2Chester Beatty Laboratories, Fulham Road,
London SW3 6JB, UK.
Current attempts to develop selective anti-tumour agents
include the coupling of plant toxins (or their isolated A
chains) to monoclonal antibodies with specificity for tumour
cells; however not all antibody-A chain conjugates are
effective. One such immunotoxin, comprising a tumour-
specific monoclonal antibody (1 I/160) linked to ricin A
chain, was inactive in in vitro cytotoxicity assays against
HSN,C rat sarcoma target cells. However, addition of ricin B
chain as a second-stage reagent resulted in an immuno-
specific cytotoxicity comparable with that of ricin. In vivo
studies have shown that i.v. inoculated B chain can also
potentiate growth inhibition of conjugate-coated tumour
cells in syngeneic rats: Tumour incidence at s.c. sites was
reduced to 75% or 30% by 15pg or 150,ug B chain
respectively, and lung colonisation was similarly inhibited in
a dose-dependent manner. Thus systemically administered
ricin B chain is capable of gaining access to antibody-A
chain conjugates bound to the surface of sarcoma cells in
subcutaneous and pulmonary sites, at concentrations
sufficient for a significant therapeutic effect.
Cyclosporin A inhibits the immune response to a mouse
monoclonal anti-tumour antibody in rabbits
J.A. Ledermann, R.H.J. Begent, F. Searle T. Adam &
K.D. Bagshawe
Cancer Research Campaign Laboratories, Charing Cross
Hospital, London W6 8RF, UK.
In a study of 15 patients given 2.5mg of 131I polyclonal
sheep or goat antibody against carcino-embryonic antigen
for therapy of advanced colorectal cancer 9/15 (60%)
developed human anti-antibodies measured by ELISA. For
effective tumour therapy anti-tumour antibodies need to be
given on several occasions. The presence of anti-antibodies
increases the clearance of the anti-tumour antibody and can
lead to severe hypersensitivity reactions if therapy is
repeated. We examined methods of inhibiting the immune
response to xenogeneic antibodies in rabbits, using the
immunosuppressive agent cyclosporin (CyA). The
immunogen was 200,g of the mouse monoclonal anti-
human chorionic gonadotrophin antibody, injected i.v. The
antibody was prepared from ascites and immunopurified.
Some animals were given antibody which had been
'deaggregated' by ultracentrifugation. The CyA, 20mgkg-I
i.m. was given for 6 days starting day - 1 and this regimen
was repeated when the animals were re-challenged at 14
days. In those animals given CyA the clearance of the
antibody was significantly prolonged and the rabbit anti-
mouse antibody response measured by ELISA was suppressed
in 8/8 animals given 'deaggregated' antibody and 6/8 given
the standard preparation. 'Deaggregated' antibody alone did
not inhibit the immune response.
These experiments indicate that CyA may be a suitable
agent to inhibit the anti-antibody response in humans to
xenogeneic antibodies used for tumour therapy.
The effect of human recombinant tumour necrosis factor
(rHuTNF) and rat gamma interferon (rIFN-y) on
nitrosomethylurea (NMU) induced rat mammary tumour
growth
P. Shah & R.C. Coombes
Ludwig Institute for Cancer Research, St George's Hospital
Medical School, Cranmer Terrace, London SWI 7 ORE, UK.
The NMU and DMBA rat mammary tumour models are
well established as in vivo systems for testing antitumour
activity of drugs. We therefore used the NMU-induced
primary tumour model to study the effects of rHuTNF and
rIFN-y on mammary tumour growth.
An inbred strain of female Ludwig/Wistar/Olac rats with
NMU-induced mammary tumours were randomized to either
treatment or control groups, each containing 12-18 animals.
Treatment groups received either 50,pg rHuTNF and 30,000
units rIFN-y as a combined dose or 100pg TNF alone:
control groups received saline. Tumour growth was
monitored twice weekly for 4 weeks.
Tumour size in control groups increased almost linearly
over this period. Treatment with a combined dose of rIFN-y
and rHuTNF reduced tumour growth with 44% regression
after 4 weeks. If rHuTNF was administered alone initial
tumour regression was noted in the first week (-25%) after
which the tumours appeared to regrow at rates similar to
that of control animals, ylFN alone had no effect. Evidence
from in vitro cell culture studies suggests that rIFN-y can up-
regulate TNF receptors.
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of rHuTNF and rIFN-y are effective in causing tumour
regression after a single dose, whereas each agent alone has
little or no effect. This may indicate that the combination
may be active in human breast cancer and studies are
underway to determine this.
Suppression of human granulocyte/macrophage colony
formation in vitro by natural killer cells
A.M. Dickinson, E.A. Jacobs, M.M. Reid & S.J. Proctor
Department ofHaematology, Royal Victoria Infirmary,
Newcastle upon Tyne NE] 4LP, UK.
The effect of natural killer (NK) cell activity in normal
human bone marrow on autologous granulocyte/macrophage
colony forming activity has been investigated. NK activity
was demonstrated against 51Cr labelled K562 cells in all 7
marrow samples tested (9.1+1.2% 51Cr release in 4h) and
could be significantly increased by pre-incubation of bone
marrow mononuclear cells with xIFN (18.9 +2.6). Bone
marrow pre-incubated with ocIFN produced significantly
fewer colonies in bone 7 day (29+12/105 cells) and 14 day
(38 +14/105 cells) colony assays compared with untreated
marrow (88 +36/105 cells and 128 +32/105 cells respectively).
Removal of active NK cells by Leu llb and complement
lysis in vitro significantly increased the number of colonies
observed in day 7 and day 14 assays (P<0.01). These results
support the suggestion that NK cells have a role in vitro in
the inhibition of granulocyte/macrophage colony formation
and pose the question as to their involvement in bone
marrow graft recovery following in vivo bone marrow
transplantation.
Drug resistance and alkylating agents
Elevation of glutathione S-transferase activity in aLkylating
agent-resistant cell lines
A.T. McGown & B.W. Fox
Paterson Institutefor Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
The glutathione S-transferase (GS-T) enzymes are known to
be involved in the deactivation of a wide variety of electro-
philic species within the cell. The activity of these enzymes
has been measured in cell extracts from parental Yoshida
sarcoma cells (YS) together with cell lines which have been
made resistant to the alkylating agents cyclophosphamide
(YR cyclo), busulphan (YR bus), and methylene dimethane
sulphonate (YR 8), by incremental challenge with the
relevant drug in vitro. Glutathione S-transferase activities
were determined spectrophotometrically using 1-chloro-2, 4-
dinitrobenzene (CDNB) and glutathione as cosubstrates. The
resistant cell lines all show elevated GS-T activities compared
with the parental cell line. The levels of elevation are 4-fold
for the YR bus and YR 8 cell lines, and 6-fold for the YR
cyclo cell line. All three alkylating agents can inhibit GS-T
activity against CDNB. It is proposed that a part of the
resistance mechanism operating in these cell lines is due to
an increased deactivation of alkylating species by the
elevated levels of GS-T enzymes. This may also account for
the cross resistance observed between these cell lines and
alkylating agents, as well as the decreased damage to cellular
DNA, as measured by alkaline elution and inhibition of
DNA synthesis, observed in the resistant cell lines.
The relative effectiveness of alternative platinum complex
drugs in the experimental chemotherapy of human tumour
spheroids
J. Russell, J. Adam, T.E. Wheldon & S.B. Kaye
Glasgow Institute ofRadiotherapeutics and Oncology,
Belvidere Hospital, Glasgow G31 4PG andDepartment of
Medical Oncology, University ofGlasgow, UK.
Cis-platin is a potent anticancer drug whose use is restricted
by toxicity. Less toxic analogues (JM8, JM9) have recently
been introduced but their anti-tumour potencies are not yet
well established. We have compared the cytotoxic activities
of cis-platin, JM8 and JM9 by assessing growth delay in
multicellular spheroids derived from human tumours. A
neuroblastoma line (NB1-G) and one derived from non-
small-cell lung cancer (L-DAN) were used. L-DAN was
found to be about ten times more resistant (in terms of
concentration) to both JM8 and JM9 than cis-platin. NBI-G
was 10 x more resistant to JM9 but 40 x more resistant to
JM8 than to cis-platin. The clinical effectiveness of JM8 and
JM9 may depend on whether they can be safely used at such
enhanced concentrations.
Immunochemical detection of cis-platin-DNA adducts in
human testicular and bladder tumour cell lines
P. Bedford' 2, A.M. Fichtinger-Schepman3, J.R.W. Masters2
& B.T. Hill' 2
1Imperial Cancer Research Fund Laboratories, Lincoln's Inn
Fields, London WC2A 3PX; 2Institute of Urology, Endell
Street, London WC2H 9AE, UK and 3Medical Biological
Laboratory, TNO, 2280 AA Rijswijk, The Netherlands.
Polyclonal antisera raised to synthetic platinated nucleotides
coupled to bovine serum albumin were used to quantitate
four Pt-DNA-adducts in DNA extracted from two human
teratoma cell lines (SUSA; 833K), a subline derived by
fractionated X-irradiation (SUSA-DXR10) and a bladder
carcinoma cell line (RTI 12), each exposed for 1 h to
20pgml- I cis-platin. Digested DNA was separated on an
anion exchange column and adducts measured by
competitive ELISA. The following adducts were detected:
cis-Pt(NH3)2d(pGpG) [Pt-GG], cis-Pt(NH3)2d(pApG),
monofunctionally platinated DNA: Pt(NH3)3dGMP and an
adduct derived from DNA interstrand crosslinks and
intrastrand crosslinks between guanines separated by
intervening bases: cis-Pt(NH3)2d(GMP)2. The major adduct
was Pt-GG (70%-80%) and whilst the overall distribution of
adducts was similar in all lines, the total amount of
platination varied considerably, for example:





The possibility exists that differences in induction and repair
of Pt-DNA adducts might be related to the differential
sensitivities of these lines to cis-platin.
Determination of urinary alkylated nucleic acid bases by
immunoassay
D.E.G. Shuker
International Agencyfor Research on Cancer, 150 cours
Albert-Thomas, 69372 Lyon Cedex 08, France.
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(e.g. 7-alkylguanine, 3-alkyladenine) which are subsequently
released by glycosylases and excreted in urine. The simple
and reliable determination of such alkylated bases in human
urine could be used in 'molecular epidemiology' studies to
evaluate carcinogen exposure. However, the determination of
low molecular weight adducts (e.g. methyl, ethyl, etc) of
urinary purines by procedures such as immunoassay have
hitherto been unsuccessful.
A new approach has been developed which enables
antibodies to be raised which recognise such adducts.
A novel analogue of 3-methyladenine (3-MeA) containing
a carboxyl group was covalently conjugated to methylated
BSA (7 moles hapten per mole of carrier). After following a
standard immunisation schedule in rabbits, antisera were
obtained which recognised, at high dilution, 3-MeA
conjugated to keyhole limpet haemocyanin (KLH).
Preliminary experiments indicate that the free base, 3-MeA,
is also recognised by the antisera. A quantitative assay for
urinary 3-MeA is currently being developed using a
competitive ELISA technique.
A similar protocol is also being used for other alkylated
adenines and guanines.
In vivo sensitization of nitrosourea resistant Lewis lung tumour
cells to MeCCNU, by pretreatment with MNU
T.C. Stephens, J. Eady, J.H. Peacock, G. Harris &
P.D. Lawley
Institute of Cancer Research, Surrey, UK; ICI
Pharmaceuticals Division, Cheshire, UK and Kennedy Institute
ofRheumatology, London, UK.
Mice bearing wild-type Lewis lung tumours and a MeCCNU
resistant subline, were treated sequentially in vivo with a
mono- and a bi-functional nitrosourea (MNU and
MeCCNU respectively) to test the effect of combined
treatment with these agents. MNU (10 or 30mgkg - was
administered 2h before MeCCNU (5 to 15mgkg-1) and the
response of tumours was measured 24h later using an
excision clonogenic assay. With the wild-type tumour, both
agents were active, and the combined drug effect was simply
additive. However, in the nitrosourea resistant tumour line,
MNU had very little effect alone, yet cell killing due to the
combination was much greater than additive. Biochemical
studies with radiolabelled MNU have suggested that
nitrosourea resistance was due to over expression of the
repair psuedo-enzyme, 06-methylguanine-DNA methyl-
transferase. This may account for the synergistic combined
response in the resistant tumour line as follows: Pre-
treatment with MNU should lead to depletion of repair
pseudo-enzyme in nitrosourea resistant cells, as the mono-
functional lesions are repaired. Subsequent treatment with a
bi-functional agent should then be much more effective. If
the MeCCNU treatment was delayed until 24h after MNU,
when new repair pseudo-enzyme had been synthesized,
synergy was lost. In the wild-type tumour, which has very
little repair capacity, lesions produced by each agent should
be simply additive.
A comparison of DNA-protein crosslinking in chromatin
following methylene dimethane sulphonate and formaldehyde
treatment
P.M. O'Connor & B.W. Fox
Paterson Institutefor Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
Methylene dimethane sulphonate (MDMS) possesses
excellent antitumour activity against the rodent Yoshida
lymphosarcoma and is currently undergoing Phase II clinical
trials in Europe. MDMS is, however, rapidly hydrolysed
with a half life of 22min at 37°C to release formaldehyde
(HCHO), and methane sulphonic acid (MSA). Both MDMS
and HCHO produce DNA-protein cross-linking, but only
MDMS causes DNA-DNA interstrand crosslinks. MDMS
induced cytotoxicity in Yoshida (YS) cells could be
correlated with DNA-DNA inter-strand crosslinks and not
with DNA-protein crosslinks as assayed in the Alkaline
Elution procedure.
However, SDS-polyacrylamide gel electrophoresis of
DNA-crosslinked proteins following MDMS and HCHO
teatment revealed some interesting differences in the proteins
crosslinked to DNA. Only, MDMS cross-linked proteins of
29 and 48 Kd to DNA. Whilst, HCHO crosslinked a 26Kd
protein to DNA that was not observed following MDMS
treatment. HCHO was shown to be responsible for all DNA-
protein crosslinking seen after MDMS treatment. The
differences in proteins crosslinked to DNA by MDMS and
HCHO could be attributed to the simultaneous release of
MSA in the molecular environment of the nucleophilic site.
The 26Kd 'HCHO related' protein has been identified as
a H4-H2b histone protein dimer and the 29Kd 'MDMS
related' protein as a H2a-H2b histone dimer. The selective
formation of the H2a-H2b histone dimer following MDMS
treatment is believed to result from a pH dependent
alteration in nucleosome structure induced by MSA. The
48 Kd 'MDMS related' protein is still under study.
Induction of hypoxia in tumours in order to exploit the
cytotoxicity of bioreductive drugs
I.J. Stratford & G.E. Adams
MRC Radiobiology Unit, Chilton, Didcot, Oxon OX]] ORD,
UK.
RSU 1069 is a compound which shows 100 x greater toxicity
towards hypoxic relative to aerobic mammalian cells in vitro.
In air the compound acts as a typical monofunctional
alkylating agent whereas in hypoxia RSU 1069 is reduced to
yield a highly active bifunctional cytotoxic species. In the
past, treating tumour bearing animals with bioreductive
compounds, such as RSU 1069, as single agents, has shown
little benefit. This is due to the fact that solid tumours are a
mixed population of hypoxic and aerobic cells and the latter
will be resistant to bioreductive agent therapy. In this study,
we have taken the approach of selectively rendering tumours
hypoxic allowing the potential toxicity of RSU 1069 to be
fully expressed in vivo. We have used two methods for
selectively reducing tumour oxygenation. Firstly, by using
the agent BW12C, a compound that causes an increase in
the 02 affinity of haemoglobin and secondly, by the use of
anti-hypertensive agent, hydralazine. Both these methods can
result in tumours being rendered close to 100% hypoxic for
several hours. Treatment of mice bearing the Lewis Lung
carcinoma with 5mgkg-I hydralazine i.v. 15min following
administration of 80mgkg-1 RSU 1069 i.p. results in a
reduction in tumour cell survival to 5 x 10-3, whereas RSU
1069 alone results in only 50% cell kill. Hydralazine itself
has no cytotoxic effect at this dose. A similarly substantial
degree of cell kill is also to be found in the KHT sarcoma
using this drug combination. Further, hydralazine does not
cause any significant increase in the whole body toxicity of
RSU 1069 indicating that this approach may be
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Hyperthermia-stimulated nitroreductive bioactivation of the
2-nitromidazole benznidazole in vitro and in vivo
M.I. Walton, N.M. Bleehen & P. Workman
MRC Unit and University Department of Clinical Oncology
and Radiotherapeutics, Hills Road, Cambridge CB2 2QH,
UK.
Hyperthermia enhances the cytotoxicity of nitroheterocyclic
drugs in vitro and in vivo, possibly through increased
reductive metabolism of the nitro group. Using an HPLC
assay for the 2-nitroimidazole benznidazole (BENZO) and its
corresponding amine metabolite, we have studied the effects
of temperature (33-44 C) on BENZO amine formation
kinetics in vitro. Reactions were carried out using mouse
liver microsomes and whole KHT tumour homogenates
under N2 in the presence of NADPH and NADH.
Hyperthermia markedly increased BENZO amine formation
rates in both microsomes and tumour homogenates up to
41'C e.g. tumour reduction rates were increased by 35%
from 42.5 to 57.4pmolmin-1mg - protein at 41 compared
to 370C. At 44"C microsomal reduction rates were increased
by 0-54% depending on substrate concentration, whereas
tumour rates were substantially increased (26-79%) at both
1 and 0.1 mm BENZO. We have also studied the effects of
local hyperthermia (LH) on BENZO reduction to its amine
metabolite in C3H/He mice with KHT i.m. leg tumours. LH
(waterbath +radiofrequency heating; 43.5°C x 30min) was
given to conscious mice 2.5h after 2.5mmolkg-1 BENZO
i.p. LH greatly increased tumour amine levels compared to
controls, e.g. by 81% from 4.75+1.6 to 8.61+0.91jigg-1
(mean+2s.e., n =6; P<0.01) immediately after heating.
Parent BENZO concentrations were correspondingly
decreased, e.g. by 58% from 137+37.4 to 57.2+5.84,gg-1
(P<0.01). Plasma and liver BENZO and BENZO amine
concentrations were similar in heated and control mice.
These results clearly demonstrate that hyperthermia can
enhance the reductive bioactivation of BENZO in vitro and
in vivo. In view of the targetable nature of LH, these results
have important implications for its use in combination with
bioreductively activated antitumour agents.
Posters
NCL-5D3: An anti-cytokeratin monoclonal antibody raised
against proteins released by breast cancer cells in tissue culture
and recognising simple epithelia
B. Angus, J. Purvis, D. Stock, S. Kiberu, E. Routledge,
B. Westley, F. Carpenter & C.H.W. Horne
Department ofPathology, University ofNewcastle upon Tyne,
UK.
Proteins secreted or shed by breast cancer cells are of interest
as potential tumour markers. The aim of our study was to
generate monoclonal antibodies against proteins secreted or
shed by MCF7 breast cancer cells in tissue culture. A
standard hybridoma protocol using BALB-C mice and NSI
cells was followed. The immunogen used was an 'all protein'
preparation derived from serum free supernatants of
confluent MCF7 cell cultures. Antibodies were screened by
immunocytochemistry using an indirect immunoperoxidase
technique on breast carcinoma tissue sections. The fusion
described here yielded 12 antibodies showing reactivity, and
two of these showed high specificity for tumour cells with
low background staining. One has not yet been fully
evaluated. The other has been designated NCL-5D3.
Comparison with the anticytokeratin antibody PKK1 shows
a very similar westen blot pattern, with reactivity against
several bands between 38 and 46Kd. Screening against a
wide variety of normal and neoplastic tissues using an
indirect immunoperoxidase technique on formalin fixed
paraffin embedded tissues has demonstrated reactivity with
all simple epithelia tested and with almost all tumours
derived from such epithelia. For example, 60 out of 60
breast carcinomas showed strong reactivity. No reactivity
was observed against non-epithelial tissues or against
stratified squamous epithelium, and only a small proportion
(5 of 17) of squamous carcinomas showed weak reactivity.
As the antibody works well with fixed, embedded tissue and
shows more intense reactivity than some currently available
monoclonal antibodies recognising simple epithelia, NCL-
5D3 should prove of value in diagnostic histopathology.
Characterisation of ZR-75-1 human breast cancer cells grown
in phenol red free tissue culture medium
H.W. van den Berg & M. Lynch
Department of Therapeutics and Pharmacology, The Queen's
University ofBelfast, Northern Ireland, UK.
It has been shown recently that the pH indicator phenol red,
(PR), has significant oestrogenic activity at concentrations
used in tissue culture medium, (Berthois et al, Proc. Natl
Acad, Sci., USA, 83, 2496, 1986). This finding has important
implications for studies designed to elucidate the mechanisms
of action of oestrogens and anti-oestrogens using human
breast cancer cell lines in long-term culture.
In culture medium containing PR and 5% dextran coated
charcoal stripped foetal calf serum (FCSdcc), cell population
doubling time, (DT), of ZR-75-1 human breast cancer cells
was 2-2.9 days for cells initially plated at 1-5 x 104 per
microwell plate. Cells expressed both ER, (147+ 19fmolmg-1
protein) and PGR, (80+24fmolmg- I protein) as assessed
using a whole cell binding assay. Cells transferred to PR
free medium containing 5% FCSdcc showed an immediate
slowing of growth rate at an initial seeding density of 5 x 104
cells per well, (DT 4.1-5 days). Continuous exposure to
oestradiol, (10-9 M), shortened DT to 3 days. This effect
was most consistent when the serum concentration was raised
to 20%. PR deprived cells retained sensitivity to oestrogen
reversible growth inhibition by 4-hydroxy tamoxifen
(10-9_ 10-7 M). Cells plated at densities <4 x 104/well failed
to proliferate in the absence of phenol red.
The DT of cells deprived of PR for 4 months has extended
to 8.4-10 days and remains at 5.6-6 days in the presence of
oestradiol. ER content, (157+15fmolmg-1), is not
significantly different from that of routinely cultured cells
whilst PGR are undetectable but inducible by oestrogen
treatment.
Our data show that ZR-75-1 cells are capable of
proliferation in the absence of oestrogenic stimulus but
proliferation is density dependent. Our observations would
be consistent with the proposal that cells are capable of low
level autonomous secretion of oestrogen inducible growth
factor(s).
Quantitation of microvilli density on MCF-7 cell surface
J. Nelson, R. Clarke, N.V. McFerran & R.F. Murphy
Department ofBiochemistry, The Queen's University of
Belfast, Belfast BT9 7BL, UK.
Oestrogen is known to stimulate the production of microvilli
(MV) in target cells. Phenol red is ubiquitously used in tissue194 JOINT MEETING OF THE BACR AND THE ACP
culture media, but it has recently been shown to be a weak
oestrogen (Berthois et al., Proc. Natl Acad, Sci, USA, 83,
2496, 1986). We have examined the effect of phenol red
withdrawal on hormone free MCF-7 cells which have been
maintained in steroid-free medium (containing phenol red)
for 2 years. Cell surfaces of fixed cells were examined by
scanning electron microscopy and MV density per 4821m2
was measured by computerized image analysis (McFerran &
Quigley, Biochem. Soc. Trans., 12, 1000, 1984). It was found
that MV density decreased following phenol red withdrawal
and reached a minimum after 2 weeks. Restimulation of
phenol red- and steroid-withdrawn cells resulted in increases
in MV density as shown in the Table.
MV density (percentage of control)
Phenol red free Restimulated
HFMCF-7 1 week 2 week (E2)' (PR)a
100 (+14) 61 (+21) 14 (+10) 110 (+28) 89 (+35)
dE2: 10 - M oestradiol. PR: 481im phenol red.
Cells were steroid and phenol red free for 2 weeks prior to
restimulation for 3 days.
Morphological and functional characteristics of mouse
mammary carcinoma cells separated on nycodenz columns
T.C. Ford, T. Lai & M.O. Symes
University Department ofSurgery, Bristol Royal Infirmary,
Bristol BS2 8HW, UK.
Tissue from 4 mouse mammary carcinomas was
enzymatically disaggregated and cells from the resulting cell
suspension were fractionated on a discontinuous density
gradient column (5-20%) of Nycodenz (Nycomed A.S.
Oslo). The cell fractions separating at the 10-15 and 15-20%
interfaces (density 1.082 and 1.110gml- 1 respectively)
contained a mean of 83.2+ 10.8 (s.d.) and 79.9+17.4 tumour
cells. Compared with the original cell suspension these cell
bands contained less cell aggregates and cell debris. Also the
cells in the bands showed an equivalent ability to grow in
tissue culture and to form pulmonary tumours on i.v.
injection into isogenic mice, when compared with the tumour
cells in the original suspension. The relatively pure
preparations of carcinoma cells thus separated may be of
value in limiting the unwanted effect of normal cell
contamination when testing the neoplastic cells in vitro for
sensitivity to drugs or hormones.
The effects of glucagon on ZR-75-1 human breast cancer cells
M. Cremin, R. Clarke, J. Nelson & R.F. Murphy
Department ofBiochemistry, The Queen's University of
Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast
BT9 7BL, Northern Ireland, UK.
We have examined the effects of glucagon on the oestrogen
responsive ZR-75-1 human breast cancer cell-line. While
10 - OM to 10-6 M glucagon fails to influence the rate of
DNA synthesis, the rate of [3H]-leucine incorporation into
gross protein is stimulated to greater than 150% of that
determined in untreated cell populations. Maximal
stimulation is observed following exposure to concentrations
of glucagon from 10-9M to 10- 7 M.
Specific binding of [125I]-glucagon was demonstrated using
a competitive binding assay. Bmax and Kd of glucagon
binding are 5.18+0.68fmol 10-6 cells and 1.02nM
respectively. This Kd is comparable with that found for the
high affinity receptors in canine hepatocytes (Bonnevie-
Nielsen & Tager, J. Biol. Chem., 258, 11313, 1983) and
reflects the concentration range where maximal biological
response is observed.
The effect of 17f oestradiol (E2) and tamoxifen (TAM) on the
membrane fluidity of both oestrogen responsive and
unresponsive human breast cancer cells
R. Clarke', H.W. van den Berg2, J. Nelson' &
R.F. Murphy'
Departments of 'Biochemistry and 2Therapeutics, The Queen 's
University ofBelfast, Medical Biology Centre, 97 Lisburn
Road, Belfast BT9 7BL, UK.
Whilst the majority of breast tumours which respond to
endocrine manipulation contain oestrogen receptors (ER)
some tumours which do not have ER respond to these
therapies. We have examined the ability of pharmacological
and suprapharmacological concentrations of both E2 and
TAM to modulate the membrane fluidity of MCF-7 (E2
responsive) and MDA-MB-436 (E2 unresponsive) cells as
determined by the steady-state polarisation of fluorescence of
the probe 1,6 diphenylhexatriene. The ability of E2 and
TAM to influence cell proliferation was also determined. E2
produces an equivalent increase in membrane fluidity in both
cell lines, oestrogenic effects being observed only in MCF-7
cells. In both MCF-7 and MDA-MB-436 cells 1O- M E2 is
equitoxic and produces similar perturbations in membrane
fluidity. 10 6 M TAM decreases the membrane fluidity in
both cell lines but inhibition of proliferation reversible by E2
is observed only in MCF-7 cells. 10- M TAM is less
cytotoxic towards MDA-MB-436 cells than MCF-7 cells and
produces less perturbation of membrane fluidity.
The inhibitory effects of high doses of E2 and TAM are
unlikely to be mediated through the ER and may be the
result of altered membrane function. We have previously
demonstrated that 10 -6M E2 reduces the steady-state levels
of methotrexate in both MCF-7 (Clarke et al, Br. J. Cancer,
51, 365, 1985) and MDA-MB-436 cells (Clarke et al, Eur. J.
Cancer Clin. Oncol., 17, 1275, 1983). These results may
reflect a physical restriction of the folate membrane-
transport system caused by the E2-induced reductions in
membrane fluidity.
Energy expenditure and protein synthesis rates in an animal
model of cancer cachexia
J.A. Plumb', K.C.H. Fearon2, K. Carter2, H.J.G. Burns2 &
K.C. Calman3
Departments of 'Medical Oncologi', 2Surgery and
3Postgraduate Medical Education, University of Glasgowv,
Glasgow, UK.
Although anorexia is often associated with cancer cachexia
the reduced food intake alone is not sufficient to produce a
severe weight loss. Increased rates of both protein synthesis
and energy expenditure have been proposed to account for
the weight loss. We have investigated both possibilities in an
animal model of cancer cachexia. A chemically induced
adenocarcinoma of the mouse colon (MAC-16) grown
subcutaneously in NMR1 mice produces a 20% loss of body
wt after 4 weeks. However, the food intake of the mice
remains constant until the fourth week after tumour
implantation. At this time the tumour represents only 6% ofJOINT MEETING OF THE BACR AND THE ACP 195
the mouse body wt. Energy expenditure was measured over
a 24h period by indirect calorimetry both before and 1, 2, 3
and 4 weeks after tumour implantation. Although weight
loss commenced one week after tumour implantation there
was no change in either oxygen consumption or carbon
dioxide production, expressed per mouse, even after 4 weeks
of tumour growth. However, since the mice lost weight
during tumour growth the rate of energy expenditure
increased when expressed g-1 body wt. Protein synthesis
rates were measured in vivo by the flooding phenylalanine
method. Although the protein content of the gastrocnemious
muscle was decreased by 35% four weeks after tumour
implantation there was no change in the rate of protein
synthesis in skeletal muscle. Thus in this model weight loss
cannot be explained by a decreased food intake, an increased
energy expenditure or an increase in the rate of protein
synthesis.
Cachectic factor(s) produced by the MAC 16 adenocarcinoma
R.A. Brennan, S.A. Beck & M.J. Tisdale
pyrimidine nucleotide pools are in a state of dynamic
equilibrium. Studies of L1210 cells incubated with 5[3H]
deoxyuridine revealed that the rapid inhibition of TS
following short exposures (<4h) to either CB3717 or its
2-desamino analogue (desamino-CB3717) recovers rapidly
following resuspension in fresh medium. However, with
longer exposure times prolonged TS inhibition was observed,
presumably due to the formation of non-effluxable products
(e.g. polyglutamates). After 15 h exposure (to a dose
10 x IC50, in the presence of 1OgM Thd) the release of
tritiated water (via TS) from these cells was inhibited by
>90% in the absence of extracellular compound. Following
resuspension in fresh medium containing Thd, this inhibition
was maintained (>75% after 8 h). Similarly we have
demonstrated the inhibition of tritiated water release in
L1210 cells following in vivo treatment with both analogues
(100mgkg-1, i.v.). The inhibition observed with desamino-
CB3717 was much greater and more prolonged than that
seen with CB3717. It is therefore now possible to compare
the effects of analogues upon the target enzyme while
retaining effects due to route of administration,
pharmacokinetics etc.
CRC Experimental Chemotherapy Group, Department of
Pharmaceutical Sciences, Aston University, Birmingham B4
7ET, UK.
The MAC 16 is a transplantable colon adenocarcinoma
which produces extensive weight loss in tumour-bearing
animals without a reduction in food or water intake. In
males a 0.6g tumour will produce 33% loss of body weight
within 35 days of tumour transplantation. Body composition
analysis shows a progressive decrease in adipose tissue and
muscle mass without a change in body water. While plasma
glutamine levels are elevated 25% in tumour-bearing animals
the plasma concentrations of most other amino acids
including glycine are reduced by 30-40% and thus the
situation differs from chronic malnutrition. Cell-free extracts
of the MAC 16 tumour cause a release of free fatty acids
(FFA) from mouse fat pads while extracts from two colon
carcinomas, which do not produce cachexia in recipient
animals, MAC 13 and MAC15A, have no effect on FFA
release. The FFA releasing activity of the MAC 16 tumour is
dramatically reduced after acid or heat treatment. Cell-free
extracts of the MAC 16 tumour also cause an enhanced
release of amino acids from mouse diaphragm, while extracts
from MAC 15A do not. These results suggest that the
cachexia produced by the MAC 16 tumour may be due to
the presence of a tumour-associated catabolic factor.
Thymidylate synthase (TS) activity in L1210 cells following
in vitro or in vivo exposure to quinazoline antifolates
G.A. Taylor, A.L. Jackman, K. Balmanno & A.H. Calvert
Drug Development Section, Institute ofCancer Research,
Sutton, Surrey, UK.
NI°-propargyl-5,8-dideazafolate (CB3717) lacks antitumour
activity against a range of rodent tumours despite
demonstrable clinical efficacy. This apparent anomaly may
be due, at least in part, to rodents having higher circulating
levels of thymidine (THd) which may circumvent the
cytotoxic locus of CB3717, i.e. inhibition of TS. In the
absence of a suitable tumour model methods have been
developed to measure the in situ activity of enzymes of
deoxypyrimidine metabolism in tumour cells following in
vitro or in vivo exposure to CB3717 and its congeners. This
involves monitoring the in vitro distribution of radiolabelled
precursors under conditions where the intracellular deoxy-
Polyglutamation of the thymidylate synthase (TS) inhibitor
NI0-propargyl-5,8-dideazafolic acid (CB3717) in L1210 cells
in vitro
E. Sikora, A.L. Jackman, D.R. Newell & A.H. Calvert
Drug Development Section, Institute ofCancer Research,
Sutton, UK.
Polyglutamation is a common intracellular fate for both
natural folates and synthetic antifolates. We have
investigated the formation and retention of CB3717
polyglutamates in L1210 cells. Cells were exposed to 50/M
3H-CB3717 (10 xIC50) in the presence of thymidine (10pM)
to prevent cell death. CB3717 polyglutamates were identified
by co-chromatography of 3H-metabolites on HPLC
(lOxO.46cm Polygosil 5,um C18 column, 5-16% CH3CN in
0.1 M NaAc pH 5, 15 min) with standards and by their ability
to inhibit TS. The results showed extensive CB3717
polyglutmate formation.
Incubation Cellular 3H % Cellular 3H as
time (h) (PM) CB3717(Glul) Glu3 Glu4 Glu5
6 4.5+ 1.5 92,71 0,2 5,17 2,4
12 6.8+3.6 57+3 3+1 23+4 13+1
24 5.9+3.4 51+5 1+1 20+1 21+3
After 24h incubation followed by resuspension in drug free
medium for 6 and 24h, parent CB3717 comprised only 5%
and 2% of the cellular 3H, respectively. In contrast, CB3717
glu4 and glu5 were retained with levels declining solely due
to dilution during cell division. Measurement of whole cell
TS activity using [6-3H]deoxyuridine incorporation into
DNA indicated that complete suppression of activity (< 10%
control) was maintained throughout the 24h resuspension
period. Thus despite poor cellular accumulation CB3717
undergoes polyglutamation (-50% at 50,pM) in L1210 cells
in vitro. The products are retained following removal of
extracellular drug and by virtue of their potent activity give
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Some biological properties of 2-desamino-NI0-substituted 5,8-
dideazafolates
B.M. O'Connor, A.L. Jackman, J.A.M. Bishop, T.R. Jones,
T.J. Thornton & A.H. Calvert
Institute ofCancer Research, Sutton, Surrey, UK.
N'l-substituted 5,8-dideazafolates are dual inhibitors of
thymidylate synthase (TS) and dihydrofolate reductase
(DHFR) although inhibition of TS appears to be the usual
cytotoxic event. The N'0-propargyl compound (CB3717) acts
purely as a TS inhibitor and has anti-tumour activity in
man. We have now synthesised 2-desamino-5,8-dideaza-
folates with aliphatic N'0-substituents which are up to 10-
fold more cytotoxic despite being poorer inhibitors of TS
and DHFR. In both series the N'0-propargyl compound was
the most potent against TS (I50 desamino-CB3717 = 16pM;
'50 CB3717 =0.02pM) i.e., propargyl >ethyl >methyl >allyl >
hydrogen. Against DHFR hydrogen>methyl >ethyl>allyl>
propargyl (desamino-CB3717 Ki =2.25pm; CB3717=
0.075 pUM). Hence propargyl has the lowest TS/DHFR ratio,
an important property for a compound to be rate-limiting on
TS. The activities against 3 cell lines are shown below. The




Wi-L2 L1210 (DHFR over- R7A/L1210
N'O (IC50 PM) (IC50pM) producing) (ratio)
H 0.26 (0.48) 0.43 (2.68) 426 (300) 991 (111)
CH3 0.72 (1.60) 0.91 (4.5) 335 (230) 368 (51)
CH2CH3 2.78 (1.32) 2.65 (9.0) 390 (240) 144 (27)
CH2CH=CH2 1.87 2.48 (6.0) - -
CH2C-CH 0.55 (2.45) 0.4 (3.4) 7 (38) 19 (11)
In both series the R7A/L1210 ratio decreased as the N10-
chain length increased (paralleling the decrease in the Ki
TS/Ki DHFR ratio). The greater degree of cross-resistance
towards the desamino series is not readily explained.
2-desamino-10-propargyl-5,8-dideazafolic acid
(desamino-CB3717) a thymidylate synthase (TS) inhibitor
devoid of renal and hepatic toxicities in mice
A.L. Jackman', D.R. Newell', G.A. Taylor',
B.M. O'Connor', L. Hughes2 & A.H. Calvert'
'Institute of Cancer Research, Sutton, Surrey and 21C1
Pharmaceuticals, Macclesfield, Cheshire, UK.
N' "-Propargyl-5,8-dideazafolate (CB3717) has demonstrated
the clinical potential of inhibiting TS in that it has activity
against breast, ovary and liver cancer. However the dose-
limiting renal toxicity together with reversible hepatic
toxicity has led us to seek less toxic analogues. We report
here the interesting biological properties of desamino-
CB3717, an inhibitor of L1210 TS (Ki=26.4+3.53nM).
Despite being 7-fold less potent than CB3717 as an inhibi-
tor of TS it is 10-fold more potent than CB 3717 against cul-
tured mouse L1210 cells (IC50 =0.35 pM). Other properties
include (i) weak inhibition of dihydrofolate reductase
(Ki =2.25 +0.23 pM), (ii) thymidine reversal of cytotoxicity
(3.5pM) in L1210 cells (iii) inactivity at 200pM against a TS
over-producing cell line (L1210:C15). Following a single i.v.
injection of 100mgkg - desamino-CB3717 to L1210 i.p.
tumour-bearing mice, tumour TS activity was inhibited by
>60% for 6 h with recovery by 24h. The effect was more
pronounced and for a longer duration than with CB3717 at
the same dose despite a very much more rapid plasma
clearance (1752mlh-kg-1; CB3717=300mlh-kg-1). In
acute toxicity studies (0-24h) desamino-CB3717 was
considerably less toxic than CB3717 in mice. A 500mgkg
i.v. dose of desamino-CB3717 (plasma AUC 620pM h)
caused no renal or hepatic toxicities. This contrasted with a
100mgkg dose of CB3717 (plasma AUC 680pM h) which
caused toxicity to both these organs as evidenced by histo-
pathological damage to the kidneys and elevations in plasma
urea (100%), and alanine transaminase (4000%). The
reduced toxicity of desamino-CB3717 is possibly a result of
its greater solubility (>1000-fold more soluble than CB3717
at physiological pH).
Potentiation of CB3717 toxicity by dipyridamole in A549 cells
N.J. Curtin & A.L. Harris
Cancer Research Unit, University of Newcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP,
UK.
CB3717 is an antifolate inhibitor of thymidylate synthase
which does not affect other pathways. The only means of
circumventing such inhibition is via salvage of exogenous
thymidine. Dipyridamole is a nucleoside transport inhibitor
that has been shown to enhance the toxicity of some drugs
by the prevention of salvage and others by the prevention of
the efflux of toxic metabolites.
Using A549 lung carcinoma cells, we have shown that
1 pM dipyridamole reduces the uptake of [3H]thymidine by
over 95% in both control and CB3717 treated cells. At this
concentration, dipyridamole does not affect cell growth
but significantly reduces the ID,0 of CB3717 from
2.376+0.533pM to 0.979+0.279pM (P<0.001). Elimination
of exogenous salvagable thymidine by the use of dialysed
serum also caused a significant reduction in the ID50 of
CB3717 to 1.497+0.956pM (P<0.05). The greater poten-
tiation of CB3717 toxicity by the dipyridamole suggests a
second mechanism for dipyridamole action. If the toxicity
of thymidylate synthase inhibition is due to misincorporation
of dUTP into DNA followed by its excision, leading to
strand breaks, then the intracellular level of dUTP will be
important. Our experiments show that 1UM dipyridamole
inhibits the efflux of [3H5]deoxyuridine by almost 90%. This
may help maintain high intracellular deoxyuridine nucleotide
concentrations and increase uracil misincorporation.
The potentiation of CB3717 toxicity by dipyridamole, via
two mechanisms at concentrations achievable in patients,
suggests that dipyridamole would be a useful means of
enhancing the chemotherapeutic potential of CB3717 in
patients.
Selective radiosensitisation by an antibody-bromodeoxyuridine
A. Smith, J.A. Gardner, D.M. Tidd & H.M. Warenius
Department of Radiation Oncology, Clatterbridge Hospital,
Bebington, Wirral, Merseyside L63 4JY, UK.
The application of ricin or ricin A-chain conjugates as
selective cytotoxins in vivo has proven to be a difficult
objective to achieve both because of the affinity of the whole
toxins for non-target cells and because of other pharmaco-
kinetic considerations. The substitution of less interactive
molecular species in place of ricin may go some way towards
resolving these problems and we present here a study on the
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2'-deoxyuridine to the human adenocarcinoma cell line
HT29/5. The route of intra-cellular delivery chosen was by
conjugation to transferrin (thereby utilising the transferrin
receptor internalisation pathway) or to the AUA1
monoclonal antibody. To increase the loading of the carrier
with bromodeoxyuridine without impairing its ability to bind
to its cellular target the radiosensitiser was first linked to
poly-L-lysine which was in turn conjugated via succinimidyl
4-(p-maleimidophenol) to the carrier. The resultant
conjugate, when employed in vitro, displayed an ability to
selectively radiosensitise HT29/5 cells to both photon and
neutron irradiation.
Heat shock and other agents which induce thermotolerance
bring about the terminal differentiation of HL-60 human
promyelocytic leukaemia cells
F.M. Richards & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Birmingham B4 7ET, UK.
HL-60 cells will undergo terminal differentiation to mature
granulocytes in response to a wide variety of agents. It has
previously been shown that the optimum concentration for
the induction of differentiation by all the agents was only
marginally below the cytotoxic concentration (Langdon &
Hickman, Cancer Res., 47, 140, 1987). This suggests that
differentiation induction in HL-60 cells may be an adaptive
response to a sub-toxic threat or stress.
HL-60 cells were incubated for 4 days with agents known
to induce a stress response and short term resistance to a
subsequent stress such as a heat shock (thermotolerance) in
other cell types. The local anaesthetic lidocaine (3mM)
induced 48.34+5.89 (n=4) percent of cells to differentiate
(NBT+). Procaine (5mM) similarly induced 46.32+17.57%
(n=4) and 6,uM sodium arsenite induced 30.10+11.50%
(n=5), which was significantly higher than in untreated
controls (2.09+ 1.31% n =8).
When HL-60 cells were incubated for 60min at 43.5°C
(heat shocked) followed by a recovery period of 4 days at
370C, 20.06+7.29 (n =6) percent of the cells differentiated.
This is the first example of a physical rather than chemical
stress inducing differentiation of HL-60 cells. We consider
that a stress response may be important in those events
leading to the induction of terminal differentiation in HL-60
cells.
Inhibition by adriamycin of the calcium-mediated ankyrin
breakdown in human erythrocytes
K.Y. Tang, M.G. Thompson & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Aston Triangle,
Birmingham B4 7ET, UK.
In response to treatment with 5gM calcium ionophore
(A23187) in the presence of calcium, human erythrocytes
underwent calcium-concentration-dependent and time-
dependent echinocytosis. This morphological transition could
be observed as early as 30sec after ionophore addition. SDS-
PAGE of the human erythrocyte cytoskeleton revealed the
breakdown of two cytoskeletal components: ankyrin (Mr
200,000) and band 4.1 (Mr 82,000). However, only ankyrin
degradation was rapid enough to account for the rapid onset
of calcium-induced echinocytosis. The anthracycline anti-
tumour drug, adriamycin, was found to exert protective
effect atgainst calcium-induced echinocytosis. In control
incubations there were - 70-80% echinocytes after 5 min
calcium-loading (150gM) at 37°C. In comparison, there were
only 15-20% echinocytes when erythrocytes were pre-
incubated with 1O UM adriamycin. This potent inhibition of
echinocyte formation by adriamycin was observed at calcium
concentrations from 0-150/M. At concentrations above
200tM, pre-incubation of adriamycin has no significant
effect on the morphological transition process compared
with the control. SDS-PAGE of isolated erythrocyte
membrane vesicles show that adriamycin did not cause
significant protein cross-linking. However, adriamycin was
found to be capable of inhibiting the calcium-mediated
breakdown of ankyrin at calcium concentrations as high as
400,m. This inhibition of ankyrin degradation was closely
correlated to the ability of adriamycin to protect human
erythrocytes against calcium-induced echinocytosis. The
erythrocyte membrane and cytoskeleton are widely
considered to be an excellent model for other cell types;
Adriamycin may, therefore, exert part of its activity at this
locus.
Growth inhibition of a human lung tumour xenograft by
selective manipulation of cellular energy metabolism
J. Plumb, R.M. Sri-Pathmanathan & K.C.H. Fearon
Department of Medical Oncology, University ofGlasgow,
Glasgow G12 9LX, UK.
Rhodamine 6G (R6G), a mitochondrial dye, has been shown
to act via inhibition of oxidative phosphorylation.
Incubation of a human non-small cell lung cancer cell line,
WIL, in the presence of R6G (1-10 iM) resulted in a
decrease in the rate of oxygen consumption by the cells by
up to 50%. In contrast, the rate of anaerobic metabolism,
estimated as the rate of lactate production by the cells, was
increased by up to 60% in the presence of R6G (1-1O0M).
The magnitude of both these changes was dose dependent.
However, even at a concentration of 1O M, R6G had no
significant effect on either oxygen uptake or lactate
production by freshly prepared rat liver hepatocytes.
The doubling time of the WlL tumour, grown as a
xenograft in athymic mice, was increased by about 30% after
a single i.p. injection of R6G (2mgkg-1). A single i.p.
injection of 5-fluorouracil (50mgkg-1), a known inhibitor of
mitochondrial biogenesis, had no effect on tumour doubling
time. However, combination of R6G (2mgkg -1) and 5-
fluorouracil (50mgkg-1) resulted in an increase in tumour
doubling time of greater than 100%.
These results demonstrate a selective inhibition of aerobic
metabolism in tumour cells by R6G which may be
compensated for, in part, by an increase in the rate of
anaerobic metabolism. Inhibition of tumour growth in vivo
by R6G is enhanced by a non-cytotoxic dose of 5-
fluorouracil. This may be the result of an inhibition of
tumour cell mitochondrial biogenesis.
Evidence for polyamine involvement in feeder cell enhancement
of tumour cell clonogenicity
A.P. Wilson
Oncology Research Laboratory, Derby City Hospital,
Uttoxeter Road, Derby DE3 3NE, UK.
The use of feeder cells as a means of improving
clonogenicity of tumour cells (TC) is well-documented.
Conditioned medium from feeder cells is variable in its
ability to enhance clonogenicity of the same cells, and little is
known concerning the mechanisms underlying the epithelial
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(MC) and an ovarian tumour cell line (TC) has been used to
investigate possible mechanisms, and results suggest that
polyamines may be implicated. In the model used MC can
respond to mitogenic stimulation and clonogenicity of MC
can therefore be determined in parallel with TC. Results
suggest that the responsiveness of MC to EGF influences
interactions between MC, TC, EGF and an amine oxidase
inhibitor- iproniazid, (IP). Late passage MC with reduced
responsiveness to EGF fail to enhance to growth in the
presence of EGF. Stimulation can be restored in the
presence of IP which does not itself affect either TC or MC
clonogenicity. Conversely early passage MC, which are very
responsive to EGF still stimulate to clonogenicity in the
presence and absence of EGF. In these circumstances, IP has
no effect on enhancement of TC clonogenicity by MC.
Experiments are in progress to evaluate the role of
polyamine metabolism in more detail.
Investigations into the mode of action of trimelamol
I.R. Judson, C.J. Rutty, G. Abel, M. Graham, B.C. Millar'
& K.R. Harrap
Drug Development Section and 1Section ofMedicine, Institute
of Cancer Research, Sutton, Surrey, UK.
The mode of action of cytotoxic melamines is unknown.
Although the requirement for N-hydroxymethyl groups is
well established, whether formed by metabolic activation
(HMM, PMM) or chemical synthesis (Trimelamol), there is
still little evidence to indicate that DNA alkylation is the
cause of cytotoxicity. Trimelamol (T) at 100lIM for 4h did
not affect calf thymus DNA template activity. Exposure to T
at lOO1UM for 2h caused 46% inhibition of 3H-TdR
incorporation by PC6 cells in vitro but this was completely
abolished by semicarbazide (SC) pretreatment (i.e.,
formaldehyde (F) trapping). However, SC had little effect on
the inhibition of growth of PC6 cells in vitro by T 125-
400pM, merely reducing mean inhibition from 62% to 55%.
Hence F release contributes little to toxicity in this cell line.
Treatment of Balb C- mice bearing PC6 ascites tumour with
T 50mgkg- 1 i.v. daily x 3 gave a 77% prolongation in
survival. In addition to showing in vivo sensitivity, the PC6
tumour proved to be predictive for anti-tumour activity of T
in man both in terms of an effective plasma concentration
and schedule dependent differences in therapeutic index.
Hence the PC6 is a suitable model for mechanistic
investigations. A 29% inhibitory effect on 3H-TdR
incorporation by PC6 ascites cells removed 2h after T
100mgkg- 1 i.v., was virtually absent (5%) by 5 h. Flow
cytometric analysis of T-treated PC6 cells failed to show a
G2 block suggesting that DNA-DNA x-linking is not an
important event. Nevertheless T did cause imbalanced
growth in PC6 cells at 50-100UM in vitro as shown by an
increase in cell size (70%) and protein content (67%) at 24h.
This was associated with a small reduction in G1 and an
increase in S phase cells. Thus T appears to affect the
regulation of cell division in this sensitive cell line but the
mechanism of this activity remains obscure.
Effects of N-methylformamide (NMF) on the cell cycle of
murine TLX5 lymphoma cells in vitro: Characterization of a
reversible quiescent G, phase substate
C.A. Bill, A. Gescher & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
NMF is one of a number of polar solvents which can induce
the terminal differentiation of certain malignant cell lines in
vitro. We have previously demonstrated an NMF
concentration-dependent decrease in the growth rate and an
associated G1 phase accumulation of murine TLX5
lymphoma cells in vitro (Bill et al, Br. J. Cancer, 54, 168,
1986). In this study we investigated further the G1 phase
sub-compartments of TLX5 cells incubated with NMF in
vitro and assessed whether or not terminal differentiation
had resulted from the drug exposure. Simultaneous DNA
and RNA analysis of TLX5 cells treated with NMF in vitro
by flow cytometry revealed a concentration-dependent
decrease in cellular RNA content, indicative of an early G1
phase arrest. TLX5 cells exposed to 170mm NMF for 48h
resulted in 99.7% of the G1 population in the
subcompartment with the lowest RNA content, termed G1A9
whereas for TLX5 cells at plateau phase for 3 days GI A
contained 88.5% of G, phase cells. TLX5 cells were
incubated with 106mm NMF for 48 h, cells were then
washed free of the drug and cultured in fresh medium. There
was an initial fall in viability (82 +3% to 45+4%) as
measured by trypan blue exclusion and rise in the viable G,
phase population (77% to 95%) 24h after NMF removal.
However, by 72h a normal control cell cycle distribution
was evident. Anchorage independent growth analysis of these
cells in soft agar, plated immediately after NMF was
removed from the medium gave a clonogenic efficiency of
54.5 +4.3% of the control value, indicating complete
proliferative recovery of the viable cell population. We
conclude that murine TLX5 lymphoma cells exposed to
NMF in vitro are not terminally differentiated, but reside in
a quiescent substate which was reversed on drug removal.
N-methyldeuteroformamide, an antineoplastic isotopomer of
N-methylformamide with markedly reduced toxicity
D. Chubb, M.D. Threadgill & A. Gescher
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
Results of clinical trials of N-methylformamide
(OHCNHCH3, NMF) indicate that its therapeutic potential
is low. The major toxicities of NMF in patients were
nonspecific malaise and liver damage. During investiga-
tions on the formyl-deuterated isotopomer of NMF
(ODCNHCH3, D-NMF) a primary kinetic isotope effect on
the metabolism of NMF to methylamine and N-aeetyl-S-(N-
methylcarbamoyl)cysteine (Threadgill et al, Br. J. Cancer, 54,
193, 1986) was discovered. In order to establish whether this
metabolic pathway is involved in the mechanism of the
antitumour activity of NMF, the efficacy of D-NMF was
tested against the M5076 reticulum cell sarcoma grown in
female BDF1 mice. The compound was administered i.p.
daily for 17 consecutive days and tumour volumes were
measured at regular intervals. D-NMF at 100mgkg-I was
inactive and at 200mgkg-I it afforded a T/C value of 28
(mean of 5 mice), which is almost identical to the activity
observed with 100mgkg-' NMF. At a dose of D-NMF of
400mgkg- 1, tumour volume was not measurable. The
difference between D-NMF and NMF in toxicity was most
dramatic. At 800mgkg - D-NMF did not cause weight loss,
whereas 300mgkg-1 of NMF was near the LD50 in BDF1
mice. Two conclusions can be drawn from these results: (i)
Cleavage of the formyl C-H bond appears to be a prelude to
the generation of both the antitumour activity and toxicities
of NMF. (ii) The startling reduction of toxicity on
substitution of the formyl H with D indicates that the dose-
limiting toxicity of NMF in mice is possibly mediated by
processes other than or additional to the hepatic lesion.JOINT MEETING OF THE BACR AND THE ACP 199
Characterisation of the growth of human promyelocytic HL-60
cells implanted into millipore chambers in vivo
L. Hughes, D. Chubb & J.A. Hickman
CRC Experimental Chiemotherapy Group, Pharmaceutical
Sciences Institute, Aston Universityl, Birmingham B4 7ET,
UK.
A number of in vitro systems have been used to examine the
potential of a variety of agents to induce the terminal
differentiation of malignant cells. Few attempts have been
made to conduct such experiments under conditions of
appropriate drug pharmacodynamics in vitro, and fewer
have utilised an in vivo assay of drug-induced terminal
differentiation. We have investigated the growth charac-
teristics of the human promyelocytic leukaemia HL-60 cells
when they were implanted in millipore chambers, into
20g, female CBA/CA mice. Growth characteristics in
chambers were dependent on a number of variables. When
150p1 of 1 x 106 HL-60 cellsml- ' in RPMI 1640 medium
(+10% foetal calf serum), which had an in vitro doubling
time of 24h, were implanted in chambers, with a pore size of
0.45 pm, immediate and rapid growth (doubling time =8 h)
was observed when the chambers were adjacent to the
incision wound (final cell density= 1.3 x 107 cells ml I on day
2). When distal from the wound site a growth lag of 72 h
was observed, followed by log. phase growth (doubling
time =24h) to plateau at 168 h at 2 x 107cellsml-'. Under
these conditions, growth characteristics were optimally
reproducible when an initial cell density of 1 x 106 cells ml-1
and a 0.45pm Millipore filter was used. In the absence of
serum in the chamber, spontaneous differentiation, assessed
by biochemical and morphological tests, was < 10% in cells
which had been implanted 22 days earlier. We consider this
to be a potentially useful model for assessing drug-induced
terminal cell differentiation in vivo.
Anti-tumour activity of TCNU in transplantable colon tumours
in NMRI mice
M.C. Bibby & J.A. Double
Clinical Oncology, Unit, University of Brad/ord, Bradftwrd,
West Yorkshire BD7 JDP, UK.
I - (2 - chloroethyl) 3 - [ 2 - (dimethylaminosulphonyl) ethyl I - 1 -
nitrosourea (TCNU) is a new nitrosourea with greater water
solubility. Following improved activity over other
nitrosoureas in experimental tumour systems it has
undergone Phase I evaluation. Objective responses have been
seen in squamous cell, adenocarcinoma and large cell
carcinoma of the lung as well as in mesothelioma and breast
cancer. Phase 11 evaluation in non-small cell lung cancer,
melanoma, breast cancer and colorectal carcinoma are now
in progress. The purpose of this study was to examine its
activity in a panel of transplantable adenocarcinomas of the
mouse colon with varying sensitivities to standard
nitrosoureas. Chemosensitivity was assessed in three tumour
lines, the ascitic line MAC 15A, a poorly differentiated
subcutaneous solid tumour MAC 13 and a well
differentiated solid tumour MAC 26. Effects of treatment
were determined as previously described (Double et al, Br. J.
Cancer, 54, 595, 1986). Antitumour activity was also assessed
in systemic tumours produced by i.v. inoculation of MAC
I5A cells. TCNU was active against all tumour lines. This
represents an improvement over standard nitrosoureas.
Response of MAC 13 was similar to those seen with
standard nitrosoureas whereas improved responses were seen
in MAC 15A and MAC 26. The activity against MAC 26
was particularly interesting as this tumour is unresponsive to
standard nitrosoureas. These latter improvements may
indicate that the water solubility of TCNU may alter
pharmacokinetics which may have therapeutic implications.
Tissue distribution and pharmacokinetic investigations are
currently in progress.
Antitumour screening models relevant to the development of
platinum drugs
K.R. Harrap, M. Jones, P.M. Goddard, R.M. Orr & Z.H.
Siddik
Drug Development Section, The Institute of Cancer Research,
Sutton, Surrey, UK.
Carboplatin (CBDCA, JM8, Paraplatin) was developed in
the expectation that it would possess clinical activity
comparable to that of the parent drug, cis-platin, yet be
much better tolerated [Harrap K.R., Cancer Treat. Rev., 12,
(Supp A), 21 1985]. It was not expected to possess activity in
cis-platin-resistant disease, since only platinum complexes
containing a diaminocyclohexane ligand possessed this
property in preclinical screening models [Burchenal, J.H.
Rec. Res. Cancer Res., 4, 146, 1980]. The lowered clinical
toxicity of carboplatin has been demonstrated [Calvert, A.H.
et al, Cancer Chemother. Pharmacol., 9, 140, 1982], while
also the drug is active in a small, yet significant, proportion
of ovarian cancer patients who have relapsed on previous
cis-platin therapy [Wiltshaw, E. Cancer Treat. Rev., 12,
(Supp A), 67, 1985]. Further, the spectrum of clinical
activities possessed by carboplatin may not coincide with
that of cis-platin (Cannetta et al, Cancer Treat. Rev., 12,
(Supp A), 125, 1985). These findings suggest that more
effective platinum derivatives may be discovered with
suitably predictive screening models. The limitations and
disparate predictiveness of widely used experimental tumours
(L1210 and ADJ/PC6 plasmacytoma) and their cis-platin-
resistant variants are presented in the light of the established
clinical requirements. Preliminary studies with a number of
human ovarian tumour xenografts grown in the nude mouse
suggest that a panel of such tumours, characterised for
sensitivity against appropriate reference platinum drugs (cis-
platin, carboplatin, iproplatin, tetraplatin), may be of greater
utility in the development of novel platinum agents.
Relationship between pharmacokinetics and stability of TCNU
and in vitro sensitivity of mouse colon tumour cells
R.M. Phillips, P.M. Loadman, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University of BradfJrd, Bradford,
West Yorkshire BD7 IDP, UK.
Preliminary studies in this laboratory with I-(2-chloroethyl)
3-[2-(dimethylaminosulphonyl)ethyl]- I -nitrosourea (TCNU)
have been shown to be highly active against transplantable
mouse colon tumours (MAC). In vivo pharmacokinetics
and in vitro stability of TCNU have been studied using a
reverse phase HPLC technique giving a sensitivity of
5 ngml- 1 Rate of breakdown of TCNU at 37°C in vitro
in the dark was 0.14gmin-I in mouse plasma, 0.08gmin-I
in human plasma, 0.10gmin-1 in PBS and 0.llgmin-1 in
RPMI 1640 with 10% foetal calf serum. Rate of breakdown
in 0.9% saline at 20C on the bench was 0.02gmin- 1.
Non tumour bearing NMRI mice were injected i.p. with
therapeutic doses of TCNU in 0.9% saline and plasma
profiles measured between 0-4 h. TCNU was not detectable
in the plasma at 2h. In vitro cell lines were derived from
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teristics and histology MAC 13, MAC 15A and MAC 26.
Chemosensitivity to TCNU was determined at a range of
concentration and exposure times for each of these lines
using a modified clonogenic assay (Hamburger & Salmon,
Science, 187, 461, 1977) and cytotoxic effects of treatment
were expressed in terms of percentage survival. Drug levels
within in vivo achievable plasma concentrations were
employed. All 3 cell lines responded to TCNU and the
spectrum of chemosensitivity was similar to that previously
seen in vivo with MAC 13 being the most sensitive and MAC
26 being less responsive. This study demonstrates that in
vitro chemosensitivity using a clonogenic assay at relevant
biologically achievable concentrations predicts for in vivo
activity of TCNU in 3 histologically different transplantable
mouse colon tumours.
Characterisation of a cis-platin-induced DNA damage in a
human bladder tumour continuous cell line
S.A. Shellard', P. Bedford1'2, M.C. Walker2, J.R.W.
Masters2 & B.T. Hill"2
1Laboratory ofCellular Chemotherapy, Imperial Cancer
Research Fund, London WC2A 3PX and 2Institute of
Urology, St Paul's Hospital, London WC2H 9AE, UK.
Two sublines have been derived from a human bladder
carcinoma cell line (RT112-P) by either continuous exposure
to cis-platin (RT112-CP+) or to fractionated X-irradiation
(RTI 12-DXR8). In vitro sensitivities to cis-platin were
determined by clonogenic assay following a 1 h exposure to
drug. The RTI 12-DXR8 subline exhibited a 1.6-fold hyper-
sensitivity and the RTl 12-CP+ subline a 2-fold resistance to
cis-platin compared to the parent cells (IC50 for RTI 12-P is
.1 ygml-1). Similar patterns of cross-resistance and
collateral sensitivity to carboplatin and iproplatin were also
observed. Since DNA is considered an important target for
the cytotoxic action of cis-platin, DNA-DNA interstrand
crosslinking and single-strand breakage were quantitated in
these lines at 0, 5, 14 and 24h, following a 1 h in vitro
exposure to drug, by the technique of alkaline elution. Inter-
strand crosslinks were induced to a far greater extent in the
sensitive subline and to a similar extent in the resistant
subline, when compared to the parent, with peak levels of
126.5, 52.8 and 58.2 rad-equivalents respectively. A
significantly increased uptake of 195mcis-platin was noted in
the sensitive subline with a similar uptake in the resistant
line compared to the parent cells, whereas the extent of
binding to DNA was comparable in all three lines.
Significantly increased levels of both glutathione and
glutathione reductase occurred in the RTl 12-CP+ cells
compared to the parent and RTl 12-DXR8 cells, which had
similar levels. Therefore, the underlying mechanisms of
resistance or collateeal sensitivity to cis-platin may not be
conversely related.
The effect of mitozantrone on viability and differentiation of
human promyelocytic leukaemia (HL60) cells
L.H. Patterson, M. Ruffet, M.A. Aulton, J.K. Sugden &
M.J. Taylor
School ofPharmacy, Leicester Polytechnic LE3 9BH, UK.
The effect of mitozantrone on HL60 cells was investigated
since this drug is indicated in the treatment of certain
myelogenous leukaemias. HL60 cells (3x 10 ml-') in log
phase growth maintained in RPMI 1640 medium
supplemented with foetal calf serum (10%) were incubated at
37C in the presence of 0.1 M mitozantrone for 24h. The
cells were then washed to remove drug and incubated for a
further 4 days in fresh medium. Induction of differentiation
was monitored by assessment of phagocytosis of
compliment-coated yeast cells and phorbol ester mediated
superoxide anion production as measured by nitrobluetetra-
zolium (NTB) reduction. The results shown in the table
which are typical of 2 separate experiments indicate that
mitozantrone produces a progressive inhibition of HL60 cell
survival even after the drug is removed (days 2 and 5) from
the incubation medium. Furthermore mitozantrone has
promoted differentiation in 14-28% of the remaining cells.
These results are consistent with the concept that the
cytotoxic threat to HL60 cells is sufficient to induce
differentiation.
0 /0
Incubation Viable cells NBT Phago-
Treatment time (days) (x 105) % Viability reduction cytosis
None 1 3.5 95 1 1
2 7.2 94 1 1
5 7.6 92 2 3
Mitozantrone 1 1.6 66 5 4
(0.lPM) 2 0.4 22 28 14
5 0.1 7 14 25
Monitoring of exposure to alkylating agents by analysis of
N-terminal protein adducts
P.B. Farmer, E. Bailey & B.J. Passingham
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM5 4EF, UK.
The interaction of proteins with alkylating carcinogens
frequently results in the formation of covalent bound
adducts of the carcinogen with specific nucleophilic sites in
amino acids. Amrongst these sites is the amino group of the
N-terminal amino acid, an example of the reaction being the
formation of N-(2-hydroxyethyl)valine at the N-terminal
valine of haemoglobin following exposure to ethylene oxide.
This adduct has been quantified in human haemoglobin by
Tornqvist et al., (Anal. Biochem., 154, 255, 1986) following
its conversion to a penta-fluorophenylthiohydantoin
derivative by a modified Edman degradation procedure. We
have now modified this analytical approach and applied our
method to the determination by GC-MS of hydroxy-
ethylvaline in the globin of human subjects. The method
involves the following steps: 1. Addition of stable isotope
labelled internal standard (globin treated with d4-ethylene
oxide); 2. Reaction of globin (50mg) in formamide solution
with pentafluorophenyl isothiocyanate; 3. Extraction of
N-(2-hydroxyethyl)valine pentafluorophenylthiohydantoin; 4.
Derivatisation with a trimethylsilylating agent; 5. Electron
impact capillary GC-MS using selected ion recording of m/z
440 and 444. The sensitivity of the method is sufficient to
detect 'background' hydroxyethylvaline in control subjects of
<100pmolg-1 globin and is currently being used to
measure levels of the adduct in smokers, (who are exposed
to ethylene oxide through the inhalation of ethene), and in
non-smokers.JOINT MEETING OF THE BACR AND THE ACP 201
The effect of blood transfusion on tumour spread
P.J. Clarke & D. Tarin
NufIield Department of Pathology, (University ofOxford),
John Radeliffe Hospital, Oxford OX3 9DU, UK.
Routine blood transfusion in patients awaiting cadaver renal
transplantation has improved graft survival rates at one
year. Although the immunological mechanisms involved
remain unclear, there is concern that, if a similar process
occurs in transfused cancer patients, this may be reflected in
a poorer prognosis. Retrospective clinical studies have
supported this theory.
The effect of blood transfusion was therefore studied using
3 transplantable mouse tumour lines (UV-2237, KHT and
B16-FO0). On day - 14, animals were transfused with
0.25 ml of allogeneic blood. Tumour inoculation into the
appropriate syngeneic host was performed on day 0 and
subcutaneous tumour growth was assessed by weekly
measurements. Metastatic spread of tumour to the lungs and
other organs was determined at autopsy and histologically.
There was no difference in tumour growth rate in those
animals which were transfused compared with saline infused
controls. However there was an increase in the number of
pulmonary metastases in certain, but not all, of the
transfused groups. If a similar phenomenon occurs in man,
these findings may have important implications.
New B lymphoblastoid parents for human fusion
H.Y. Youd, S. Speirs & H.M. Warenius
Department ofRadiation Oncology, Clatterbridge Hospital,
Bebington, Wirral, Merseyside L63 4JY, UK.
One of the main problems concerned with the production of
human monoclonal antibodies has been the limited avail-
ability of a suitable fusion partner. Past problems include
low Ig production, low fusion success rate, and instability of
hybrids. We are concerned with the production of alternative
fusion partners and comparing them with other lines used in
Human X Human B lymphocyte fusions. Using lymphocytes
taken from a patient with plasma cell leukaemia (PCL) at
plasmaphoresis, we attempted to obtain better immortal lines
by growing the cells in nude mice, which up to the present
has been unsuccessful, but by hybridisation with UC729-6
four cell lines have been produced. The hybrid nature of the
cells have been confirmed by examination of the ploidy on a
FACS 420. Tissue typing for histocompatibility antigens
showed in addition to the presence of antigens associated
with the UC729-6, those of the plasma cell leukaemia.
Surface and cytoplasmic immunoglobulin characteristics have
been examined using the FACS and enzyme linked immuno-
absorbent assay. All cell lines produced IgA, lambda of the
PCL parent and varying levels of IgM, known to be
produced by UC729-6. The cloning, plating efficiency and
growth characteristics in comparison of UC279-6 and LICR-
LON-HMY2, are much improved. These new lines have
been in culture for 18 months, can be preserved in liquid
nitrogen and recovered with high viable cell yield; they are
now being used a fusion partner to produce hybrids with
spleen cell and from a patient with idiopathic thrombo-
cytopenic purpura and lymph node cells from patients with
colonic cancer.
Interferon (IFN) modulation of MHC antigen expression and
cytostasis on human tumour cell lines in vitro
R.K. Iles', C. Navarrete2, R.T.D. Oliver1 & H. Festenstein2
'Medical Oncology Unit, Department of Urology and
2Department ofImmunology, The London Hospital Medical
College, London El, UK.
Fourteen cell lines: 12 of genitourinary tumour origin and 2
from normal or SV40 immortalised skin were studied for
their major histocompatibility complex (MHC) antigen
expression and subsequent modulation by IFNax and IFNy.
The cytostatic effect of the IFNs on these cell lines was also
measured.
In order to quantify MHC antigen expression, as detected
by monomorphic class I and class II monoclonal antibodies
(W6/32 and EDUI), three methods were used: Fluorescent
activated cell sorter (FACS), enzyme linked immunosorbant
assay (ELISA) and in situ immunofluorescence microscopy.
Results from all 3 were combined to give more representative
estimates. Cytostasis was measured as relative %3H-
thymidine incorporation compared to untreated controls.
The results show heterogeneous MHC antigen expression
and cytostasis responses to both IFNs between the different
cell lines. When these two parameters were compared, we
found a strong correlation between class II expression
responses and cytostasis, i.e. strong class II induction -
positive cytostasis and vice versa. In contingency table
analysis (Fisher's exact test) P<0.05 and P<0.01 for IFNa
and IFNy respectively.
These results indicate for all the cell lines studied, alterations
in IFN cellular kinetic pathways, which are common for
these two biological phenomena, may result in diminished
responsiveness to IFN modulation, particularly for IFNy
which induces the expression of class II antigens
It can be postulated that the down regulation of IFN
induced responses may be important in the development of
neoplasia. However it is also possible that the results occur
as a consequence of the neoplasia.
Monoclonal antiidiotypic antibodies and immune responses
to tumours
P. Dunn, 0. Leger, C. Johnson, S. Pease, J. Styles &
C. Dean
Institute ofCancer Research, Block X, Clifton Avenue,
Sutton, Surrey, UK.
The Hooded rat sarcoma HSN metastasises to the lungs
when grown in immune suppressed hosts. In immuno-
competent syngeneic rats spontaneous metastasis is rare and
growth of the tumour elicits the production of antibodies
directed against a 180kD surface protein. Hybridomas
secreting specific monoclonal antibodies of differing isotype
have been prepared from tumour bearers. All of the
monoclonal antibodies obtained compete with each other for
binding to HSN cells.
Monoclonal antiidiotypic antibodies (Ab2) directed against
combining site idiotopes of two of the specific antibodies
have been prepared by immunising syngeneic rats with the
tumour specific Ab,. The antiidiotypes obtained (HIM/l/230
and HIM/8/88) are individually specific for the immunising
antibodies 11/160, Y2b or ALN/I 1/53, Y2a) We conclude that
there are two overlapping epitopes on the 180kD antigen
and these elicit antibody responses in tumour bearers that
are isotype specific. One of the antiidiotypes (HIM/l/230,
Y2a) has been used to 'vaccinate' naive Hooded rats. The
animals generate antibodies (Ab3) which include those with
specificity similar to the Ab, (11/160) isolated from tumour
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bearers. The vaccinated rats show resistance to a subsequent
challenge with tumour.
DNA cross-linking and platinum resistance in ovarian
carcinoma cell lines
G.J. Beattie, I.P. Hayward & J.F. Smyth
Medical Oncology Unit, Department of Clinical Oncology,
Western General Hospital, Edinburgh EH4 2XU, UK.
The difference in sensitivity to cis-platinum (cis-DDP)
between 2 human ovarian adenocarcinoma cell lines estab-
lished from ascites samples from one patient before (PEOI)
and after (PE04) the onset of clinical resistance to the
drug was studied using the technique of alkaline elution.
After 5 h of treatment with 50pM cis-DDP no significant
difference in total cross-linking as expressed in rad equiva-
lents was observed between the two cell lines. There was how-
ever a 2-3 fold difference in protease-resistant cross-linking
between PEOI and PE04; see table.
Total cross-linking Protease-resistant cross-linking
PEOI 468 (±35) 231 (+23)
PE04 422 (+ 32) 97 (+ 8)
These figures are in agreement with the 3-fold difference in
sensitivity obtained in clonogenic assays using these cell
lines. Protease-resistant cross-linking showed a linear-dose
response as measured 4h after a 2 h dose of 5-50jM cis-
DPP. Here a 2-fold difference in protease-resistant cross-
linking was observed over the range studied. A subline
derived from PEOI (PEOI cis-DPPR) with 25-fold resistance
to cis-DPP acquired in vitro showed even less protease-
resistant cross-linking than either PEO0 or PE04. These data
suggest that the same total amount of platinum/DNA
adducts occur in PEOI and PE04 but DNA-interstrand cross-
links are reduced in PE04 and further reduced in PEOI cis-
DDPR. This would implicate either specific DNA lesions or
particular DNA repair pathways in the resistance observed.
This work is being extended to study DNA damage in vivo
in peripheral blood lymphocytes from patients with ovarian
carcinoma currently being treated with cis-platinum.
Quantitation of DNA adducts caused by chemotherapeutic
drugs using monoclonal antibodies
M.J. Tilby, J.M. Styles, C.A. Johnson, R. Knox, J.J. Roberts
& C.J. Dean
Institute of Cancer Research, Block X, Clifton Avenue,
Belnmont, UK.
We have produced a number of monoclonal antibodies that
bind to DNA that has been alkylated with melphalan but
not to normal DNA. One of these has been used in a
sensitive enzyme-linked immunoabsorbent assay (ELISA) to
detect DNA damage caused by therapeutic doses of this
drug. We present data showing that the sensitivity of this
technique permits detection of less than I adduct in 106
bases and that the assay correlates with the less sensitive
radiochemical detection of melphalan adducts. We are using
these antibodies to study the formation and repair of DNA
lesions in lymphocytes of patients undergoing melphalan
therapy and to study the distribution of DNA damage in
various cell types.
More recently we have produced monoclonal antibodies
that bind to DNA that has been modified with cis-platinum
and these are being used in similar studies.
Reactivity of 3-substituted imidazotetrazinones towards DNA,
RNA and protein
V.L. Bull & M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Aston Triangle,
Birmingham B4 7ET, UK.
The reactivity of mitozolomide and the 3-methyl
(CCRG81045) and 3-ethyl (CCRG82019) analogues, towards
DNA, RNA and protein has been investigated both with the
isolated macromolecules and in cells sensitive (GM892A,
Mer-) or resistant (Raji, Mer+) to drug action. The extent
of total alkylation of all three macromolecules increases as
the concentration of drug increases, and towards isolated
DNA and RNA the extent of alkylation by CCRG81045 is
about twice that of mitozolomide, and both are 5 to 10 times
more reactive than CCRG82019. Mitozolomide is about 10-
fold more reactive towards isolated protein than the other
two imidazotetrazinones. When macromolecules are isolated
from cells treated with these agents, the relative extents of
alkylation differ from that observed with isolated macro-
molecules. For all three macromolecules in both cell lines,
the levels of alkyl adducts remaining 24h after mitozolomide
treatment exceeds that of the other two agents. While the
levels of alkyl adducts remaining on DNA and RNA in cells
after CCRG81045 and CCRG82019 treatment approximates
to that seen with isolated macromolecules, there are more
chloroethyl adducts remaining 2h after mitozolomide treat-
ment (0.1 mM) on DNA in intact cells (0.48pmol drug bound
Ig-l DNA) than on isolated DNA (0.12pmol drug bound
,g 1 DNA). The levels of alkyl adducts remaining on DNA
and RNA after treatment with all three agents is greater in
Mer- than Mer+ cells, but there is no difference in the levels
of alkyl adducts on protein. These results suggest that the
inability to repair specific base alkylations may be
responsible for the selective cytotoxicity of the imidazo-
tetrazinones.
Expression of cytochrome P450S in tumour-derived cell lines
L.A. Stanley', A.R.R. Scott', N. Spurr2 & C.R. Wolf I
Imperial Cancer Research Fund, I Molecular Pharmacology
Laboratory, Hugh Robson Building, George Square,
Edinburgh and 2Human Genetic Resources Laboratory, Clare
Hall, Potter's Bar, Hertfordshire, UK.
The level of drug-metabolising enzymes in a tumour is
important in determining its response to chemotherapy.
Regulation of cytochrome P450 (P450) expression by drugs
and endogenous factors (e.g. interferons (Ifns), interleukins
(ILs), and tumour necrosis factor (TNF)) is also potentially
important where chronic inflammation is associated with
exposure to carcinogens (e.g. in the smoker's lung). In order
to select a cell culture model to examine this problem,
constitutive P450 expression in several cell lines has been
studied immunochemically, along with regulation of this
expression by P450 inducing agents such as phenobarbital,
dexamethasone, Aroclor 1254, and 1,2-benz-anthracene. The
results show that the human tumour-derived cell lines
HepG2 (hepatoma), NCI-H322 (non-small cell lung
carcinoma), MCF-7 (breast carcinoma) and LS174T (colon
carcinoma) express the P450 isozyme MCib. This enzyme has
high activity in the metabolism of a wide variety of drugs
and chemical carcinogens. The above cell lines will therefore
be of value in studying the effects of inflammatory mediators
such as Ifny, IL-1, and TNF on P450 expression and
elucidating the role of P450 MCIb in the disposition of
carcinogens and chemotherapeutic drugs.JOINT MEETING OF THE BACR AND THE ACP 203
Elevated expression of glutathione-S-transferase subunits in
granulocytes following drug priming
C.R. Wolf', A.D. Lewis' & J.D. Hayes2
'Imperial Cancer Research Fund, Laboratory ofMolecular
Pharmacology and Drug Metabolism, George Square,
Edinburgh EH8 9XD and 2Department of Clinical
Clhemotherapy, Edinburgh Royal Infirmary, Edinburgh, UK.
We have studied the response of bone marrow cells to
cytotoxic drugs as a model for evaluating the regulation of
glutathione-dependent enzymes as stress response proteins.
The model chosen is based on the observation that when
mice are dosed with a low 'priming' dose of cyclophosamide,
they become resistant to a subsequent potentially lethal dose
given 5 to 6 days later (Millar et al, Br. J. Cancer, 32, 193,
1975). We have shown previously that both glutathione
(Gsh) and glutathione-S-transferases (Gst) (which have been
implicated in the detoxification of the cytotoxic metabolites
of cyclophosamide) are increased at the points of maximum
protection. We have now extended this study to identify the
Gst isoenzymes affected. SDS/PAGE analysis of bone
marrow proteins following 'priming' with cyclophosamide
has shown an elevation of a polypeptide that comigrated
with rat YbYb Gst subunit. An elevation in levels of a
protein equivalent to the neutral YbYb subunit was
confirmed by Western blot experiments. A slight elevation in
the basic (YaYa) subunit was also observed. The elevation in
the YbYb subunit was shown to occur within the
granulocyte cell population and could be seen in both
peripheral cells as well as those from the bone marrow.
Lymphocytes in contrast, contained high levels of acidic
YfYf and low levels of YbYb subunits. The levels of the
Gsts in these cells were unchanged following priming. In
view of the importance of these enzymes in the protection of
cells from cytotoxic electrophiles, e.g. cancer chemo-
therapeutic agents, the study of the Gst gene expression may
provide information about factors which regulate drug
resistance in tumour and normal cells.
Expression of glutathione-S-transferases in tumour cell lines
A.D. Lewis', J.D. Hayes2 & C.R. Wolf'
'Imperial Cancer Research Fund, Laboratory ofMolecular
Pharmacology and Drug Metabolism, George Square,
Edinburgh EH8 9XD and 2Department ofClinical
Chemotherapy, Edinburgh Royal Infirmary, Edinburgh, UK.
Glutathione and glutathione-dependent enzymes such as the
glutathione-S-transferases (Gsts) play a central role in the
protection of cells from cytotoxic and carcinogenic
compounds. However, relatively little is known about the
glutathione levels and Gst expression in tumour cells.
Nevertheless, there is evidence which indicates that it is an
important factor in tumour cell susceptibility to anticancer
drugs. As a consequence the expression of Gst in 10 tumour
cell lines of different origin has been studied. A large
variation in Gst activity, determined using CDNB as a
substrate was measured. The human breast cancer cell line
MCF-7 had extremely low activity and was 100 fold less
than either the ovarian cell line PE-04 or the non-small cell
lung carcinoma line H358. Western blots of soluble fractions
from these lines using antibodies raised against human Gsts
basic (e, YaYa), neutral (,u, YbYb) and acidic (x., YfYf)
showed high levels of the acidic YfYf poltpeptide (an
enzyme which has been associated with drug resistance) in
most of the cell lines studied. Ovarian adenocarcinoma cell
line PE-04, lung carcinoma line H358 and the human
bladder carcinoma line EJ contained highest levels of this
enzyme. Mouse hepatoma line HEPA 1 contained extremely
low amounts of the YfYf subunit and no visible band was
seen in the MCF-7 cells. No basic YaYa Gst was found at
significant levels in any of these cell lines. Neutral enzyme
YbYb was only detected in MCF-7, HEPA I and foetal
fibroblasts. Interestingly the data shows that different
tumour cell lines have marked differences in their Gst
isoenzyme expression and levels. The possibility exists
therefore that these variations are related to the susceptibility
of tumours to chemotherapy.
Cross-resistance of a daunorubicin resistant cell line towards
anthrapyrazolone
D.G. Poppitt, A.T. McGown & B.W. Fox
Paterson Institutefor Cancer Research, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
The anthrapyrazole class of intercalating agents have been
developed in order to reduce free radical production
associated with the anthraquinone anti-tumour drugs. Two
P388 cell lines resistant to daunorubicin have been developed
from the parental cell line by incremental challenge with the
drug in vitro. Growth inhibition studies on these cell lines
show cross resistance towards anthrapyrazolone. The ID50
values (concentration of drug required to cause a 50%
decrease in cell growth) are shown in the table. Resistance to
daunorubicin in these cell lines has been shown to be
associated with a 4-fold decreased cellular accumulation of
drug.
Cell line ID50 daunorubicin ID50 anthrapyrazolone
P388 19 x 10 9M 8 x 10 9M
P388R8/13 6.5 x10 7M 7 x 10 7 M
P388R8/22 2.7 x10 6 M 1.8 x 10 6 M
(McGown et al, Cancer Chemother. Pharmacol., 11, 113,
1983). Biochemical extraction of anthrapyrazolone following
treatment (1 h; 37"C) from the parental and resistant cell
lines however shows no difference in drug accumulation. Co-
incubation with verapamil (10tIm), which causes the resistant
cells to incorporate daunorubicin to the same level as the
parental cells, causes a small (- 20%) but significant
(P<0.05) increase in athrapyrazolone accumulation in each
of the cell lines tested.
Resistance to daunorubicin in these cell lines is
accompanied by cross resistance to anthrapyrazolone.
However, no differential drug accumulation could be
observed between the parental and resistant cell lines.
Inhibition of adriamycin superoxide formation and lipid
peroxidation by the anthrapyrazolone C1941
M.A. Graham', D.R. Newell' & L.H. Patterson2
'Drug Development Section, Institute of Cancer Research,
Sutton, Surrey and 2The School of Pharmacy, Leicester
Polytechnic, UK.
Reactive free radical formation and the subsequent induction
of lipid peroxidation have been implicated in the serious
dose limiting cardiotoxicity of adriamycin (Myers et al,
Science, 197, 165, 1977). Adriamycin can undergo a one204 JOINT MEETING OF THE BACR AND THE ACP
electron reduction to form a drug free radical which can
react directly with molecular oxygen to form superoxide
(02-) and thence other activated oxygen species such as the
hydroxyl radical OH and H202' These activated oxygen
species can in turn initiate lipid peroxidation and other
destructive cellular events such as membrane damage,
enzyme inactivation and DNA strand cleavage. The anthra-
pyrazole C1941 is one of a new series of DNA complexing
drugs which have demonstrated high level antitumour
activity against a broad spectrum of murine tumours
(Leopold et al., Cancer Res., 45, 5532, 1985) and is currently
undergoing phase I clinical evaluation. We have examined
the effect of C1941 on adriamycin free radical generation,
superoxide formation and lipid peroxidation, using rat liver
microsomes fortified with NADPH. The results show that
C1941 can inhibit adriamycin (50 iM) induced NADPH
consumption (56% inhibition at 50 jiM C1941). Electron spin
resonance studies have shown that C1941 can diminish the
adriamycin drug free radical signal in a dose dependent
manner. Similarly adriamycin superoxide formation (using
purified cyt. P450 reductase) can be inhibited by C1941
(IC50 =75pM). An examination of the effects of the two
agents on lipid peroxidation reveals that C1941 is a potent
inhibitor of adriamycin stimulated lipid peroxidation
(IC50 = 5gM). In conclusion therefore, the inhibitory effect of
C1941 on adriamycin activation may form the basis for the
combined use of the two drugs in attempts to diminish
adriamycin cardiotoxicity.
Interaction of doxorubicin and mitozantrone with myoglobin
T.J. Lavelle & L.H. Patterson
School ofPharmacy, Leicester Polytechnic, Leicester LE]
9BH, UK.
The interaction of doxorubicin and mitozantrone with
myoglobin has been investigated to establish whether this
haemoprotein could be involved in the cardiotoxic actions of
these antitumour agents. Oxymyoglobin (MbFe(II)02) and
metmyoglobin (MbFe(III)) were prepared as described by
Taylor & Hochstein, (Biochem. Pharmacol., 27, 2079, 1978)
and the effects of doxorubicin and/or mitozantrone on
them monitored spectrophotometrically between 450-650nm.
Doxorubicin was shown to stimulate autooxidation of
MbFe(II)02 to MbFe(III) (basal rate typically 100pmolmin-1)
by up to 500% in a dose dependent manner. This resulted
in doxorubicin dependent reactive oxygen formation as indi-
cated by stimulation of adrenochrome formation from
adrenaline and greater than 90% inhibition of MbFe(II)02
conversion in the presence of the reactive oxygen scavengers
superoxide dismutase plus catalase. Mitozantrone also
stimulated MbFe(II)02 oxidation (up to 150%) but only at
drug concentrations up to 50pM, after which mitozantrone
produced progressively less stimulation and above 200 IM
actually inhibited the oxidation process. Furthermore mito-
zantrone (400 jM) totally inhibited doxorubicin dependent
MbFe(II)02 oxidation. The results show that doxorubicin and
to a lesser extent mitozantrone can interact with MbFe(II)02
to produce metmyoglobin. The reactive oxygen liberated by
this process can directly oxidise MbFe(II)02 thereby
exacerbating formation of metmyoglobin which cannot
function as an oxygen storage protein. Furthermore reactive
oxygen formation by this mechanism may contribute to
other cardiotoxic consequences associated with doxorubicin
and mitozantrone.
Inherent adriamycin resistance in a murine tumour cell line.
H: Influence of verapamil on adriamycin intracellular drug
levels, metabolism and binding to DNA
J. Cummings, R. Milroy, S. Merry, J.G. Morrison &
S.B. Kaye
Department ofMedical Oncology, Glasgow, UK.
The mechanism(s) by which verapamil (VPM) enhances the
chemosensitivity of drug resistant tumour cells remains
unclear. We have demonstrated that 6.6/M VPM increases
chemosensitivity of our mouse tumour line (MOG-XMTl) to
Adriamycin (ADR) by up to 20-fold. Three possible
mechanisms have been investigated in an attempt to explain
this finding: increased intracellular ADR levels, changes in
drug metabolism and changes in DNA binding affinity. For
uptake studies intracellular drug and metabolite
concentrations were measured by HPLC after exposure to
5pgml - I ADR. Competitive binding was performed on
DNA isolated and purified from 108 cells (n=3). Apparent
binding affinity constants (Kb(app)) and number of binding
sites to DNA (n) were calculated by Scatchard analysis. In
cell monolayers VPM at a concentration of 6.6gM had no
effect on intracellular ADR concentrations and no effect on
qualitative or quantitative pathways of metabolism was
observed. VPM at a concentration range of 1 x 10-3 to
I X 10-6M had no effect on the binding of ADR to isolated
purified DNA (Kb(app) 2.2 x 10-6M, n=0.28). We conclude
that whilst VPM alters chemosensitivity in XMTI, it does so
without altering drug accumulation, metabolism, or the
capacity of ADR to bind to DNA. Our recent observations
suggest that VPM may be acting by altering intracellular
drug distribution, rather than overall concentration and
further studies involving subcellular fractionation are in
progress.
Ethoxyquin induces preneoplastic changes in rat kidney
M.M. Manson, J.A. Green & H.E. Driver
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM5 4EF, UK.
The antioxidant ethoxyquin (EQ) has been shown both to
inhibit tumour formation, mainly in liver, and also to act as
a tumour promoter in some extrahepatic tissues. At a dose
(0.5% in the diet) which completely inhibited induction of
hepatocellular preneoplastic foci by aflatoxin B1,
considerable renal damage was observed in 30 week old
Fischer rats after 23 weeks of EQ treatment. Many of the
pathological changes resembled those of chronic progressive
glomerulonephrosis (CPGN), normally seen in very old
animals, suggesting that EQ was accelerating the ageing
process. Formation of haemosiderin and large amounts of
lipofuscin were prominent in tubular cells. In addition to the
changes of CPGN, EQ treated kidneys contained many
hyperplastic tubules and small nodules of epithelial pro-
liferation, often obliterating the lumen. Such changes are
potentially preneoplastic and may be the precursors of
adenocarcinomas. These hyperplastic tubules differed in a
number of respects from those occasionally seen in CPGN
and support for their preneoplastic nature was obtained by
their basophilic staining with H and E, loss of GGT activity
and PAS-positive brush borders, and strong staining for
guanidinobenzoatase; hyperplastic tubules of CPGN do not
stain for this tumour-associated enzyme. EQ-treated kidneys
also showed induction for one or more isozymes of gamma
glutamyl transpeptidase and glutathione S-transferase P (7-7
form), mainly in undamaged tubules of the outer cortex.
Results suggested that EQ might be exerting a carcinogenic
action in the kidney.JOINT MEETING OF THE BACR AND THE ACP 205
DNA repair characteristics of Walker cells sensitive or
resistant to difunctional agents
R.J. Knox & J.J. Roberts
Department of Molecular Pharmacology, Institute of Cancer
Research, Sutton, Surrey SM2 5PX, UK.
The Walker 256 carcinoma cell (WS) is inherently sensitive
only to difunctional agents such as cis-platin. Resistant
Walker cells (WR) show comparable sensitivity as
conventional cell lines. Both WS and WR cell lines are
transfectable with pSV2gpt in suspension culture. Reaction
of this plasmid with cis-platin or the monofunctional
reacting Pt(Dien) prior to transfection caused a dose
dependant decrease in the subsequent expression of XGPRT.
At the same binding of Pt to the plasmid DNA a large
difference in the effects of the monofunctional as opposed to
the difunctional agent was apparent and this was a reflection
of the relative cytotoxicities of these agents towards
mammalian cells. However no significant difference was seen
between WS or WR cells on the expression of pSV2gpt
reacted with cis-platin even though WS cells are 20 fold
more sensitive to this agent than WR cells. Based upon a
knowledge of the proportions of the various adducts formed
in DNA reacted with cis-platin, the lesion that inactivates
expression of XGPRT was probably the intra-strand
crosslink. Due to the size of the plasmid inter-strand
crosslinks were not present in the plasmid DNA at these
inactivating doses. Sensitivity to such relatively rare lesions is
probably the basis of the defect in certain cells types such as
the WS.
Synthesis and structure of DNA containing 06-methylguanine,
06-ethylguanine and 04-methylthymine
B.F.L. Li', P.F. Swann', M. Kalnik2 & D.J. Patel2
'Biochemistry Department, Middlesex Hospital Medical
School, London WIP 7PN, UK and 2Department of
Biochemistry and Biophysics, College ofPhysicians and
Surgeons, Columbia University, New York NY 10032, USA.
An understanding of the recognition of modified DNA by
DNA repair enzymes may throw light on some general
aspects of protein DNA recognition. Self-complementary
dodecadeoxynucleotides containing either one o6-
methylguanine (06-meG), one 06-ethylguanine (06-etG), or
one 04-methylthymine (04-meT) residue have been
synthesized by the phosphotriester approach in solution.
They anneal to give double-stranded DNA in solution. The
structure of double helices containing 06-meG: cytosine (C),
06-meG: thymine (T), 06-etG: C, and G: 04-meT base-pairs
have been studied by NMR. The helices were right-handed
with every nucleoside having the anti glycosidic torsion angle
found in B-DNA. The modified bases stacked into the helix,
and the alkyl groups were shown to be in the major groove
of the DNA. NMR and optical melting profiles indicate that
the helices are less stable than the non-alkylated parents but
only in helices containing 06-etG did the 3 spectrum give
evidence of severe distortion of the phosphodiester backbone
of the DNA. It has previously been believed that 06-meG
forms a stable base-pair with T and that 04-meT forms one
with G, and that in these base-pairs the imino protons of T
and G are hydrogen bonded to N(l) or N(3) of the alkylated
base. However, NMR shows that these protons are not
involved in strong hydrogen bonds and casts doubt on the
accepted structures for 04-meT:G and 06-alkylG:T mispairs.
Repair of synthetic DNA: Kinetics of repair of
oligodeoxy-nucleodites containing 06-alkylguanine
or 04-methylthymine by E.Coli
06-alkylguanine-DNA-alkyltransferase
R. Graves, B.F.L. Li & P.F. Swann
Biochemistry Department, Middlesex Hospital Medical
School, London WIP 7PN, UK.
Self-complementary synthetic dodecadeoxynucleoties con-
taining either one 06-methlyguanine, one 06-ethylguanine,
or one 04-methylthymine have been synthesized by the
phosphotriester approach in solution or on solid phase
supports. They have been used as substrates for DNA repair
by the 18 kD 06-alkylguanine-DNA-alkyltransferase of
E.coli or its 39kD precursor, the 39kD product of the ada
gene. The protein removed the alkyl cell group from all the
alkylated bases. The reaction followed second-order chemical
kinetics. The rates constants were:
06-methylguanine residues k =2.73 x 107 M-1 sec-
06-ethylguanine residues k=2.58 x 104 M -1 sec -
04-methylthymine residues k =2.52 x 103 M-1 sec-1
The rate of repair of 06-methylguanine residues is close to
the diffusion controlled limit (7 xl09M - sec-1) for second
order chemical reactions. The availability of the defined
sequence DNA-fragments containing modified bases
promises to allow very sensitive and absolutely specific assay
of DNA repair enzymes and to open the way to studies of,
for example, mechanism of repair enzymes and the influence
of DNA sequence on repair.
High uptake of RSU 1069 into B16 melanoma
J. Walling', J. Deaconl'2 & I. Stratford'
'MRC Radiobiology Unit, Chilton, Didcot, Oxon and
2Institute ofCancer Research, Sutton, Surrey, UK.
Pharmacokinetic studies of the hypoxic cell radiosensitizer
RSU 1069 in B16 melanoma have revealed marked selective
uptake. (Deacon et al., Int. J. Radiat. Oncol. Biol. Phys., 12,
1087, 1986). This contrasts with low tumour to plasma ratios
obtained in a previous study of RSU 1069 in the KHT
sarcoma (Workman & Walton, Int. J. Radiat. Oncol. Biol.
Phys., 10, 1307, 1984). We describe here experiments
designed to determine the basis for the very large difference
between these tumour systems for their uptake of RSU 1069.
The pharmacokinetics of RSU 1069 has been studied in
C57 mice carrying the B16 or Lewis Lung tumours and in
C3H mice bearing the KHT tumour. In each strain of mouse
the maximum brain to plasma ratio was always less than 1.0,
whereas the tumour/plasma ratio was 3.8, 0.5 and 0.4 for the
B16, KHT and Lewis Lung tumours respectively. In order to
test whether the differences observed have a cellular basis,
drug uptake experiments were carried out in vitro using
freshly exised tumour cells from B16, KHT, Lewis Lung,
HX34 and HX118 tumours, the latter two are human
amelanotic and melanotic melanoma xenografts respectively.
Uptake of RSU 1069 into B16 melanoma cells in vitro is pH
dependent. Values of the ratio of internal to external
concentration (Ci/Ce) were 0.99, 1.35, 1.88 and 3.04 when
cells were exposed at pH 5.4, 6.4, 7.4 and 8.4 respectively. In
contrast RSU 1069 is not selectively taken up by any of the
other tumour cell types in vitro, a Ci/Ce of unity being
obtained over the pH range 5.4-8.4.
The results suggest the high tumour/plasma ratio to a
characteristic of B16 cells alone and may indicate an intra-
cellular pH difference (relative to the other cell types) that
facilitates transport of the weak base, RSU 1069, into B16
cells.206 JOINT MEETING OF THE BACR AND THE ACP
A model for the study of treatment response in human normal
and tumour cells in vitro
C. Mothersill', C.B. Seymour', A. Cusack', A. O'Brien2,
M. Moriarty1 & T.P. Hennessy3
1Saint Luke's Hospital, Rathgar, Dublin 6, 2Meath Hospital,
Dublin 8 and 3St James's Hospital, Dublin 8, Eire.
Since all known chemotherapy and radiation treatments
affect normal cells to a certain extent, the establishment of
favourable differential sensitivities is fundamental to the
success of treatment with a particular agent. This type of
information can be gained by animal testing and using
cultured cells but ultimately use of the agent in the patient is
the only way to determine the response.
Our group has developed a model for testing the response
of oesophageal explants from tumour and surrounding
normal tissue in the same patient to chemotherapy and
radiation, both singly and in combination. The test allows
treatment combinations and time and order of adminis-
tration of agents to the tissue to be accurately controlled.
Cytotoxicity - determined by measuring the area of out-
growth from an explant two weeks after plating - is the
most useful short-term endpoint although many others are
possible.
Results on the differential cytotoxicity of bleomycin with
and without radiation in adenocarcinoma of the oesophagus
and surrounding normal tissue from the same patient
indicate that low levels of bleomycin with or without
radiation preferentially spare tumour cells while high levels,
in combination with any dose of radiation tested, but not
without radiation spare the normal cells and give a
significantly high amount of relative tumour cell kill.
In vitro fibrin formation by ascitic and peritoneal fluids:
A novel system for the study of fibrin-cell interactions
A.P. Wilson
Oncology, Research Laboratory, Derby City Hospital,
Uttoxeter Road, DerbY DE3 3NE, UK.
A large number of ascitic/peritoneal fluids have been tests
for colony-stimulating-activity against tumour cells (TC) and
transforming activity against mesothelial cells (MC) in a soft
agar assay. A proportion of these fluids were found to
induce varying degrees of spreading of MC in soft agar,
leading to monolayer formation in some cases. Limited
spreading of tumour cells also occurred. Addition of some of
these fluids to monolayers of TC or MC resulted in visible
formation of a fibrin mat which bound to the surface of MC
but not to 4/4 ovarian tumour cell lines. Only one of these
fluids had measurable levels of fibrinogen, though all had
high levels of FDP. It was noteworthy that the majority of
fluids which caused high-grade spreading came from patients
who had not been exposed to chemotherapy. Fibrin mats in
association with cells could be identified under phase
contrast in the soft agar, and spreading of cells was
presumably due to interaction between fibrin and the cell. It
is suggested that the soft agar model provides a novel system
for studying interactions between fibrin and normal cells or
TC. The system also allows study of clonal heterogeneity in
TC populations with respect to fibrin binding, as well as
drug modulation of fibrin/cell interactions.
Synthesis of oncogene anti-sense oligonucleotides and
oligonucleotide analogues
D.M. Tidd & H.M. Warenius
University, of Liverpool, CRC Department of Radiation
Oncology, Clatterbridge Hospital, Bebington, Wirral L63 4JY,
UK.
Multicellular tumour spheroids as an in vitro model for
antibody-targeted radiotherapy of cancer
K.A. Walker, T. Murray, T.W. Wheldon, A. Gregor &
I.M. Hann
Glasgowt Institute of Radiotberapeutics and Oncology,,
Belvidere Hospital, GlasgowA G31 4PG and Radioisotope
Dispensary, Glasgovw Western Infirmary, and Royal Hospital
for Sick Cbildr-en, Yorkhill, Glasgow, UK.
Tumour spheroids have been used to provide in vitro
simulation of antibody-targeted irradiation of micro-
metastases. A human neuroblastoma spheroid line (NBI-G)
was exposed to 1311 irradiation by incubation for 2h with
free 131 1, 1311 bound to non-specific protein and 131 1
conjugated to the anti-neuroectodermal monoclonal antibody
UJ1 3A. Cells were then repeatedly washed to remove
unbound activity and spheroid growth observed for up to 4
weeks. Spheroid response to 1311 irradiation was assessed as
growth delay and could be compared with the effects of
known doses of external beam X-rays. The results
demonstrated the relative effectiveness of 1311-UJ 1 3A
irradiation of neuroblastoma spheroids. A dose-response
relationship was obtained by varying the concentration of
the 131 1-UJ13A conjugate. The tumour spheroid model
provides a new approach to evaluation of antibody-targeted
radiotherapy of microscopic tumours using different
antibodies, antibody fragments and alternative radionuclides.
Anti-sense oligodeoxynucleotides (20-mers) complementary
to the untranslated sequence and codon 12 region of the
human EJ/T24 Ha-ras gene have been synthesized and are
being tested for effects on gene expression in ras-transformed
NIH 3T3 cells. A system for post-synthesis end-on coupling
of deprotected oligonucleotides to cell delivery molecules
such as antibodies or polypeptides has been perfected. This
comprises the coupling of the new agent 9-fluorenyl-
methoxycarbonyl-6-amino- I -hexanol-I-0-(2-chlorophenyl- I -
benzotriazolyl)phosphate as the last step of phosphotriester
synthesis. Following normal deprotection procedures a
strongly nucleophilic free amino group is generated which
participates readily in protein cross-linking reactions. The
simplicity of the entire procedure was demonstrated by the
synthesis of oligo(dT)20-5'-0-(6-amino-I-hexanol) phosphate
and its subsequent crosslinking to poly-L-lysine with
dithiobis (succinimidyl propionate). We have also
investigated the synthesis of oligonucleotide analogues
containing modifications to the normal phosphodiester
linkage. The novel analogue monomer, 5'-0-dimethoxytrityl-
thymidine-3'-0-(4-anisidino)phosphate was synthesized and
incorporated into oligonucleotides, however, the coupling
efficiency was only 50% and therefore it could only be used
realistically as a means of protecting 3'-termini from
exonucleolytic degradation. Higher coupling efficiencies were
achieved with fully protected 2'-deoxy-ribonucleoside-3'-0-(1-
benzo-triazolyl)methylphosphonates (50-80%) and oncogene
anti-sense oligonucleotides incorporating these entities are
being synthesized in an attempt to influence gene expression
from without.JOINT MEETING OF THE BACR AND THE ACP 207
Synthesis and evaluation of substituted flavones as inhibitors
of tyrosine protein kinase
B.D.M. Cunningham, M.D. Threadgill & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
A number of proto- and viral oncogene products, which are
considered to be involved in malignant transformation, are
tyrosine specific protein kinases. Quercetin, 3,3',4',5,7-penta-
hydroxyflavone, a naturally occurring plant product, has
been shown to inhibit the transforming gene product of the
Rous Sarcoma virus, pp6Osrc (Glossman et al., Naunyn
Schmeidebergs Arch. Pharmacol., 317, 100, 1981). pp6osrc is
responsible for the transformation of certain cell types and
its activity is required for the maintenance of the
transformed phenotype. Since the inhibition of pp6Osrc by
quercetin is only one of its many activities, it is the aim of
this project to synthesise rationally a series of analogues of
quercetin that may show specific activity against pp6osrc and
other associated tyrosine protein kinases. Compounds were
synthesized by the acylation of 4,6-disubstituted 2-hydroxy-
acetophenones with 3,4-disubstituted benzoyl chlorides,
followed by base catalyzed rearrangement and acid catalyzed
ring closure. The results of cytotoxicity assays using
Abelson-transformed NIH3T3 cells (ANN-1 cells) which
express the Abelson tyrosine-protein kinase, show a range
of I.C.5os from 8pM (3'4'-dihydroxyflavone) to 91 yM
(quercetin).
5
Genotypic heterogeneity of human colorectal tumour cell
populations
N.Y. Yassen', G. Jacob2. C.W. Potter'. A. Potter3. A.
Watmore3 & R.C. Rees'
'Department of Virolog,; 2Depar tnmetit ofSurgery, Univer-sity
of SIw/field Medical School and 3Centre for Human Genetics,
Langhill, Manchester Road, Sheffield 10, UK.
Cytogenetic analysis of 6 long-term colon adenocarcinoma
cell lines has been undertaken, and the results compared with
those obtained from freshly derived short-term cultured (6 h)
tumour cells. With established cell lines the cytogenetic
characteristics included deletions, translocation events,
addition and absence of chromosomes as well as the
identification of a number of marker chromosomes, and
other chromosomal abnormalities. A consistent feature of
the cell lines was the prominent involvement of
chromosomes numbers 5, 7, It, 19 and 20, and the absence
of the Y chromosome in tumours of male origin. In many of
the commonly used SW cell lines up to five genotypically
distinct subpopulations could be identified inferring
considerable heterogeneity within any given cell line.
Analysis of freshly derived colon adenocarcinoma cells
also showed genotypic heterogeneity within a given
population, and the predominant population exhibited many
of the characteristics associated with established cell lines:
vi,-. additional chromosomes 5, 7, 11 and 20 and abnormal-
ities in chromosomes 2, 3 and 19. It will be of considerable
importance in further studies to define the phenotypic and
biological characteristics associated with apparent genotypic
changes.
Tumour metastases can be augmented by drug treatment
P.J. Clarke & D. Tarin
Nuffield Department of Pathology, (University of Oxford),
John Radcli/fi? Hospital, Oxfrd OX3 9DU, UK.
The cells within a tumour are known to be heterogeneous
with regard to their metastatic capability. Environmental
agents and drug treatments can both induce stable
alterations in gene expression which are then reflected in
heritable behavioural changes. To study the possible effect
of such drugs on metastasis, the tumorigenicity and
metastatic behaviour of a murine mammary tumour (P574)
were studied before and after treatment in vitro with two
drugs, 5-aza-2'-deoxycytidine (a hypomethylating agent), and
tetradecanoylphorbolacetate (TPA), a known promotor of
murine skin tumours.
P574 cells were treated in vitro with a single dose of either
drug (5 ,um 5-aza-2'-deoxycytidine, 10 ngml- 1 TPA) for
times varying from 1-24h. After 24h recovery, cells were
inoculated into the fat pad of syngeneic mice and the effects
on tumour growth and metastatic behaviour were
documented.
P574 normally has a latent period of tumourigenicity of 12
weeks and is only weakly spontaneously metastatic. Both
drugs accelerated the growth of fat pad tumours and
significantly increased the numbers of pulmonary metastases.
This increase in spontaneous tumour spread must reflect a
heritable change induced by the drug treatments as many
generations of cell division occur between tumour cell
inoculation and metastases.
Modulation of type IV collagenase and plasminogen activation
secretion in hamster fibrosarcoma sublines and clones
possessing differing metastatic potential
R.C. Rees, D.M. Teale & I.A. Khidair
Departtment of Virology, University, ofShe/field Medical
School, Beech Hill Road, Shel/ield SJO 2RX, UK.
The effect of basement membrane components (laminin,
fibronectin and type IV collagen) on type IV collagenase and
plasminogen activator secretion was investigated in a
primary HSV-2 induced hamster fibrosarcoma, and its in
vivo derived sublines and in vitro derived clones of previously
defined high or low metastatic potential. Fibronectin and
type IV collagen were ineffective in influencing the
expression of either type IV collagenase or plasminogen
activator activity. Laminin however, at concentrations of 1-
lOpgml-1, when added to serum-free cultured supernatants,
increased the release of type IV collagenase by up to 100%
for the parental cell line. Three highly metastatic sublines
(two in vivo derived, and one in vitro cloned) showed
increases of up to 300% in type IV collagenase secretion
upon laminin stimulation; in contrast non-metastatic sublines
(two in vivo and one in vitro cloned) showed no increase in
type IV collagenase activity in response to laminin.
Plasminogen activator released from either the parental cell
line or its metastatic sublines and clones was unaffected by
the addition of laminin. These studies infer a role for
laminin, via its interaction with the laminin receptor site on
tumour cells, leading to an increase in type IV collagenase
secretion; this process may contribute to the process of
tumour metastases and invasion of tumour cells through
basement membrane matrices.208 JOINT MEETING OF THE BACR AND THE ACP
Mutant ras genes influence early stages in spontaneous
metastasis
S.A. Eccles', H. Purviesl* & C.J. Marshall2
'Institute ofCancer Research, Sutton, Surrey and 2Chester
Beatty Laboratories, London, UK.
Introduction of an activated c-Ha-ras-1 gene by transfection
with the pSV2-neo vector has been shown to enhance the
spontaneous metastatic capacity of syngeneic mouse
mammary carcinoma cells from <10% incidence to >90%.
(Vousden et al., Int. J. Cancer, 37, 425, 1986). Control
transfectants (pSV2-neo alone) showed a slightly increased
tendency to metastasize which was rapidly lost during in
vitro or in vivo passage, whereas the ras-induced metastatic
phenotype appeared stable. Various parameters are being
investigated with the aim of elucidating the mechanism of
action of this oncogene. Ras mutants with a serine residue at
codon 12 were capable of inducing metastasis of transfected
cells, indicating that the glycine-+valine mutation is not
unique in this capacity. The ras transfectants were found not
to differ significantly from the parental or pSV2-neo controls
in terms of: growth rate, immunogenicity, ploidy, collagenase
activity, size distribution of cell surface glycopeptides, or
lung colonisation potential. We infer from these data that
the ras oncogene influences as yet unidentified events early in
the metastatic process (e.g. cell detachment, invasion, intra-
vasation), and these aspects are now being investigated.
growth and with DNA cytophotometric analysis. In 6 cases
of surgical resection of adenocarcinoma (3) or squamous
carcinoma (3) of the oesophagus, specimens of tumour and
macroscopically normal mucosa were cultured in vitro for 28
days. The extent of growth was correlated with results from
sample biopsies submitted for histopathological examination.
DNA cytophotometry was also studied using a single cell
scanning microdensitometer. Biopsies of oesophageal and
gastric mucosa from endoscopically normal patients were
used to determine the normal diploid DNA content.
The study showed no correlation between normal or
tumour cell growth in vitro and histological tumour type,
stage, grade, ploidy value dysplasia, carcinoma in situ or
presence or absence of Barret's mucosa. Tumour tissue in
general grew significantly less than normal tissue (P<0.01)
and there was a significantly greater amount of growth in
samples of tumour tissue from patients with regional nodal
metastasis (P<0.01). However, when growth of macro-
scopically normal mucosa was correlated with the presence
or absence of regional node metastases, the presence of
positive nodes was associated with significantly less normal
mucosal cell growth in vitro (P<0.05). The association of
tumour cell growth in vitro with metastatic spread might be
expected but the reason for reduced normal growth in these
circumstances is unclear. The results indicate that apart from
metastatic status, the histopathology of the tumour has no
relevance to the subsequent growth of either normal or
tumour cells in vitro.
Observations on the fluorescent staining of melanocytes in
benign naevi and malignant melanoma
F.S. Steven, U. Suresh, T. Wong & M.M. Griffin
Department ofBiochemistry and Molecular Biology, University
ofManchester, Manchester M13 9PT and Department of
Histopathology, Withington Hospital, Manchester M20 8LR,
UK.
Guanidinobenzoatase is a cell surface, trypsin-like, protease
capable of degrading fibronectin. Cells possessing this
enzyme exhibit cell surface fluorescence when treated with a
competitive inhibitor such as 9-amino-acridine. Melanocytes
in routine wax embedded skin sections could be classified as
benign naevus cells or malignant melanoma cells according
to their ability to bind 9-aminoacridine. This binding ability
was controlled by the presence in benign naevus cells of an
inhibitor whilst in the malignant melanoma cells the
inhibitor was absent.
The inhibitor could be displaced experimentally and
exchanged with an inhibitor of guanidinobenzoatase
obtained from fresh liver homogenates. We suggest
guanidinobenzoatase and its inhibitor may have roles in the
control of cell migration.
A histopathological and DNA cytophotometric study of benign
and malignant oesophageal tissue cultured in vitro
A. O'Brien', A. Cusack2, C. Mothersill2, C. Seymour2,
M. Moriarty2 & T.P.J. Hennessy'
' University Department ofSurgery, St James's Hospital,
Dublin 8 and 2Department ofRadiobiology, St Luke's
Hospital, Rathgar, Dublin 6, Eire.
In an attempt to look at the problem of growing human
oesophageal mucosal cells in culture our group have
correlated the histopathological findings with observed
Dietary calcium supplementation reduces carcinogenesis and
crypt cell production rates in normal and adapting colonic
epithelium
G.V.N. Appleton, P.W. Davies, J.B. Bristol & R.C.N.
Williamson
University Department ofSurgery, Bristol Royal Infirmary,
Bristol BS2 8HW, UK.
Small bowel resection and intrarectal administration of
sodium deoxycholate each stimulate cell proliferation and
promote carcinogenesis in the large intestine; oral
supplements of calcium reduce the mitogenic effect of bile
acids on colorectal mucosa. Potential suppression of
intestinal adaptation and carcinogenesis by intraluminal
calcium was tested in 120 male Sprague-Dawley rats
weighing 186+9g. Rats were randomised to receive azoxy-
methane s.c. 15 mgkg-wk - for 6wk or vehicle, followed
by 80% mid small bowel resection or transection with
reanastomosis. Half the animals in each group received
supplemental calcium in the drinking water (calcium lactate
24gl-1). Crypt cell production rate (CCPR) in descending
colon was determined 7wk postoperatively in vehicle-treated
rats; in the remainder colonic tumour yield was assessed at
26wk. Among rats with transection, calcium supplements
reduced colonic CCPR by 26% from 4.49+0.33 to
3.32+0.40 cells per crypt/h (P<0.05) and more than halved
tumour yield from 4.3 to 1.8 tumours per rat (P=0.0007).
Jejunoileal resection increased both CCPR (by 51-61%:
P<0.001) and tumour yield (by 65-105%: P<0.005), but
again calcium lowered CCPR by 31% (7.23 +0.44 vs.
4.98+0.70; P<0.02) and tumour yield by 46% (6.9 vs. 3.7;
P=0.0006). Increased dietary levels of calcium diminish both
adaptive and neoplastic growth in the colon, and calcium
also blunts the co-carcinogenic stimulus of massive
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Survival of multiple cycles of DNA synthesis detected in single
mammalian cells using cytochalasin B. A flow cytometric
method
J.B. Court, C. Burn & J.L. Moore
Radiation Sciences Laboratory, Velindre Hospital, Cardiff
CF4 7XL, Wales, UK.
We have developed an assay for Chinese hamster ovary cell
viability that is based on the ability to multinucleate in the
presence of the fungal metabolite cytochalasin B (CB)
following exposure to radiation or to cytotoxic drugs. The
degree of multinucleation achieved can be assessed after a
given incubation period in CB either by a count of nuclei/cell
or by measurement of the cellular DNA content. The
method is intended to permit estimation of the survival of
DNA synthesis in situations where cells cannot be fully
monodispersed. Using a flow-cytometric method to find the
cellular DNA content and to enumerate the absolute number
of cells per culture, we have investigated the effect of cell
density and glucose concentration on the cellular DNA
content achieved after 50h incubation in the presence of CB.
Above densities of -80,000 cells cm2 the proportion of
seeded cells accumulating at least 3 times the DNA content
of untreated GI cells is reduced, though the effect on the
measured survival following 20Gy irradiation is small. The
proportion of cells exceeding a DNA content of 3 xGI is
sensitive to the concentration of glucose in the incubation
medium. We postulate that the reduction in the cellular
surface area/volume ratio that may occur as cultures become
dense limits the acquisition of medium energy sources.
We have also investigated the shape of survival curves
following irradiation or drug exposure. The survival of cells
able to exceed a DNA content of 3 xGI after 50h in CB
seems to decrease exponentially with dose. Generally,
survival is markedly greater than the corresponding
clonogenic survival.